📢 New Companion Diagnostic Approval – our blood-based comprehensive genomic profiling (CGP) test is now FDA-approved to identify patients with ER-positive, HER2-negative, ESR1-mutated advanced #breastcancer.
Read more: www.foundationmedicine.com/press-release/fda-foundationon…
Foundation Medicine
Foundation Medicine, Inc. is an American company based in Boston, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas. More on Wikipedia
-
Foundation Medicine
@FoundationATCG
-
Foundation Medicine
@FoundationATCG
This Cancer Biomarker Awareness Day, we’re helping to spread the word on #biomarkertesting and how it can be a crucial tool in a patient’s cancer care experience. #cbad26
Hear more: youtu.be/fY2hgLMZfRI -
Foundation Medicine
@FoundationATCG
Imagine detecting cancer recurrence before it can appear with standard imaging approaches. That’s now possible thanks to molecular residual disease (MRD) testing.
Foundation Medicine
@FoundationATCG
Get the basics on #mrd testing and cancer recurrence monitoring in our new Precision Points blog post: www.foundationmedicine.com/blog/new-era-mrd-testing
-
Foundation Medicine
@FoundationATCG
At Foundation Medicine, our rich history of scientific firsts in comprehensive genomic profiling has changed the course of precision medicine and forged a path for high-quality genomic testing in cancer.
Foundation Medicine
@FoundationATCG
We’re continuing to make advancements in diagnostic solutions to help support patients, healthcare teams and industry partners across the cancer care continuum. Connect with our team at #islb2026 - visit booth 16: www.foundationmedicine.com/event/join-foundation-medicine…
-
Foundation Medicine
@FoundationATCG
Foundation Medicine will be at #amp2026, booth 1701! Come learn about our latest offerings, including our MRD test for early-stage breast cancer, and how we can support pathology teams in delivering actionable genomic insights to help advance #precisionmedicine.
Foundation Medicine
@FoundationATCG
Heading to Seattle? Join our workshops on 11/11 or schedule a meeting to connect & explore how we can support your team: www.foundationmedicine.com/event/join-foundation-medicine…
#amp2026
*FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA. -
Foundation Medicine
@FoundationATCG
At Foundation Medicine, our rich history of scientific firsts in comprehensive genomic profiling has changed the course of precision medicine and forged a path for high-quality genomic testing in cancer.
Foundation Medicine
@FoundationATCG
We’re continuing to make advancements in diagnostic solutions to help support patients, healthcare teams and industry partners across the cancer care continuum. Connect with our team at #islb2026 - visit booth 16: www.foundationmedicine.com/event/join-foundation-medicine…
-
Foundation Medicine
@FoundationATCG
Caregivers are an important source of strength, comfort & support for people living with cancer. Hear more from Casey, her perspectives on being a caregiver & how biomarker testing has helped play a role in her husband Keith’s treatment experience: youtu.be/Zc3qjxiLgOo
-
Foundation Medicine
@FoundationATCG
This #lungcancerawarenessmonth, we recognize everyone impacted by lung cancer. We remain committed to advancing precision medicine to deepen our understanding of each patient’s cancer and help inform more personalized care.
-
Foundation Medicine
@FoundationATCG
Why does comprehensive genomic profiling (CGP) matter for advanced patient w/breast cancer? Tune in to this episode of “Genomics in Moments” to hear more about how CGP can help patients & their healthcare teams make informed treatment decisions in #breastcancer care.
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
We are proud to be a @TheScientistLLC Top Innovations award recipient in Healthcare and Diagnostics for FoundationOne®MRD! This award honors cutting-edge technology shaping the future of life science, biotechnology and healthcare.
Foundation Medicine
@FoundationATCG
This recognition reinforces Foundation Medicine's commitment to providing comprehensive testing solutions to transform care at each stage of the patient experience: www.foundationmedicine.com/press-release/top-innovation-s…
-
Foundation Medicine
@FoundationATCG
#research at #esmo26 assessed the real-world landscape of approved and emerging tumor-agnostic biomarkers across 385,420 solid tumor samples profiled with Foundation Medicine’s tissue-based comprehensive genomic profiling.
Foundation Medicine
@FoundationATCG
Hear more from our team at this year’s meeting – find time with us at Booth 1030, Hall 10. fpgo.io/r/t4RyJw
-
Foundation Medicine
@FoundationATCG
We are thrilled to announce the appointment of Chadi Nabhan, M.D., MBA, as Foundation Medicine's new chief medical officer, effective November 16, 2026.
Foundation Medicine
@FoundationATCG
Dr. Nabhan is an accomplished medical oncologist and hematologist with over 25 years of multi-disciplinary experience covering clinical oncology, academic research, genomics and healthcare technology.
Foundation Medicine
@FoundationATCG
Please join us in giving Dr. Nabhan a warm welcome! You can read the full announcement here: www.foundationmedicine.com/press-release/chief-medical-of…
-
Foundation Medicine
@FoundationATCG
Poster presentations at #esmo26 explore methylthioadenosine phosphorylase (MTAP) loss in two genomic landscape studies in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
Foundation Medicine
@FoundationATCG
Discuss and hear more about this research with our team – booth 1030, hall 10. Learn more: fpgo.io/r/qbf31J
-
Foundation Medicine
@FoundationATCG
With 12 pieces of research being presented, including two rapid oral presentations, our team is looking forward to joining the international oncology community at #esmo26!
Foundation Medicine
@FoundationATCG
Come learn more about Foundation Medicine and how we are helping to advance precision medicine through our high-quality tests and services. Explore our accepted research: www.foundationmedicine.com/press-release/esmo-congress-2026
-
Foundation Medicine
@FoundationATCG
#esmo26 rapid oral presentations highlight insights for #prostatecancer, exploring the clinical impact of CH HRR alterations on outcomes for PARPi use in mCRPC & evaluating the effectiveness of ctDNA tumor fraction as a prognostic biomarker for patients w/ HRR gene-mutated mCRPC.
Foundation Medicine
@FoundationATCG
Meet with our team at this year’s meeting, Booth 1030 in Hall 10. Learn more: www.foundationmedicine.com/event/esmo-congress-2026
-
Foundation Medicine
@FoundationATCG
Engage and connect with the Foundation Medicine team for our series of “Booth Talks,” featuring discussions on the latest advancements in cancer care. Expert-led presentation will provide more information on the latest innovations happening in precision medicine and diagnostics.
Foundation Medicine
@FoundationATCG
Explore the topics below and learn more: www.foundationmedicine.com/event/esmo-congress-2026
-
Foundation Medicine
@FoundationATCG
Join Foundation Medicine at #esmo26! Our team looks forward to engaging with the international oncology community on the latest research advancing precision medicine and oncology care.
Foundation Medicine
@FoundationATCG
Visit us at Booth 1030, Hall 10 to attend expert-led discussions and hear more information about our high-quality tests and services, including our new molecular residual disease (MRD) offering.
Foundation Medicine
@FoundationATCG
Learn more about our programming at this year’s meeting – we hope to see you there! www.foundationmedicine.com/event/esmo-congress-2026
-
Foundation Medicine
@FoundationATCG
Join us at @OGPREMED's Biomarkers, CDx & Precision Medicine Europe 2026 event! Connect with our team, including during a sponsored plenary session, to discuss more about biomarker development, precision medicine and the future of clinical development.
Foundation Medicine
@FoundationATCG
Find time with us and learn more: www.foundationmedicine.com/event/biomarkers-cdx-precision…
-
Foundation Medicine
@FoundationATCG
Foundation Medicine will be at this year’s #statsummit! We’re excited to join @statnews for impactful discussions around the latest breakthroughs happening in science, medicine and patient care.
Foundation Medicine
@FoundationATCG
Our fireside chat, featuring Chief Commercial Officer, Troy Schurr, will dive into the growing importance of molecular residual disease (MRD) in cancer care and the future of MRD testing. Learn more and register today: www.statnews.com/stat-summit-boston/
-
Foundation Medicine
@FoundationATCG
An extended analysis of the TRACER study showcased the value of early detection of breast cancer recurrence & long-term disease monitoring utilizing FoundationOne®MRD.
*FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.
Foundation Medicine
@FoundationATCG
Explore key findings and more: www.esmoopen.com/action/showPdf?pii=S2059-7029(26)02279-9
-
Foundation Medicine
@FoundationATCG
This Breast Cancer Awareness Month, we recognize the strength of the breast cancer community & the continued need for progress in research & care. Proud to support efforts to advance precision medicine and help bring more personalized options to people facing breast cancer. 🩷
-
Foundation Medicine
@FoundationATCG
Cancer care is complex and requires a personalized, data-driven approach to enable confident care decisions. Foundation Medicine puts quality first - explore how high-quality cancer biomarker tests provide patients with accuracy and clarity. Learn more: fpgo.io/r/5w0QZn
-
Foundation Medicine
@FoundationATCG
We’re getting ready and excited for this year’s 16th Annual World CB & CDx Summit! We look forward to connecting with industry professionals on what’s next for precision medicine, including the evolving biomarker landscape, companion diagnostics, disease monitoring and more.
Foundation Medicine
@FoundationATCG
Heading to Boston? We’d love a chance to meet. Discover more about our programming at this year’s event and a time to meet with our team: www.foundationmedicine.com/event/world-cb-cdx-2026
-
Foundation Medicine
@FoundationATCG
Foundation Medicine’s high-quality cancer #biomarkertests provide accurate information about a tumor’s mutations so that healthcare teams can help patients receive the #cancertreatment that may work best for them. Explore more: www.foundationmedicine.com/qualityfirst
-
Foundation Medicine
@FoundationATCG
Our new molecular residual disease (MRD) test offers healthcare teams ultra-sensitive MRD detection, high-specificity and accelerated results. Learn more about our MRD test: www.foundationmedicine.com/solution/foundationone-mrd
-
Foundation Medicine
@FoundationATCG
#lungcancer research being presented as a mini oral presentation at #wclc26 analyzed the prevalence of MTAP loss in NSCLC tissue and liquid biopsies, utilizing Foundation Medicine’s tumor- & blood-based comprehensive genomic profiling.
Foundation Medicine
@FoundationATCG
Attending the meeting? Visit Foundation Medicine at booth 726 and connect with our team. Learn more: www.foundationmedicine.com/event/wclc-2026
-
Foundation Medicine
@FoundationATCG
At #wclc26, we're excited to highlight 2 new posters: one on the clinical impact of NGS & targeted therapy across NSCLC histologic subtypes; the other analyzing homozygous losses & outcomes w/ standard of care treatment.
Foundation Medicine
@FoundationATCG
Hear more from our team at booth 726. Learn more: www.foundationmedicine.com/event/wclc-2026
-
Foundation Medicine
@FoundationATCG
Our upcoming sponsored webinar with @GenomeWeb webinar will delve into lessons learned from bringing complex biomarkers through development – from global clinical trials, CDx approval and commercial launches. Sign up today! event.on24.com/eventRegistration/unavailable?&eventid=545…
-
Foundation Medicine
@FoundationATCG
Join Foundation Medicine for our “Booth Talk Series” at #wclc26. Hear from our team of experts on the latest advancements that are driving innovation in precision diagnostics and lung cancer treatment. Review the session topics below.
Foundation Medicine
@FoundationATCG
Learn about Foundation Medicine and more: www.foundationmedicine.com/event/wclc-2026
-
Foundation Medicine
@FoundationATCG
Connect with Foundation Medicine at #wclc26! Visit us to learn about the latest advancements in CGP and NGS at booth 726. More details here: www.foundationmedicine.com/event/wclc-2026
-
Foundation Medicine
@FoundationATCG
In September, we join the global effort to raise awareness for #bloodcancers, #childhoodcancers, #ovariancancer and #prostatecancer. We are proud to foster awareness, support research and help advance innovation, this month and beyond.
-
Foundation Medicine
@FoundationATCG
High-quality cancer #biomarkertests provide clear answers to help inform #treatment decisions. Because Foundation Medicine puts quality first, our tests make a difference. Learn more: www.foundationmedicine.com/qualityfirst
-
Foundation Medicine
@FoundationATCG
Stay up to date with the latest insights and innovations happening in #precisionmedicine through our series of #biopharma webinars. Hear more from our team of experts – explore more: gateway.on24.com/wcc/eh/5226698/foundation-medicine-webinars
-
Foundation Medicine
@FoundationATCG
A #cancer #diagnosis or recurrence can make everything seem unclear. Foundation Medicine’s high-quality #biomarkertests identify the unique mutations behind a patient’s cancer to help match them with the medicine more likely to work for them.
Foundation Medicine
@FoundationATCG
Click here for more: www.foundationmedicine.com/qualityfirst
-
Foundation Medicine
@FoundationATCG
#research published in Clinical Cancer Research proposes circulating tumor DNA (ctDNA) tumor fraction as an actionable biomarker to help identify patients with non-small cell lung cancer (NSCLC) who may benefit from combination chemo-immunotherapy.
Foundation Medicine
@FoundationATCG
Full study findings and more here: aacrjournals.org/clincancerres/article/doi/10.1158/1078-0…
-
Foundation Medicine
@FoundationATCG
Every patient deserves the opportunity to be on an effective #medicine. Foundation Medicine’s high-quality cancer #biomarkertests help clarify next steps and match patients like Karen with the treatment more likely to work so they can get back to doing what they love.
Foundation Medicine
@FoundationATCG
Learn more: www.foundationmedicine.com/qualityfirst
-
Foundation Medicine
@FoundationATCG
Precision #cancercare can only be as good as the quality and accuracy of the #biomarkertest used to inform treatment. Find out more about Foundation Medicine’s tests and how we put quality first: www.foundationmedicine.com/qualityfirst
-
Foundation Medicine
@FoundationATCG
#researchspotlight – Research published in JCO Oncology Practice demonstrated a significant reduction in lab testing turnaround time (TAT) for Foundation Medicine’s tissue-based comprehensive genomic profiling (CGP), but no change in CGP ordering or specimen processing TAT.
Foundation Medicine
@FoundationATCG
Explore key findings and more below. Read the full publication here: ascopubs.org/doi/10.1200/OP-25-01191
-
Foundation Medicine
@FoundationATCG
Foundation Medicine’s high-quality cancer #biomarkertests generate reports that can clearly distill complex information to help patients like Greg and their healthcare teams decide on the #treatment plan more likely to work for them. Explore more: www.foundationmedicine.com/qualityfirst
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Not all biomarker tests are created equal, impacting the accuracy, reliability and clarity of information these tests provide. Foundation Medicine’s high-quality cancer #biomarkertests can help inform a personalized treatment plan for patients with #cancer.
Foundation Medicine
@FoundationATCG
Learn more: www.foundationmedicine.com/qualityfirst
-
Foundation Medicine
@FoundationATCG
Excited to announce the launch of our new campaign: Quality First. High-quality cancer #biomarkertests uncover the specific mutations behind a patient’s #cancer and provide personalized treatment options more likely to work for them, rather than a “one-size-fits-all” approach.
This media couldn't be displayed. See it on the original post.
Foundation Medicine
@FoundationATCG
Learn more: www.foundationmedicine.com/press-release/quality-first
-
Foundation Medicine
@FoundationATCG
Foundation Medicine will be at the Liquid Biopsy for Precision Oncology Summit East Coast! We’re looking forward to connecting with industry leaders and discussing the latest innovations in liquid biopsy development, including advancements in MRD detection.
Foundation Medicine
@FoundationATCG
Heading to Boston for the meeting? Our team would love the chance to connect – find time with us: www.foundationmedicine.com/join-foundation-medicine-years…
-
Foundation Medicine
@FoundationATCG
Our latest Genomics in Moments video dives into Quantity Not Sufficient (QNS). #dyk limited tissue doesn’t have to limit genomic insights that can help inform treatment decisions? Watch to learn more.
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
We’re looking forward to joining researchers and oncology leaders at #esmogi26 in Munich. Our research at the meeting includes a new poster on the impact of liquid biopsy comprehensive genomic profiling on time to treatment initiation in #gi #cancers.
Foundation Medicine
@FoundationATCG
Learn more about Foundation Medicine at this year’s congress – visit us at booth 23: www.foundationmedicine.com/event/esmo-gi-2026
-
Foundation Medicine
@FoundationATCG
#research from the team published in JCO Precision Oncology analyzed the genomics of MTAP loss in over 500,000 solid tumor specimens. Click through below for more information and key findings. Explore the full publication here: ascopubs.org/doi/10.1200/PO-26-00037
-
Foundation Medicine
@FoundationATCG
Connect with Foundation Medicine at #esmogi26! Visit us to learn about the latest advancements in comprehensive genomic profiling at Booth 23. More details here: www.foundationmedicine.com/event/esmo-gi-2026
-
Foundation Medicine
@FoundationATCG
FoundationOne®MRD* reinforces our commitment to transforming cancer care throughout a patient’s treatment experience.
*FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA
Foundation Medicine
@FoundationATCG
This MRD test expands our portfolio to include new monitoring capabilities, furthering our impact in helping to monitor treatment response and disease recurrence: www.foundationmedicine.com/press-release/foundationone-mrd
-
Foundation Medicine
@FoundationATCG
We look forward to attending #eha2026 and connecting with the global hematology community. Heading to Stockholm? Visit us at booth G1.01 (Hall C) - reach out to our team to learn more: share.hsforms.com/19G7YoXd6RmaXhqbqqvY62w3qh2
-
Foundation Medicine
@FoundationATCG
#research published in @NatureComms demonstrated the clinical validation of circulating tumor DNA (ctDNA) tumor fraction dynamics as a prognostic biomarker in patients with metastatic triple negative breast cancer (mTNBC) receiving chemo with or without immunotherapy.
Foundation Medicine
@FoundationATCG
Results also showcased the value of serial circulating tumor DNA (ctDNA) monitoring in patients who are responding to treatment. Read more: www.nature.com/articles/s41467-026-73085-1
-
Foundation Medicine
@FoundationATCG
#asco26 has come to an end and our team is looking back at our time in Chicago last weekend! Thank you to all who stopped by our booth and connected with our team. #wearefmi
-
Foundation Medicine
@FoundationATCG
Proud to introduce FoundationOne®MRD,* the first-of-its-kind molecular residual disease test to combine structural variants and digital PCR.
*FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.
Foundation Medicine
@FoundationATCG
Find out more: www.foundationmedicine.com/press-release/foundationone-mrd
-
Foundation Medicine
@FoundationATCG
New companion diagnostic announcement - our tissue-based comprehensive genomic profiling (CGP) test has been FDA-approved to identify patients with hormone receptor-positive, HER2-negative #breastcancer with a PIK3CA mutation for a targeted therapy combination.
Foundation Medicine
@FoundationATCG
Click here to learn more: www.foundationmedicine.com/press-release/fda-foundationon…
-
Foundation Medicine
@FoundationATCG
Interested in how Foundation Medicine’s new molecular residual disease assay* can support your clinical trials? Register for our webinar: event.on24.com/wcc/r/5362201/7DA67F23E54286551C4BE0262C4D…
*FoundationOne®MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.
Foundation Medicine
@FoundationATCG
Introducing the first and only MRD assay* to leverage the reliability of structural variants with the speed of digital PCR.
*FoundationOne®MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.
Foundation Medicine
@FoundationATCG
Join our upcoming webinar to learn more: event.on24.com/wcc/r/5362201/7DA67F23E54286551C4BE0262C4D…
-
Foundation Medicine
@FoundationATCG
Companion Diagnostic Approval - our tissue and blood-based comprehensive genomic profiling (CGP) tests have been approved by the FDA as companion diagnostics for a combination therapy to identify patients w/ HRR gene-mutated mCRPC: www.foundationmedicine.com/press-release/fda-approval-tis…
Foundation Medicine
@FoundationATCG
These two approvals further strengthen Foundation Medicine’s leadership in companion diagnostic development, and the critical role biomarker testing plays in connecting patients to targeted treatments. Read more: www.foundationmedicine.com/press-release/fda-approval-tis…
-
Foundation Medicine
@FoundationATCG
Hear more about Foundation Medicine’s new research at #asco26 from Merrida Childress, Ph.D., Associate Director of Clinical Development. Stop by booth 19145 to learn more about this and other research being presented at the meeting.
-
Foundation Medicine
@FoundationATCG
Come use your decoder glasses to reveal hidden insights from our data at booth 19145. #asco26
-
Foundation Medicine
@FoundationATCG
#asco26 is off to a great start! Stop by booth 19145 to meet with the Foundation Medicine team and learn more about our high-quality portfolio of tests and servics. Plus, come hear more about our new MRD test, which is now available.
-
Foundation Medicine
@FoundationATCG
#announcement – learn more about our strategic collaboration with SWOG Clinical Trials Partnerships: www.foundationmedicine.com/press-release/swog-ctp
-
Foundation Medicine
@FoundationATCG
Results reported from the experimental arm of the phase II COPE trial provide insights on the impact of serial ctDNA genomic profiling for treatment guidance and outcomes for patients with non-small cell lung cancer. #asco26
Foundation Medicine
@FoundationATCG
Explore more from the Foundation Medicine team - booth 19145: www.foundationmedicine.com/event/asco-2026
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is presenting numerous pieces of research at #asco26. Hear more about our research on MTAP loss from Alexa Schrock, PhD, Senior Director, Clinical Development and visit booth 19145 to learn more.
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Our team is excited to be Chicago this weekend for #asco26. Visit us at booth 19145 to learn more about our high-quality tests and services, including our new MRD test.
-
Foundation Medicine
@FoundationATCG
Utilizing real-world genomic data, two new pieces of #research being presented at #asco26 explore the prevalence and co-occurrence patterns of HRDsig status in two disease areas: advanced breast cancer and advanced gallbladder adenocarcinoma.
Foundation Medicine
@FoundationATCG
In Chicago? Meet the Foundation Medicine team at booth 19145: www.foundationmedicine.com/event/asco-2026
-
Foundation Medicine
@FoundationATCG
A great discussion between @matthewherper and our CEO Dan Malarek on new frontiers in cancer diagnostics and where precision medicine is going.
@statnews #asco26 -
Foundation Medicine
@FoundationATCG
Excited to kick off the weekend in Chicago at the STAT@ASCO event where our CEO Daniel Malarek will be talking about New Frontiers in Cancer Diagnostics!
#asco26 -
Foundation Medicine
@FoundationATCG
We're thrilled to announce the launch of our FoundationOne®MRD* tumor-informed molecular residual disease test. Read more: www.foundationmedicine.com/press-release/foundationone-mrd
*FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA -
Foundation Medicine
@FoundationATCG
Updates in #rarecancer research: New insights from the TRACK study found that comprehensive genomic profiling identified pathogenic alterations in nearly all rare cancer patients, with tissue-agnostic, actionable biomarkers seen in 9% of tumor types.
Foundation Medicine
@FoundationATCG
At #asco26? Chat with the Foundation Medicine team at booth 19145: www.foundationmedicine.com/event/asco-2026
-
Foundation Medicine
@FoundationATCG
#researchhighlights from Foundation Medicine at #asco26: copy number loss. Two studies will provide insights on common homozygous gene losses in head and neck cancer and the ability of liquid biopsy CGP to detect MTAP loss.
Foundation Medicine
@FoundationATCG
More information about Foundation Medicine at this year’s meeting at the link here: www.foundationmedicine.com/event/asco-2026
-
Foundation Medicine
@FoundationATCG
We are excited to launch advanced digital solutions for healthcare providers through an integration with @Roche_navify Clinical Hub, including AI-powered clinical trial matching, publication search, patient education materials & digitized guideline mapping.
Foundation Medicine
@FoundationATCG
Learn more: www.foundationmedicine.com/press-release/digital-solutions
-
Foundation Medicine
@FoundationATCG
A recent publication explored the key role of biomarker testing utilizing Foundation Medicine’s tissue-based comprehensive genomic profiling assay. Results showcase the importance of CGP testing to identify actionable biomarkers across all subtypes of non-small cell lung cancer.
Foundation Medicine
@FoundationATCG
Read more: www.sciencedirect.com/science/article/pii/S1556086426001486
-
Foundation Medicine
@FoundationATCG
New insights on copy number loss detection, circulating tumor DNA (ctDNA) genomic profiling, our proprietary homologous recombination deficiency signature (HRDsig) & more at #asco26. Explore our research being presented:
www.foundationmedicine.com/press-release/asco-2026 -
Foundation Medicine
@FoundationATCG
Excited to announce that our tissue-based comprehensive genomic profiling (CGP) test has been approved by the FDA as a companion diagnostic for another targeted therapy to identify patients with MET Exon 14 skipping alterations in NSCLC: www.foundationmedicine.com/press-release/fda-approval-fou…
Foundation Medicine
@FoundationATCG
Foundation Medicine’s blood-based CGP test was previously approved as the first companion diagnostic to identify patients who may be eligible for this targeted therapy.
Foundation Medicine
@FoundationATCG
This marks Foundation Medicine’s first approval leveraging its real-world data-powered CDx offering, a service that supports drug and diagnostic label expansion using expertly curated real-world evidence with integrated regulatory support. Read more: www.foundationmedicine.com/press-release/fda-approval-fou…
-
Foundation Medicine
@FoundationATCG
Our research published in @CCR_AACR introduces Foundation Medicine’s research use only AmpRatio biomarker, an NGS-based approach that precisely measures the magnitude of gene amplification by accounting for tumor ploidy. Scroll through to explore more insights.
Foundation Medicine
@FoundationATCG
Full publication available here: aacrjournals.org/clincancerres/article/doi/10.1158/1078-0…
-
Foundation Medicine
@FoundationATCG
We’re excited to join @statnews again this year at the STAT@ASCO: Science vs. Cancer event as the presenting sponsor, featuring a session with our CEO Dan Malarek. Going to be in Chicago? Join us: www.statnews.com/event/stat-at-asco-2026/
-
Foundation Medicine
@FoundationATCG
We are excited to provide a pharmacogenetic offering along w/ our portfolio of high-quality comprehensive genomic profiling tests. This new test can help healthcare providers gain a deeper understanding to help guide cancer therapy selection & support more effective patient care.
Foundation Medicine
@FoundationATCG
Read more about our latest announcement: www.foundationmedicine.com/press-release/foundationone-pgx
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is heading to Chicago for #asco26! We’re excited to showcase our latest research, high-quality testing portfolio and our biopharma services and capabilities. Our team would love to meet with you, schedule time today: www.foundationmedicine.com/event/asco-2026
-
Foundation Medicine
@FoundationATCG
#dyk MTAP loss is a highly prevalent alteration actively being targeted in clinical trials, but its complexity can derail programs if not addressed early. Hear more about peer-reviewed data & see how biomarker decisions can impact clinical trials. Sign up: event.on24.com/wcc/r/5312309/52ABD378542B9D4B16E94EA79DF4…
-
Foundation Medicine
@FoundationATCG
This month, we’re helping shine a light on the importance of #skincancer and #melanoma awareness. By encouraging sun-safe habits and greater education, we can help spread more information about the signs and risks.
-
Foundation Medicine
@FoundationATCG
Through our partnership with Fulgent Genetics, our new offering helps identify genetic differences that can influence how medicines are metabolized and processed by the body, including genes such as DPYD. Explore more about our latest product: www.foundationmedicine.com/press-release/foundationone-pgx
-
Foundation Medicine
@FoundationATCG
🧬 Today we recognize DNA Day and the impact of genomics in science, medicine and patient care. We are proud to play a role in all the progress happening today and look forward to continuing to help drive advancements in precision medicine.
-
Foundation Medicine
@FoundationATCG
#research published in @NatureComms highlights the potential utility of circulating tumor DNA (ctDNA) monitoring for informing early treatment response in patients with advanced breast cancer.
Foundation Medicine
@FoundationATCG
Results suggest approaches utilizing ctDNA genomics and dynamics and estrogen receptor activity to help guide future treatment strategies.
Foundation Medicine
@FoundationATCG
Explore the publication “ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer” here: idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat…
-
Foundation Medicine
@FoundationATCG
Join us at #coa2026 in Orlando! Meet our team to learn how we support innovation in community oncology with high quality testing and genomic insights: www.foundationmedicine.com/event/coa-2026
-
Foundation Medicine
@FoundationATCG
Our collaboration with @bmsnews will develop a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Learn more: www.foundationmedicine.com/press-release/bms-expansion-mtap
-
Foundation Medicine
@FoundationATCG
Proud to highlight new #research from our team at #aacr26. A new study utilized a tissue-informed molecular residual disease assay developed by Foundation Medicine. Findings showcased the potential utility of this assay in a pan-tumor & early cancer setting.
Foundation Medicine
@FoundationATCG
Chat with a member of our team and learn more about us – visit booth 2125: www.foundationmedicine.com/event/fmi-meeting-2026
-
Foundation Medicine
@FoundationATCG
At #aacr26, we’re presenting new #research that assessed copy number loss prevalence in 400,000+ pan-tumor samples using Foundation Medicine’s tissue-based comprehensive genomic profiling. To hear more about these findings and to connect with our team, visit booth 2125.
Foundation Medicine
@FoundationATCG
For more information, visit: www.foundationmedicine.com/event/fmi-meeting-2026
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is heading to #aacr26! Excited to join the cancer research community for conversations on the latest innovations in precision medicine and cancer care. We hope to see you in San Diego! Explore more at the link here: www.foundationmedicine.com/event/fmi-meeting-2026
-
Foundation Medicine
@FoundationATCG
We’re heading to San Juan for #sgoam26! Connect with the Foundation Medicine team to learn more about our high-quality genomic tests and services for gynecologic cancers at booth 112. Explore more: www.foundationmedicine.com/event/sgo-2026
-
Foundation Medicine
@FoundationATCG
As March comes to a close, we’re proud to share Trevor’s story and more about the impact that biomarker testing has had in his experience with being diagnosed and living with stage IV colon cancer. Hear more from Trevor: youtu.be/bA4lyBfs-XM
#colorectalcancerawarenessmonthThis media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
In 2025, we demonstrated strong evidence that helped differentiate our portfolio of biomarker tests through the publication of over 200 pieces of research. Looking forward to the year ahead and showcasing where Foundation Medicine can make a difference in precision medicine.
Foundation Medicine
@FoundationATCG
💡 Explore insights from our latest research in our new blog: www.foundationmedicine.com/blog/h2-2025-research-recap
-
Foundation Medicine
@FoundationATCG
We're proud to participate in the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Visit our booth to learn how our comprehensive genomic profiling & biomarker-driven solutions support biopharma partners from discovery through global commercialization.
Foundation Medicine
@FoundationATCG
Explore our programming or schedule a meeting with our team: www.foundationmedicine.com/event/jwcdx-eu-2026-biopharma
-
Foundation Medicine
@FoundationATCG
Join us for an upcoming live webinar: How WGS is Changing Drug Development in Complex Diseases.
Tune in to learn more about expanding precision strategies beyond oncology. Register here: event.on24.com/wcc/r/5254181/6B1E6DA8ED9C51B9AFA4517A9267… -
Foundation Medicine
@FoundationATCG
We’re heading to San Antonio for #uscap2026! Come learn more about Foundation Medicine and our high-quality tests and services at booth 443. Explore more: www.foundationmedicine.com/event/uscap-2026
-
Foundation Medicine
@FoundationATCG
Now available through Foundation Medicine’s FlexOMx Lab™ - Whole Genome Sequencing Germline for research use. Drawing on our rich history of scientific firsts in precision oncology, we are applying that expertise to new disease areas.
Foundation Medicine
@FoundationATCG
We are proud to provide this expansion of our portfolio of genomic solutions for biopharmaceutical partners to support translational research programs and clinical trials. Explore more: www.foundationmedicine.com/press-release/wgs-germline-ruo
-
Foundation Medicine
@FoundationATCG
Proud to support @theNCI and @EAonc ComboMATCH initiative. Now with the inclusion of our high-quality blood-based biomarker test, results will continue to help determine trial eligibility for patients who may benefit from the effectiveness of biomarker-targeted cancer treatment.
Foundation Medicine
@FoundationATCG
Explore this news about the @theNCI and @EAonc ComboMATCH initiative: www.foundationmedicine.com/press-release/expanded-comboma…
-
Foundation Medicine
@FoundationATCG
March is Colorectal Cancer Awareness Month. We are proud to support the colorectal cancer community in spreading greater awareness around prevention, early detection and access to resources for this disease.
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is looking forward to engaging with the latest research in genitourinary (GU) cancers at #gu26. New #research from the team showcases new insights around MTAP loss in GU cancers. Stop by booth 8 to meet with us.
Learn more: www.foundationmedicine.com/event/asco-gu-2026 -
Foundation Medicine
@FoundationATCG
We’re presenting several #prostatecancer posters at #gu26 covering insights on HRDsig, TP53 mutations & the clinical validity of Foundation Medicine’s tissue-based companion diagnostic test to identify BRCA+ & other HRR+ patients w/ metastatic castration-sensitive prostate cancer
Foundation Medicine
@FoundationATCG
Interested in learning more? Connect with our team at booth 8, click the link here to find time: www.foundationmedicine.com/event/asco-gu-2026
-
Foundation Medicine
@FoundationATCG
Miss. Not. One. at #gu26! Connect with our team at booth 8 & discover how advancements in comprehensive genomic profiling can help healthcare providers make confident, personalized treatment decisions for their patients with advanced cancer. Learn more: www.foundationmedicine.com/event/asco-gu-2026
-
Foundation Medicine
@FoundationATCG
Deep dive into gene fusions and how testing for fusions with DNA and RNA is so important for their detection in our latest “Genomics in Moments” video. Watch below.
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
February is Gallbladder and Bile Duct Cancer Awareness Month. By supporting education around these rare cancers —and continuing to spread awareness—we can help encourage conversations, drive greater understanding and provide resources to those affected by these diseases.
-
Foundation Medicine
@FoundationATCG
New #research from our team explored the potential benefits of concurrent RNA-based next-generation sequencing (NGS) with DNA-based NGS to help improve genomic rearrangement detection. Learn more from the study published in @OncJournal: academic.oup.com/oncolo/advance-article/doi/10.1093/oncol…
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is heading to the 10th Annual Liquid Biopsy for Precision Oncology Summit! With a full schedule of events, including a plenary session, dinner program & booth exhibit, our team is looking forward to connecting on the latest innovations in liquid biopsy.
Foundation Medicine
@FoundationATCG
lick the link to explore our programming and to request time to meet with us at the meeting – we hope to see you in San Diego: www.foundationmedicine.com/event/foundation-medicine-10th…
-
Foundation Medicine
@FoundationATCG
True or false: methyl thioadenosine phosphorylase (MTAP) loss is a rare alteration? Healthcare providers, if you’re not seeing MTAP loss in ~1 in 10 solid tumors, you may be missing out on clinical trial opportunities. Explore our abstract for more: ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3067
-
Foundation Medicine
@FoundationATCG
Explore a new review article published in @Cancer_Cell – “Circulating tumor DNA as a biomarker in early phase clinical trials.” Read more: www.sciencedirect.com/science/article/pii/S1535610825005045
-
Foundation Medicine
@FoundationATCG
"By integrating our high-quality genomic data with ConcertAl's electronic health data, we have created one of the most powerful new real-world data sets that enables insights to be turned into strategic decisions at critical milestones for our partners."
Foundation Medicine
@FoundationATCG
Read more about our new collaboration with @ConcertAI: www.foundationmedicine.com/press-release/concertai
-
Foundation Medicine
@FoundationATCG
New #study at #gi26 utilizes genomic data from Foundation Medicine to explore the relationship between ERBB2 amplification and gene- and protein-level expression in GI cancers to understand combined predictive value.
Foundation Medicine
@FoundationATCG
Visit Foundation Medicine at Booth 8. Learn more: www.foundationmedicine.com/event/asco-gi-2026
-
Foundation Medicine
@FoundationATCG
Our team is excited to attend #gi26 and to join oncology leaders in discussing the latest innovations shaping gastrointestinal (GI) cancer care. #research highlights we’re looking forward to sharing include four new abstracts on MTAP loss in GI cancers.
Foundation Medicine
@FoundationATCG
Attending the meeting? Stop by booth 8 to connect with our team! Click here to learn more: www.foundationmedicine.com/event/asco-gi-2026
-
Foundation Medicine
@FoundationATCG
Connect with Foundation Medicine at #gi26! Learn more about the latest advancements in comprehensive genomic profiling at booth 8. Learn more & schedule a meeting: www.foundationmedicine.com/event/asco-gi-2026
-
Foundation Medicine
@FoundationATCG
Join us for the session “2026: The new priorities in oncology R&D and diagnostics” featuring Foundation Medicine CEO, Dan Malarek at this year’s @endpts at #jpm26 event. Learn more: events.endpoints.news/jpm26
-
Foundation Medicine
@FoundationATCG
New #prostatecancer research published in @CCR_AACR – “Additive clinical utility of microsatellite instability and tumor mutational burden to predict immune checkpoint inhibitor effectiveness in metastatic castration-resistant prostate cancer”: aacrjournals.org/clincancerres/article/doi/10.1158/1078-0…
-
Foundation Medicine
@FoundationATCG
#research leveraged real-world data to evaluate changes in ctDNA tumor fraction & blood tumor mutational burden to assess treatment response to immune checkpoint inhibitors in a pan-tumor setting. Hear more below.
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Innovations in precision medicine require collaboration, actionable insights and a commitment to advancing cutting-edge science. Explore how we are helping our #biopharma partners turn scientific promise into progress in our new blog: www.foundationmedicine.com/blog/biopharma-innovations
-
Foundation Medicine
@FoundationATCG
#dyk that MTAP loss reporting can vary across NGS vendors? In a study from Sarah Cannon Research Institute, Foundation Medicine’s tissue NGS detected MTAP loss in about 1 out of 10 solid tumors. It’s not a rare biomarker – even though it can be hard to identify accurately.
Foundation Medicine
@FoundationATCG
Explore this new study at the link here: pubmed.ncbi.nlm.nih.gov/41348984/
-
Foundation Medicine
@FoundationATCG
Our team is excited to present two new pieces of research in #breastcancer that show the importance of robust homozygous gene loss reporting in BRCA1/2 and PTEN. Learn more from Foundation Medicine at #sabcs25 - booth 1342: www.foundationmedicine.com/event/sabcs-2025
-
Foundation Medicine
@FoundationATCG
New #research in non-small cell lung cancer reflects a simulated, retrospective analysis of oncology biomarker assays. Read this publication in @OncJournal –academic.oup.com/oncolo/advance-article/doi/10.1093/oncol…
-
Foundation Medicine
@FoundationATCG
Join us at #sabcs25, December 9-12. Visit booth 1342 to learn how Foundation Medicine’s comprehensive genomic testing portfolio can help inform treatment options for advanced breast cancer patients. Learn more: www.foundationmedicine.com/event/sabcs-2025
-
Foundation Medicine
@FoundationATCG
Join us at booth B111, hall 4 at #esmoasia25 for our final booth talks, including sessions around Foundation Medicine’s tissue-based RNA sequencing test, our clonal hematopoiesis algorithm and use cases around AI and precision medicine. Find out more: www.foundationmedicine.com/event/esmo-asia-congress-2025
-
Foundation Medicine
@FoundationATCG
Our #boothtalks series are underway at #esmoasia25! Learn more about Saturday’s sessions below. Click here for more information: www.foundationmedicine.com/event/esmo-asia-congress-2025
-
Foundation Medicine
@FoundationATCG
Announcement ‼️ – 100 approved companion diagnostic indications! Through this historic milestone, we are proud to reaffirm our commitment to transforming lives in cancer and beyond and continuing to help drive a new wave of precision medicine: www.foundationmedicine.com/press-release/100-cdx
-
Foundation Medicine
@FoundationATCG
Attending #esmoasia25? Join us tomorrow as we kick off our “Booth Talks” – booth B111, hall 4. Learn about Friday's programming below. Want to connect with our team? Find the full Booth Talks schedule and more information here: www.foundationmedicine.com/event/esmo-asia-congress-2025
-
Foundation Medicine
@FoundationATCG
New publication – learn more about new research published in @PLOSONE: “Analytical validation of a homologous recombination deficiency signature (HRDsig) in pan-tumor tissue samples.” Click here: journals.plos.org/plosone/article?id=10.1371/journal.pone…
-
Foundation Medicine
@FoundationATCG
Connect with Foundation Medicine at #ash25! Interested in exploring how comprehensive genomic profiling can impact your work in #hematology? Visit booth 1816 or schedule a meeting with us to learn more about our hematologic profiling capabilities: www.foundationmedicine.com/event/biopharma-ash-2025
-
Foundation Medicine
@FoundationATCG
Join us for an industry satellite symposium at #esmoasia25 “From Insights to Outcomes: How Comprehensive Genomic Profiling Redefines Cancer Care.” Learn more below!
Connect with our team at this year’s meeting: www.foundationmedicine.com/event/esmo-asia-congress-2025 -
Foundation Medicine
@FoundationATCG
At #esmoasia25, Foundation Medicine is excited to join industry peers from across the Asia-Pacific region to discuss the latest research & innovations happening in oncology. Visit Foundation Medicine at booth B111, hall 4 to meet with our team. Learn more: www.foundationmedicine.com/event/esmo-asia-congress-2025
-
Foundation Medicine
@FoundationATCG
#newresearch – “Intratumoral heterogeneity and immunotherapy resistance: clinical implications” Read more: linkinghub.elsevier.com/retrieve/pii/S0923-7534(25)06217-9
-
Foundation Medicine
@FoundationATCG
A recent investigator-initiated study utilized Foundation Medicine’s tissue- & blood-based comprehensive genomic profiling to identify actionable alterations: “Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial”: www.nature.com/articles/s41591-025-03918-x
Foundation Medicine
@FoundationATCG
Results from this multicenter, randomized, open-label phase 2 study demonstrated that subjects who received tailored treatment over standard of care achieved significantly higher overall response rate and improved progression-free survival. More here: www.nature.com/articles/s41591-025-03918-x
-
Foundation Medicine
@FoundationATCG
We are proud to support @LUNGevity's Cancer Precision Medicine Commons to further raise awareness and education around biomarker testing this #cancerbiomarkerday. Click here for more information and resources: cancerprecisionmedicinecommons.org/resources /
-
Foundation Medicine
@FoundationATCG
Our latest webinar with @PrecMedOnline will focus on the evolving landscape of biomarker-genomic treatment for advanced non-small cell #lungcancer (NSCLC). Join us for this expert-led conversation – register today: event.on24.com/wcc/r/5109637/9DE5F51ABFFE8EF4A95723B1D27B…
-
Foundation Medicine
@FoundationATCG
Explore #newresearch🔬 published in @CRC_AACR: “Succinate dehydrogenase B (SDHB) overexpression with enzymatic dysfunction defines a distinct subtype of undifferentiated pleomorphic sarcoma.” Click here for more: aacrjournals.org/cancerrescommun/article/5/10/1934/767065…
-
Foundation Medicine
@FoundationATCG
Foundation Medicine will be at #ampath25 at booth 320! Schedule time to explore solutions that help deliver deeper #genomic insights and more actionable results: www.foundationmedicine.com/event/amp-2025
Foundation Medicine
@FoundationATCG
Heading to #ampath25 November 11-15? Stop by booth 320 to meet our team and see how Foundation Medicine maximizes tissue biopsies with our low QNS rate. Discover what makes our portfolio different! www.foundationmedicine.com/event/amp-2025
Foundation Medicine
@FoundationATCG
Let’s connect at #amp25! We’ll be discussing our new molecular residual disease (MRD) test for research use and other #precisionmedicine innovations at our corporate workshop and booth 320. Schedule time to meet: www.foundationmedicine.com/event/amp-2025
-
Foundation Medicine
@FoundationATCG
Honoring #lungcancer Awareness Month this November and all those within our community and beyond who have been impacted by the disease. Follow us this month for patient stories, resources and more.
-
Foundation Medicine
@FoundationATCG
At #islb25, our team is proud to present new #research, including the oral presentation “Circulating tumor DNA (ctDNA) detectable in buffy coat DNA (bcDNA) can resemble clonal hematopoiesis with potential biological and clinical implications”
Foundation Medicine
@FoundationATCG
Attending the meeting? Visit us at booth 201 or schedule time with our team: www.foundationmedicine.com/event/islb-2025
-
Foundation Medicine
@FoundationATCG
We’re proud to collaborate with Manifold, the AI data platform for life sciences, to bring enhanced analytics capabilities to our FoundationInsights® platform. Learn more: www.foundationmedicine.com/press-release/manifold-partner…
-
Foundation Medicine
@FoundationATCG
What is a companion diagnostic? How does it work? And what are the benefits? Explore more in our latest Precision Points Blog “Companion Diagnostic Explained”: www.foundationmedicine.com/blog/companion-diagnostics-exp…
-
Foundation Medicine
@FoundationATCG
Join us at #islb25 – November 1-3. Meet our team at booth 201 to learn more about how Foundation Medicine and our FDA-approved #liquidbiopsy test provides information that can help physicians determine treatment paths for their patients with advanced cancer.
Foundation Medicine
@FoundationATCG
Schedule time with our team at #islb25 and learn more at the link here: www.foundationmedicine.com/event/islb-2025
-
Foundation Medicine
@FoundationATCG
Hear from experts through a series of webinars on the importance of biomarker testing, specifically comprehensive genomic profiling, in #breastcancer treatment and care. Explore our “Pioneers in Practice – Breast Series” at the link here: www.youtube.com/playlist?list=PLdvW0JcZhM-KobbvewOi4kDKPL…
-
Foundation Medicine
@FoundationATCG
#newresearch publication in @NatureGenet – “Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers.” Learn more: www.nature.com/articles/s41588-025-02371-3
-
Foundation Medicine
@FoundationATCG
#newresearch being presented at #esmo25 features data utilizing Foundation Medicine’s tissue-based RNA sequencing test in #breastcancer
Foundation Medicine
@FoundationATCG
Visit us at booth 3028 in Hall 3.2! Discover more and connect with our team at this year’s meeting: www.foundationmedicine.com/event/esmo-2025
Foundation Medicine
@FoundationATCG
Learn more about the research being presented: www.foundationmedicine.com/press-release/esmo-2025
-
Foundation Medicine
@FoundationATCG
#esmo25 research features new data leveraging the research use version of Foundation Medicine’s tissue-free treatment response monitoring assay:“Circulating tumor DNA dynamics correlate with response to carboplatin with or without nivolumab in metastatic TNBC.”
Foundation Medicine
@FoundationATCG
Connect with the Foundation Medicine team and learn more about our presence at #esmo25 at the link here: www.foundationmedicine.com/event/esmo-2025
-
Foundation Medicine
@FoundationATCG
Explore the latest in research involving Foundation Medicine’s homologous recombination deficiency signature (HRDsig) across key disease areas, including ovarian, lung and gastric cancers.
Foundation Medicine
@FoundationATCG
Attending #esmo25? Visit our team at booth 3028, Hall 3.2, and click here to learn more: www.foundationmedicine.com/event/esmo-2025
Foundation Medicine
@FoundationATCG
Explore the research being presented: www.foundationmedicine.com/press-release/esmo-2025
-
Foundation Medicine
@FoundationATCG
#newresearch being presented as an oral presentation at #esmo25 includes a new study aimed at characterizing the demographic and genomic differences between patients with MET+ and MET- papillary renal cell carcinoma
Foundation Medicine
@FoundationATCG
Hear more from our team, visit booth 3028 in hall 3.2: www.foundationmedicine.com/event/esmo-2025
Foundation Medicine
@FoundationATCG
More about Foundation Medicine's research: www.foundationmedicine.com/press-release/esmo-2025
-
Foundation Medicine
@FoundationATCG
Our team is excited to attend #targets25 in Boston next week! Visit booth 216 to learn more about Foundation Medicine’s high-quality portfolio of precision diagnostic solutions. Scroll through for more about our research being presented. Connect with us: www.foundationmedicine.com/event/aacr-nci-eortc-2025
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is excited to join the oncology community at #esmo25! Click to learn more about the research being presented: www.foundationmedicine.com/press-release/esmo-2025
-
Foundation Medicine
@FoundationATCG
Visit booth 3028 in Hall 3.2 at #esmo25 for discussions around the latest advancements in cancer care. Join us for our #boothtalk series and connect with Foundation Medicine experts on our latest innovations in precision diagnostics: www.foundationmedicine.com/event/esmo-2025
-
Foundation Medicine
@FoundationATCG
Join Foundation Medicine and @PrecMedOnline for an expert presentation on how comprehensive genomic profiling can help provide insights to inform treatment decisions in HR+ HER2- advanced breast cancer. Register for the webinar today: event.on24.com/wcc/r/5068177/6A4CAA8BEDDCA69C01972A33DB67…
-
Foundation Medicine
@FoundationATCG
#newpublication in Cancer Research Communications: “Clinical validity of FoundationOne®Liquid CDx for detection of BRAF V600E in colorectal cancer.”
*FDA-approved; Rx only; doesn't guarantee treatment match or that all alterations will be found www.f1lcdxlabel.com.
Foundation Medicine
@FoundationATCG
Read the publication here: aacrjournals.org/cancerrescommun/article/5/9/1566/764558/…
-
Foundation Medicine
@FoundationATCG
Foundation Medicine will be at #esmo25! Visit us at booth 3028, located in Hall 3.2 to meet with our team. Learn more about our activities at this year’s meeting and schedule a time with us: www.foundationmedicine.com/event/esmo-2025
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is committed to advancing access to high-quality biomarker tests to deliver on the value of precision medicine. We are proud to award our 2025 IDEA Program grant to My Style Matters, Inc. & H.Y.P.E. to Empower, Inc. Learn more: www.foundationmedicine.com/press-release/idea-program-2025
-
Foundation Medicine
@FoundationATCG
Proud to recognize #breastcancerawarenessmonth this October and to help support greater education and information around the disease.
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is proud to support the National Organization for Rare Disorders’ (@RareDiseases) Rare Cancer Coalition this #rarecancerday. Let’s raise awareness and stand with the rare cancer community. Learn more: rarediseases.org/get-involved/rare-cancer-coalition/
-
Foundation Medicine
@FoundationATCG
Our Knowledge Center provides educational and informational resources on the latest in precision oncology. Check out our latest content, including a blog and podcast on “Unlocking the Future of Breast Cancer Treatment.” Click here to explore more: www.foundationmedicine.com/knowledge-center
-
Foundation Medicine
@FoundationATCG
Connect with Foundation Medicine at Biomarkers & Precision Medicine in London! Schedule a meeting to explore the latest biomarker-driven innovations: www.foundationmedicine.com/event/foundation-medicine-biom…
-
Foundation Medicine
@FoundationATCG
High-quality research helps shapes our understanding of cancer and advances precision medicine for all. Our #newresearch demonstrates the role Foundation Medicine’s tests & proprietary biomarkers play in transforming approaches to cancer care. #worldcancerresearchday
Foundation Medicine
@FoundationATCG
Highlights include new insights on circulating tumor DNA (ctDNA) tumor fraction, our homologous recombination deficiency signature (HRDsig) & more. Explore more on our Precision Points Blog: www.foundationmedicine.com/blog/q3-research-recap-blog
-
Foundation Medicine
@FoundationATCG
Excited to share the launch of our new tissue-informed whole genome sequencing molecular residual disease (Tissue-informed #wgs #mrd) test for research use in early to late-stage cancers through our FlexOMx™ Lab. Read more: www.foundationmedicine.com/press-release/mrd-test-ruo
-
Foundation Medicine
@FoundationATCG
For prostate cancer treatment, comprehensive genomic profiling (CGP) can help provide healthcare providers with the information needed to determine treatment options for their patients. For more information on the importance of CGP, click here: www.youtube.com/watch?v=biHXCEar5pA
-
Foundation Medicine
@FoundationATCG
Join Foundation Medicine at the World CB & CDx Summit in Boston! Our programming at this conference will bring together industry leaders for discussions on the latest advancements and innovations in precision medicine. Explore more & connect with our team: www.foundationmedicine.com/event/foundation-medicine-worl…
-
Foundation Medicine
@FoundationATCG
#newresearch - “Analytical validation (accuracy, reproducibility, limit of detection) and gene expression analysis of FoundationOneRNA assay for fusion detection in 189 clinical tumor specimens.” Read the publication: journals.plos.org/plosone/article?id=10.1371/journal.pone…
Foundation Medicine
@FoundationATCG
*FoundationOne RNA: LDT; Rx only; advanced cancer; doesn't guarantee treatment match.
-
Foundation Medicine
@FoundationATCG
#researchspotlight – “Transcriptomic-based classification identifies prognostic subtypes and therapeutic strategies in soft tissue sarcomas.” Click to read: www.mdpi.com/2072-6694/17/17/2861
Foundation Medicine
@FoundationATCG
This new publication in @Cancers_MDPI utilized Foundation Medicine’s tissue-based DNA and RNA sequencing tests. Learn more: www.mdpi.com/2072-6694/17/17/2861
-
Foundation Medicine
@FoundationATCG
For John, biomarker testing provided his healthcare team with insights and information to help plan treatments for metastatic #prostatecancer.
This media couldn't be displayed. See it on the original post.
Foundation Medicine
@FoundationATCG
Hear more from John: www.youtube.com/watch?v=GP1aqVV8d3s&list=PLdvW0JcZhM-LtjE…
Foundation Medicine
@FoundationATCG
More information on the advancements in prostate cancer at our blog here: www.foundationmedicine.com/blog/ushering-new-era-personal…
-
Foundation Medicine
@FoundationATCG
#newresearch showcases the value of Foundation Medicine’s comprehensive genomic profiling in simplifying the diagnostic workup of advanced epithelial and hematologic malignancies. 🔬Explore more insights and read the full publication: www.jmdjournal.org/article/S1525-1578(25)00167-9/fulltext
-
Foundation Medicine
@FoundationATCG
September is Childhood, Ovarian, Blood and Prostate Cancer Awareness Month dedicated to spreading education and awareness in these disease areas. Follow us for more content this month as we share key facts, educational information, resources and more.
-
Foundation Medicine
@FoundationATCG
Don’t miss our new letter in Clinical Cancer Research investigating a recent report about the reliability of detecting CH-derived BRCA1/2 variants using liquid biopsy: aacrjournals.org/clincancerres/article/31/16/3594/763976/…
-
Foundation Medicine
@FoundationATCG
For Bethany, Foundation Medicine’s biomarker tests helped provide an action plan for her and her care team to follow when her cancer progressed. Hear more about Bethany’s experience with #biomarkertesting. Click here for more: youtu.be/SjQlqlrN-r8
-
Foundation Medicine
@FoundationATCG
Learn more about how Foundation Medicine can partner with care teams through Epic integration. Heading to Epic UGM 2025? Our team would love the chance to meet with you there: www.foundationmedicine.com/event/epic-2025
-
Foundation Medicine
@FoundationATCG
#icymi data from the pan-tumor PARP inhibitor trial LODESTAR was reanalyzed using Foundation Medicine’s homologous recombination deficiency signature (HRDsig).
Foundation Medicine
@FoundationATCG
This pan-tumor HRD biomarker predicted benefit from rucaparib better than a homologous recombination repair (HRR) alteration alone. Check out the paper to learn more about this functional HRD readout: ascopubs.org/doi/10.1200/PO-25-00090
-
Foundation Medicine
@FoundationATCG
This #worldlungcancerday, we are proud to support patients like Greg and organizations like @ALKPositiveinc on spreading greater awareness of the disease and promoting further research, education and resources for those affected.
This media couldn't be displayed. See it on the original post.
Foundation Medicine
@FoundationATCG
More insights on the advancements in lung cancer diagnostics and treatments here: www.foundationmedicine.com/blog/mia-progress-nsclc
-
Foundation Medicine
@FoundationATCG
New Publication❗- “LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes.” Read the research here: ascopubs.org/doi/10.1200/PO-25-00090
-
Foundation Medicine
@FoundationATCG
When Summer was diagnosed with stage IV lung cancer, #biomarker #testing provided answers and options that equipped her and her medical team with a treatment plan. More resources and information on Foundation Medicine and biomarker testing: www.foundationmedicine.com/patient
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Visit our Precision Points blog to explore the latest on recent advances in precision medicine and the resources available to ensure patients can access high-quality tests that can help inform their treatment. 🔬 Click here to explore: www.foundationmedicine.com/blog
-
Foundation Medicine
@FoundationATCG
#newresearch in @OncJournal: “Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer.” Click here for the full publication: academic.oup.com/oncolo/article/30/6/oyaf159/8171902
-
Foundation Medicine
@FoundationATCG
July is UV Awareness Month, a time dedicated to share resources and education around the dangers of ultraviolet (UV) radiation. UV exposure involves risks, including sunburns and skin cancer. Read our post for some key facts.
-
Foundation Medicine
@FoundationATCG
#newresearch in @Nature_NPJ precision oncology: “Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction.” Explore the publication here: idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat…
-
Foundation Medicine
@FoundationATCG
We’re still thinking back about our time at #asco25! The meeting always provides some time to reflect upon and learn more about the latest advancements in oncology. We asked some of our team members what gives them hope about the future of cancer care. Hear what they had to say.
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Utilizing Foundation Medicine’s tissue-free treatment response monitoring assay, new #research demonstrated the clinical value of treatment response monitoring by ctDNA in real-world patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
This year, Foundation Medicine celebrates our 15th anniversary. Look back at the milestones we’ve achieved in a new blog from our CEO Dan Malarek: www.foundationmedicine.com/blog/15-year-anniversary
-
Foundation Medicine
@FoundationATCG
Honored to have joined the oncology community and to have been part of #asco25. Our team had so many great interactions and conversations last week in Chicago. #wearefmi #missnotone
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is thrilled to be attending #eha2025 in Milan, Italy, June 12-15. Excited to share what’s ahead in hematology diagnostics & how our latest advancements can support your research and drug development programs.
Foundation Medicine
@FoundationATCG
Stop by our booth F.02 or schedule a meeting with our experts to learn how we can help move your heme program forward: www.foundationmedicine.com/event/foundation-medicine-euro…
#eha2025 -
Foundation Medicine
@FoundationATCG
We’re honored to be a part of all the innovative research being presented at #asco25, including an oral presentation in #prostatecancer & our tissue-free response monitoring. Hear from Dr. Lincoln Pasquina, Director, Clinical Development at Foundation Medicine on our research.
Foundation Medicine
@FoundationATCG
Explore and learn more at the link here: www.foundationmedicine.com/event/asco-2025
-
Foundation Medicine
@FoundationATCG
New research being presented at #asco25 showcases new innovations in #breastcancer treatment and care. Hear some quick highlights from Dr. Julia Quintanilha, Senior Scientist at Foundation Medicine. Learn more: www.foundationmedicine.com/event/asco-2025
-
Foundation Medicine
@FoundationATCG
New study at #asco25 analyzes the genomic landscape of NPM1 genomic alterations in acute myeloid leukemia. Find out more and meet with our team – Booth 27021: www.foundationmedicine.com/event/asco-2025
-
Foundation Medicine
@FoundationATCG
Learn more about the latest in non-small cell #lungcancer (NSCLC) with two new presentations at #asco25. Connect with us at booth 27021: www.foundationmedicine.com/event/asco-2025
-
Foundation Medicine
@FoundationATCG
We’re in Chicago for #asco25 – come visit us at booth 27021 to learn more about Foundation Medicine. Schedule a meeting with us today: www.foundationmedicine.com/event/asco-2025 #missnotone
-
Foundation Medicine
@FoundationATCG
Two pieces of research at #asco25 feature new data on the detection of clonal hematopoiesis in #pancreaticcancer and #ovariancancer using liquid biopsies. Discover more & connect with our team – Booth 27021: www.foundationmedicine.com/event/asco-2025
-
Foundation Medicine
@FoundationATCG
Connect with Foundation Medicine in Chicago! Stop by Booth 27021 to learn more about our high-quality tests and work in precision cancer care: www.foundationmedicine.com/event/asco-2025 #asco25
-
Foundation Medicine
@FoundationATCG
Announcing our new, expanded immunohistochemistry (IHC) test offerings to include MET IHC testing as an add-on to Foundation Medicine’s comprehensive genomic profiling (CGP) test orders for patients with non-squamous non-small cell lung cancer: www.foundationmedicine.com/press-release/met-ihc-testing
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is excited to join patients, advocates, healthcare providers and biopharmaceutical partners at #asco25. With 15+ new pieces of research being presented, we look forward to joining the oncology community in Chicago. Learn more: www.foundationmedicine.com/press-release/asco-2025
-
Foundation Medicine
@FoundationATCG
Our FlexOMx Lab™ offers a suite of new, flexible lab services to continue our support of biopharma partners and their research and discovery needs. Check out the lab and its capabilities and offerings in our latest blog: www.foundationmedicine.com/blog/meet-flexomx-lab
-
Foundation Medicine
@FoundationATCG
Excited to sponsor this year’s #statatasco: The Future of Cancer Treatment event, featuring a discussion w/ Foundation Medicine CEO, Dan Malarek. Join us for an evening of conversation around the latest advancements in oncology care. Learn more: www.statnews.com/event/stat-at-asco-2025/
-
Foundation Medicine
@FoundationATCG
We’re getting ready for #asco25! Can’t wait to connect on the latest innovations and research in oncology care. Heading to Chicago? Come meet with our team at Booth 27021 or schedule a time to meet with us: www.foundationmedicine.com/event/asco-2025
-
Foundation Medicine
@FoundationATCG
#aacr25 research – a machine learning model was used to predict tumor-somatic, germline or clonal hematopoiesis (CH) status for short variants detected by liquid biopsy. This model performed well even for variants at low variant allele frequency & in frequent CH genes like TP53
Foundation Medicine
@FoundationATCG
Read this research & more: www.abstractsonline.com/pp8/
-
Foundation Medicine
@FoundationATCG
Research at #aacr25 conducted a post-hoc analysis of a phase 3 trial that explored androgen receptor alterations and potential association with the efficacy of a first-line PARPi + hormonal combination therapy in metastatic castration resistant prostate cancer.
Foundation Medicine
@FoundationATCG
Click here to learn more: www.abstractsonline.com/pp8/
-
Foundation Medicine
@FoundationATCG
Join us at the 2025 Community Oncology Conference - April 29-30. Meet with us to learn more about our high-quality tests and how we support community oncologists and their teams through precision medicine and genomic insights: www.foundationmedicine.com/event/coa-2025 #coa2025
-
Foundation Medicine
@FoundationATCG
Join us at the 2025 AUA Annual Meeting - April 26-29. Meet our team at booth 1805 to learn more about our high-quality tests and how we support the urology community through precision medicine and genomic insights: www.foundationmedicine.com/event/aua-2025 #aua25
-
Foundation Medicine
@FoundationATCG
For more than a decade, we have worked w/ leading research institutions, healthcare providers, scientists & biopharmaceutical partners to publish peer-reviewed studies that validate our portfolio of high-quality comprehensive genomic profiling tests & help advance cancer care.
Foundation Medicine
@FoundationATCG
Click the link to read our latest blog and explore insights from our 1,000+ peer-reviewed publications: www.foundationmedicine.com/blog/1000-publications
-
Foundation Medicine
@FoundationATCG
Our team will be at Epic XGM 2025! Learn more about Foundation Medicine’s integration capabilities & customer success with Epic Aura.
Foundation Medicine
@FoundationATCG
Request a time to connect and learn more here: www.foundationmedicine.com/resource/epic-form
-
Foundation Medicine
@FoundationATCG
Visit our experts at #aacr25 on April 25-30 to learn more about Foundation Medicine’s latest developments. Visit us at booth 2431 or schedule a meeting here: www.foundationmedicine.com/event/aacr-2025
-
Foundation Medicine
@FoundationATCG
Our Biopharma Partnerships team is excited to join industry leaders at this year’s 15 Annual World CB & CDx Summit Europe. Heading to London? Register for an opportunity to join Foundation Medicine's thought leadership engager or join us for our sponsored plenary session.
Foundation Medicine
@FoundationATCG
Learn more here: cdx-europe.com/full-event-guide/
-
Foundation Medicine
@FoundationATCG
Join us at #uscap2025 in Boston! Come learn more about Foundation Medicine and our portfolio of tests and services. Come say hi at booth 900 and find time to meet w/ our team or schedule a visit of our HQ in Boston: www.foundationmedicine.com/event/uscap-2025
-
Foundation Medicine
@FoundationATCG
Join us at the #mbcc25 – March 6-9. Meet our team at booth 31 to explore how Foundation Medicine’s comprehensive genomic profiling (CGP) test portfolio can help inform treatment options for your patients with advanced breast cancer. Learn more: www.foundationmedicine.com/event/miamibreast2025
-
Foundation Medicine
@FoundationATCG
#newresearch in @jitcancer - "Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types." Learn more: jitc.bmj.com/content/13/2/e010311.long
-
Foundation Medicine
@FoundationATCG
Partnership Announcement – our collaboration w/ @SumitomoPharma will work to develop a companion diagnostic utilizing Foundation Medicine's #hematology platform to identify acute leukemia patients w/ a KMT2A rearrangement or NPM1 mutations.
Foundation Medicine
@FoundationATCG
Learn more: www.foundationmedicine.com/press-release/sumitomo-pharma-…
-
Foundation Medicine
@FoundationATCG
Being presented at #gu25 - new research on homologous recombination deficiency signature genomic landscape in penile squamous carcinoma, prostate & bladder cancer & new findings around detection of copy number losses in liquid biopsy utilizing circulating tumor DNA tumor fraction
Foundation Medicine
@FoundationATCG
Explore this #research and more at the link here: meetings.asco.org/abstracts-presentations/search?query=*&…
Foundation Medicine
@FoundationATCG
Visit Foundation Medicine at booth 11: www.foundationmedicine.com/event/asco-gu-2025
-
Foundation Medicine
@FoundationATCG
Studies being presented at #gu25 include insights around how variant origin prediction (VOP) algorithm distinguishes clonal hematopoiesis (CH) from tumor variants & how equal depth sequencing of white blood cells (WBC) reveals frequent CH confounders in clinically relevant genes
Foundation Medicine
@FoundationATCG
Learn about these abstracts and other research being presented: meetings.asco.org/abstracts-presentations/search?query=*&…
Foundation Medicine
@FoundationATCG
Stop by booth 11 - click here to learn more: www.foundationmedicine.com/event/asco-gu-2025
-
Foundation Medicine reposted
Journal for ImmunoTherapy of Cancer
@jitcancer
New #jitc article: Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types jitc.bmj.com/content/13/2/e010311 @RyonGraf @FoundationATCG
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is headed to the Liquid Biopsy for Precision Oncology Summit, February
18-20 in San Diego! Join us as we explore the latest in precision oncology and connect with
industry leaders.
Foundation Medicine
@FoundationATCG
Be sure to attend our plenary session and workshop to uncover expert insights or stop by our booth to connect. See you in San Diego! Learn more: lbx-summit.com
-
Foundation Medicine
@FoundationATCG
Understanding the genomic drivers of #pediatric tumors can play a key role in treatment planning. Recent advancements in the treatment of pediatric low-grade glioma, the most common form of #childhood #brain tumor, have offered new #precisionmedicine options for patients
Foundation Medicine
@FoundationATCG
More insights in a new #blog from our Chief Medical Officer, Dr. Mia Levy: www.foundationmedicine.com/blog/precision-medicine-childh…
-
Foundation Medicine
@FoundationATCG
We're excited to participate in #gu25! Meet our team and learn about our latest research and how our comprehensive genomic portfolio of tests and biomarkers help drive patient care. Learn more & schedule a meeting: www.foundationmedicine.com/event/asco-gu-2025
-
Foundation Medicine
@FoundationATCG
Excited to announce the launch of two new #germline tests in the United States offered through a partnership with @FulgentGenetics.
Foundation Medicine
@FoundationATCG
These germline tests identify genetic variants associated with hereditary cancers and can be used by healthcare providers to understand underlying risks for patients and their families. Learn more: www.foundationmedicine.com/press-release/hereditary-germl…
-
Foundation Medicine
@FoundationATCG
Looking forward to the Friends of Cancer Research meeting, “Advancing the Future of Diagnostics and Regulatory Innovations”, and a panel discussion featuring Foundation Medicine’s Elizabeth Mansfield, Vice President, Regulatory Policy
Foundation Medicine
@FoundationATCG
To register and learn more about the meeting, please click the link here: friendsofcancerresearch.org/event/advancing-the-future-of…
-
Foundation Medicine
@FoundationATCG
We are honored to have been a part of 3 pieces of research that received merit awards at #gi25. Congratulations to the first authors of each of these pieces of research! Scroll through below for each abstract title. Full abstracts & more here: meetings.asco.org/abstracts-presentations/search?query=*&…
Foundation Medicine
@FoundationATCG
More on the award recipients: www.conquer.org/news/conquer-cancer-announces-2025-gastro…
Connect with Foundation Medicine at the meeting - click here to learn more: www.foundationmedicine.com/asco-gi-2025 -
Foundation Medicine
@FoundationATCG
Studies being presented at #gi25 feature new research around the TP53 Y220C mutation genomic landscape in #colorectal and #pancreatic #cancer. Explore these abstracts and more at the link here: meetings.asco.org/abstracts-presentations/search?q=TP53&f…
Foundation Medicine
@FoundationATCG
Visit Foundation Medicine at Booth 80: www.foundationmedicine.com/asco-gi-2025
-
Foundation Medicine
@FoundationATCG
#gi25 highlights include research on: 🧬amplification ratio landscape of gene copy number amplifications in GE cancer (ERBB2, EGFR & MET);🔬evaluating concordance between liquid & tissue biopsies in CRC and the correlation of clinical factors associated w/ ctDNA tumor fraction
Foundation Medicine
@FoundationATCG
Explore these abstracts and more research being presented: meetings.asco.org/abstracts-presentations/search?query=*&…
Foundation Medicine
@FoundationATCG
Attending the meeting? Stop by booth 80 - click here to learn more: www.foundationmedicine.com/asco-gi-2025
-
Foundation Medicine
@FoundationATCG
FDA Approval Announcement – We’re proud to share that our tissue-based companion diagnostic test has been approved to support the identification of therapeutic options for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma.
Foundation Medicine
@FoundationATCG
This approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients. Read more: www.foundationmedicine.com/press-release/fda-approval-fou…
*Rx only; advanced cancer; doesn't guarantee treatment match, www.f1cdxlabel.com
Foundation Medicine
@FoundationATCG
-
Foundation Medicine
@FoundationATCG
Heading to #gi25? Stop by Booth 80 to learn more about our portfolio of comprehensive genomic tests. Click the 🔗 to explore our latest research or to schedule a time w/ us at the meeting: www.foundationmedicine.com/asco-gi-2025
-
Foundation Medicine
@FoundationATCG
#icymi - our 2024 provided many successes in approved companion diagnostic indications, biomarker detection, offerings in hematological cancer & clinical trial advancement.
Foundation Medicine
@FoundationATCG
More reflections on the last year and thoughts on what’s ahead for Foundation Medicine in a new blog from Chief Biopharma Business Officer, Troy Schurr: www.foundationmedicine.com/blog/progress-biopharma-partne…
-
Foundation Medicine
@FoundationATCG
We are excited to share that Foundation Medicine's Chief Executive Officer, Dan Malarek, will be part of this year's Endpoints at #jpm25 event. Join us and fellow oncology leaders for the session, “Priorities in oncology R&D.”
Foundation Medicine
@FoundationATCG
Learn more about this event and register at the link here: events.endpts.com/jpm25/6976397
-
Foundation Medicine
@FoundationATCG
Cheers to a new year! Looking forward to a great 2025 ahead.
-
Foundation Medicine
@FoundationATCG
Our 2024 provided many successes in ✅ approved companion diagnostic indications, 🧬biomarker detection, 🩸offerings in hematological cancer &
🔬clinical trial advancement. We look forward to continuing to deliver value and innovation to our biopharmaceutical partners in 2025.
Foundation Medicine
@FoundationATCG
More reflections on the last year and thoughts on what’s ahead for Foundation Medicine in a new blog from Chief Biopharma Business Officer Troy Schurr: www.foundationmedicine.com/blog/progress-biopharma-partne…
-
Foundation Medicine
@FoundationATCG
Grateful for all those within our communities - our patients, partners, healthcare providers and beyond. Wishing everyone a very happy holiday season!
-
Foundation Medicine
@FoundationATCG
“Over 60% of patients will have at least one of these genomic alterations [AKT1/PIK3CA/PTEN/ESR1] when tested in the first-line setting.” – Dr. Mia Levy, Chief Medical Officer at Foundation Medicine
Foundation Medicine
@FoundationATCG
Hear more from Dr. Levy in a new Foundation Frontiers discussion that explores updates to the treatment landscape for hormone receptor-positive, HER2-negative recurrent, metastatic #breastcancer and the role of #biomarkertesting
Watch now: www.youtube.com/watch?v=eJv7VRTARJc -
Foundation Medicine
@FoundationATCG
Collaborations across the oncology landscape help drive further education and access to precision medicines for those with unmet needs. We are proud to announce we have awarded two grants in support of addressing disparities in #biomarker testing for #breast & #prostate cancer.
Foundation Medicine
@FoundationATCG
We look forward to seeing all of the great progress & work stemming from these initiatives from grant recipients @LivingBeyondBC, @KimmelCancerCtr, Patient Advocacy Foundation & @ZEROCancer. Learn more: www.foundationmedicine.com/press-release/2024-grant-recip…
-
Foundation Medicine
@FoundationATCG
Join us at #sabcs24 - December 10-13. Meet our team at booth 1149 to explore how Foundation Medicine’s comprehensive genomic profiling (CGP) test portfolio can help inform treatment options for your advanced breast cancer patients. Learn more: www.foundationmedicine.com/event/sabcs-2024
-
Foundation Medicine
@FoundationATCG
Connect w/ us at #ash24! Interested in exploring how comprehensive genomic profiling can impact your work in #hematology? Visit booth 2604 or schedule a meeting w/ us to learn more about our hematologic test offerings & solutions: www.foundationmedicine.com/event/ash-2024
-
Foundation Medicine
@FoundationATCG
New #publication – “Clinical value of comprehensive genomic profiling on clinical trial enrollment for patients with advanced solid tumors,” read more: academic.oup.com/oncolo/advance-article/doi/10.1093/oncol…
-
Foundation Medicine
@FoundationATCG
With the approval of new #targetedtherapies in the first-line setting for hormone receptor-positive, HER2-negative recurrent, metastatic #breastcancer, the treatment landscape for advanced breast cancer patients is evolving.
Foundation Medicine
@FoundationATCG
In a new Foundation Frontiers video, Dr. Mia Levy, Foundation Medicine’s chief medical officer, provides an update on the new #targetedtherapy options for advanced breast cancer and the role of #comprehensivegenomicprofiling. Watch on-demand now: www.youtube.com/watch?v=eJv7VRTARJc
-
Foundation Medicine
@FoundationATCG
#announcement - our blood-based, comprehensive genomic profiling (CGP) test has been approved by the FDA as a companion diagnostic for a targeted treatment for patients with MET Exon 14 skipping alterations in non-small cell lung cancer.
Foundation Medicine
@FoundationATCG
With this approval, our blood-based CGP test is the first FDA-approved companion diagnostic to identify patients who may be eligible for this specific targeted treatment. Learn more: www.foundationmedicine.com/press-release/fda-approval-fou…
-
Foundation Medicine
@FoundationATCG
#newpublication published in @Nature – “CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.” Explore more: www.nature.com/articles/s41586-024-07943-7
-
Foundation Medicine
@FoundationATCG
Join us at #islb24 – November 23-25. Meet our team at booth 302 to learn more about Foundation Medicine and how we provide information that can help physicians determine treatment paths for their patients with advanced cancer.
Foundation Medicine
@FoundationATCG
Schedule time with our team at #islb24 and learn more at the link here: www.foundationmedicine.com/event/islb-2024
-
Foundation Medicine
@FoundationATCG
"No patient is the same, and now, more than ever, patients with advanced disease have many personalized care paths to consider when facing a new diagnosis or progression of their cancer." New #blog on #breastcancer by Chief Medical Officer, Dr. Mia Levy: www.foundationmedicine.com/blog/treatment-advanced-breast…
-
Foundation Medicine
@FoundationATCG
Today we recognize Veterans Day. We’re proud to support all veterans within our community and honor their service and dedication. Hear more from Van, lead of our employee resource network (ERN), FMI Vets, on what the ERN and Veterans Day means to him. #wearefmi
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Join us at the #ampath24 – November 19-23. Meet our team at booth 1324 to learn more about Foundation Medicine, why our portfolio is different, and how we maximize your patient’s tissue biopsies to provide greater genomic insights.
Foundation Medicine
@FoundationATCG
Click through above to review our programming & activities at this year’s meeting and schedule time with our team at the link here: www.foundationmedicine.com/event/amp-2024
-
Foundation Medicine
@FoundationATCG
November is #lungcancer Awareness Month. We are honored to support the lung cancer community in helping to spread awareness and education around this disease.
-
Foundation Medicine
@FoundationATCG
#newresearch in @OncJournal – “Real-world pan-tumor comprehensive genomic profiling sample adequacy and success rates in tissue and liquid specimens.” Click to read more at the link here: academic.oup.com/oncolo/advance-article/doi/10.1093/oncol…
-
Foundation Medicine
@FoundationATCG
Today we recognize Metastatic Breast Cancer Awareness Day. Proud to support @LivingBeyondBC & the resources they provide for the metastatic breast cancer community. For more on metastatic breast cancer & resources, visit their website at the link here: www.lbbc.org/about-breast-cancer/types-breast-cancer/meta…
-
Foundation Medicine
@FoundationATCG
Announcement ‼️ Our blood-based comprehensive genomic profiling (CGP) test has been approved by the FDA to identify patients for a new, targeted therapy for hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Foundation Medicine
@FoundationATCG
Learn more about the approval at the link here: foundationmedicine.com/press-release/fda-approval-foundat…
-
Foundation Medicine
@FoundationATCG
#breastcancer educational webinars – upcoming sessions will focus on topics such as utilizing tissue versus liquid biopsy comprehensive genomic profiling for patients w/ breast cancer & expert reviews on why PTEN matters in advanced breast cancer.
Foundation Medicine
@FoundationATCG
Join us for one or more of our sessions remaining this month on October 9, 15 & 29 – Register today! Click here: whitehatevents.webex.com/webappng/sites/whitehatevents/we…
-
Foundation Medicine
@FoundationATCG
High-quality diagnostic tests are critical components of precision medicine. Proud to collaborate w/@muhealth as we seek to improve patient access to these tests so that patients & their healthcare providers can receive reliable information to confidently inform treatment options
-
Foundation Medicine
@FoundationATCG
Recognizing #breastcancerawarenessmonth this October. We honor all those who have been impacted by breast cancer and support all efforts to educate and spread awareness of this disease this month and beyond.
-
Foundation Medicine
@FoundationATCG
Join us and @PrecMedOnline next week for a live webinar on circulating tumor DNA (ctDNA) monitoring. Speakers will discuss ctDNA monitoring applications, case studies on ctDNA’s impact in clinical trials & more – click here to register: event.on24.com/wcc/r/4679241/ADABC1F6BCF6D186DACDCCC776E3…
-
Foundation Medicine
@FoundationATCG
#newpublication – “FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.” Read more about this new #research published in @Nature_NPJ, npj Precision Oncology, at the link here: idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nat…
-
Foundation Medicine
@FoundationATCG
Pioneers in Practice - #breastcancerawarenessmonth. This month, experts will lead webinars on topics around somatic versus germline alterations, biomarker testing guidelines, how to optimize the use of liquid biopsy & why PTEN matters in the treatment of advanced breast cancer.
Foundation Medicine
@FoundationATCG
View our full schedule of October programming and register for a webinar at the link below: whitehatevents.webex.com/webappng/sites/whitehatevents/we…
-
Foundation Medicine
@FoundationATCG
Progress in research, advancements in biomarker testing and new targeted treatments are shifting the way that #prostatecancer is treated towards more personalized options of care. Hear more from Chief Medical Officer, Dr. Mia Levy, in our latest blog: www.foundationmedicine.com/blog/ushering-new-era-personal…
-
Foundation Medicine
@FoundationATCG
Miss one of our Pioneers in Practice #webinars? Our #prostatecancer webinars are now available. Hear from experts as they share information & perspectives on biomarker testing guidelines, how to optimize the use of liquid biopsy & how ctDNA tumor fraction can impact patient care.
Foundation Medicine
@FoundationATCG
Click the link below to view all of our September webinars: whitehatcom.com/foundationmedicine
-
Foundation Medicine
@FoundationATCG
New #publication in @OncJournal – “Breadth versus depth: whole transcriptome sequencing has reduced sensitivity for detection of clinically relevant fusions compared to RNA comprehensive genomic profiling”
Foundation Medicine
@FoundationATCG
Click ⬇️ to learn more and read this new piece of research: academic.oup.com/oncolo/advance-article/doi/10.1093/oncol…
-
Foundation Medicine
@FoundationATCG
Honored to continue our relationship with @DeptVetAffairs, National Precision Oncology Program, to provide Veterans with high-quality tumor molecular profiling tests and services.
Foundation Medicine
@FoundationATCG
Our high-quality diagnostic tests being provided to the @DeptVetAffairs accurately identify the genomic mutations driving a patient’s cancer and match a patient to the most effective treatment options, including targeted therapies, immunotherapies or clinical trials.
Foundation Medicine
@FoundationATCG
Click the link below to read more about this news: www.foundationmedicine.com/press-release/second-va-contra…
-
Foundation Medicine
@FoundationATCG
New research in metastatic castration-resistant #prostatecancer showed that patients who have BRCA alterations, particularly homozygous loss of BRCA1/2, were more likely to have favorable outcomes & durable benefits from PARPi treatment compared to other biomarker-specific groups
Foundation Medicine
@FoundationATCG
Patients analyzed were grouped based on specific HRR mutation status or Foundation Medicine’s HRD signature (HRDsig)
Foundation Medicine
@FoundationATCG
Proud to share this new publication this #worldcancerresearchday. Explore this research at the link here: www.foundationmedicine.com/research/spotlight-benefit-par…
-
Foundation Medicine
@FoundationATCG
We are proud to foster an inclusive and diverse environment here at Foundation Medicine, celebrating all the unique cultures and traditions that our colleagues bring with them to work every day. Wishing everyone a happy Hispanic Heritage Month!
-
Foundation Medicine
@FoundationATCG
Join us for a Pioneers in Practice webinar this month to learn more about the latest advancements in prostate cancer treatment and care and how comprehensive genomic profiling (CGP) can be a helpful tool for providers.
Foundation Medicine
@FoundationATCG
Our next session on September 24th will focus on understanding ctDNA tumor fraction and how it can impact patient care. Click the link below to register and learn more: whitehatevents.webex.com/webappng/sites/whitehatevents/we…
-
Foundation Medicine
@FoundationATCG
We are committed to providing quality genomic information and more options in precision medicine to patients now and in the future. Through this commitment stems our approach to further expanding #access and coverage for our tests - coverage counts.
Foundation Medicine
@FoundationATCG
Our new webpage aims to help provide physicians with the latest updates on #coverage so that they are well equipped to continue making informed decisions for each of their patients. Learn more: www.foundationmedicine.com/blog/coverage-counts-new-resou…
-
Foundation Medicine
@FoundationATCG
Proud to see this new #research at #esmo24 being presented as part of the Presidential Symposium III: Eyes to the future. Click the link below to learn more: cslide.ctimeetingtech.com/esmo2024/attendee/confcal/sessi…
-
Foundation Medicine
@FoundationATCG
Excited to present new #data from the phase II CUPISCO study which demonstrated the value of comprehensive genomic profiling (CGP) based molecularly guided therapy in patients w/ newly diagnosed, unfavorable, non-squamous cancer of unknown primary.
Foundation Medicine
@FoundationATCG
Click the 🔗 to learn more about this research being presented at #esmo24: www.foundationmedicine.com/research/esmo-congress-2024-re…
-
Foundation Medicine
@FoundationATCG
A posthoc analysis of S1900A, a sub-study of the Lung-MAP trial, showed that Foundation Medicine’s homologous recombination deficiency signature (HRDsig) was a predictor of progression-free survival & overall survival for rucaparib in this NSCLC population. #esmo24
Foundation Medicine
@FoundationATCG
Explore this research being presented at #esmo24, click here to read more: www.foundationmedicine.com/research/esmo-congress-2024-re…
-
Foundation Medicine
@FoundationATCG
New #data being presented at #esmo24 features research utilizing Foundation Medicine’s homologous recombination deficiency signature (HRDsig) in endometrial cancer. Read through the abstract and study highlights at the link here: www.foundationmedicine.com/research/esmo-congress-2024-re…
-
Foundation Medicine
@FoundationATCG
New research in non-small cell lung cancer sought to describe the genomic & treatment landscape of on & off-target ALK resistance mutations detected by comprehensive genomic profiling (CGP). Click for more details & the results of this #esmo24 data: www.foundationmedicine.com/research/esmo-congress-2024-re…
-
Foundation Medicine
@FoundationATCG
September is dedicated to recognizing and spreading awareness of Childhood, Blood, Ovarian & Prostate Cancers. This month, we honor all of those who have been affected by these types of cancers as we continue our work to transform cancer care.
-
Foundation Medicine
@FoundationATCG
Join us for our NEW Pioneers in Practice #webinar series. Learn from experts throughout the month of September as they share information & perspectives on biomarker testing guidelines, how to optimize the use of liquid biopsy & how ctDNA tumor fraction can impact patient care.
Foundation Medicine
@FoundationATCG
In recognition of #prostatecancerawarenessmonth, our inaugural programming will feature sessions on the value of comprehensive genomic profiling (CGP) in prostate cancer. Click the link below to view all of our webinars and to register for a session: whitehatevents.webex.com/webappng/sites/whitehatevents/we…
-
Foundation Medicine
@FoundationATCG
Join us at #wclc24 - September 7-10. Meet our team at booth 2801 to learn more about the impact that Foundation Medicine’s portfolio of high-quality tests can have in helping guide treatment options for advanced #nsclc patients within oncology practices
Foundation Medicine
@FoundationATCG
Schedule time with our team and learn more at the link here: www.foundationmedicine.com/event/join-foundation-medicine…
#wclc24 -
Foundation Medicine
@FoundationATCG
Proud to announce our collaboration with @Syndax to develop a #companiondiagnostic to identify acute myeloid #leukemia (AML) patients harboring an NPM1 mutation.
Foundation Medicine
@FoundationATCG
As part of the collaboration, Syndax will also support Foundation Medicine’s efforts to pursue regulatory approval of an assay based on the FoundationOne®Heme* platform.
*FoundationOne Heme: LDT; Rx only; advanced cancer; doesn't guarantee treatment match.
Foundation Medicine
@FoundationATCG
Learn more about this announcement at the link below: www.foundationmedicine.com/press-release/syndax-partnership
-
Foundation Medicine
@FoundationATCG
Both our tissue- and liquid-based #genomic profiling tests are now FDA-approved to identify patients with #brca-mutated metastatic castration-resistant #prostatecancer who may benefit from a specific targeted treatment.
Foundation Medicine
@FoundationATCG
Want to learn more about this new FDA approval? Check out our full announcement ⬇️ www.foundationmedicine.com/press-release/fda-approval-cdx…
-
Foundation Medicine
@FoundationATCG
Homologous recombination deficiency (HRD) biomarkers are critical for identifying patients who may benefit from the use of PARP inhibitors and other DNA-damaging cancer drugs.
Foundation Medicine
@FoundationATCG
Using machine learning, a type of artificial intelligence, and genomic data, our team has developed a new HRDsig biomarker to demonstrate how the presence of HRD can deliver crucial insights and inform important treatment decisions for physicians and their patients with cancer.
Foundation Medicine
@FoundationATCG
Click the link here to learn more in a new #blog from our Chief Medical Officer, Dr. Mia Levy: www.foundationmedicine.com/blog/introducing-hrdsig-biomarker
-
Foundation Medicine
@FoundationATCG
We’re excited to collaborate w/ Merus towards developing Foundation Medicine’s #rna platform as a companion diagnostic for treatment options in NRG1 fusion-driven tumors. Learn more: www.foundationmedicine.com/press-release/merus-collaboration
-
Foundation Medicine
@FoundationATCG
Our team is looking forward to joining industry leaders at this year’s 14th Annual World CB & CDx Summit in Boston! Excited to dive into the latest innovations in precision oncology and companion diagnostic development.
Foundation Medicine
@FoundationATCG
Learn more & schedule a time with our team at the link here: www.foundationmedicine.com/event/foundation-medicine-worl…
-
Foundation Medicine
@FoundationATCG
Our 2024 summer internships wrapped up last week. Throughout the summer, interns provided support across our Commercial, Operations, Tech, Engineering and R&D teams, bringing their dedication, passion and hard work to the office each and every day. #wearefmi
-
Foundation Medicine
@FoundationATCG
Are you using liquid biopsy to its potential? Learn from a panel of experts as they share information and perspectives about biomarker testing guidelines and the biomarker ctDNA tumor fraction reported by Foundation Medicine’s liquid biopsy test.
Foundation Medicine
@FoundationATCG
Register today for our Foundation Frontiers webinar on advanced prostate cancer at the link here: info.foundationmedicine.com/foundationfrontiers-prostate
-
Foundation Medicine
@FoundationATCG
#study published in @CCR_AACR shows that Foundation Medicine’s homologous recombination deficiency signature (HRDsig) can offer a new approach to identify patients who may benefit from PARP inhibitors as maintenance therapy (mPARPi), even among patients w/ no BRCA1/2 alterations
Foundation Medicine
@FoundationATCG
Using real-world, de-identified data, researchers compared the effectiveness of mPARPi in real-world practice by BRCA1/2 alteration status and two genomic scar signatures, HRDsig and genomic loss of heterozygosity (gLOH)
Foundation Medicine
@FoundationATCG
Click here to read more about the #research highlights, results & takeaways at the link here: www.foundationmedicine.com/research/research-spotlight-pa…
-
Foundation Medicine
@FoundationATCG
Today we recognize World #lungcancer Day. In our work to transform cancer care, we are committed to spreading awareness and knowledge around lung cancer.
Foundation Medicine
@FoundationATCG
We’re proud to support the lung cancer community and organizations such as @GO2forLungCancr in all of their efforts in research, education and advocacy.
Foundation Medicine
@FoundationATCG
Hear more perspectives and learn about the progress that has been made in #lungcancer diagnosis, treatment and outcomes at the link here: www.foundationmedicine.com/blog/mia-progress-nsclc
-
Foundation Medicine
@FoundationATCG
#research in @TheLancet showcased positive results of CUPISCO, a randomized, precision oncology study designed to prospectively assess the efficacy of molecularly guided therapy in patients w/ unfavorable subsets of cancer-of-unknown-primary. Learn more: www.thelancet.com/journals/lancet/article/PIIS0140-6736(2…
-
Foundation Medicine
@FoundationATCG
Wishing our 2024 summer interns a very happy National Internal Day! Thank you all so much for the hard work and dedication you bring to Foundation Medicine. #wearefmi
-
Foundation Medicine
@FoundationATCG
Our third annual Diversity, Equity and Inclusion (DE&I) report reflects upon the progress we have made in the last year, our reflections on this progress, and our continued efforts to do more within our community and beyond.
Foundation Medicine
@FoundationATCG
In an ever-changing environment, we are committed in our efforts to ensuring Foundation Medicine is a diverse and inclusive place for all. Read the full report: www.foundationmedicine.com/sites/default/files/media/docu…
#wearefmi -
Foundation Medicine
@FoundationATCG
Results from a new study showcase the value of circulating tumor DNA (ctDNA) monitoring as an additional approach to evaluating clinical response to certain treatments for patients with metastatic castration resistant #prostatecancer.
Foundation Medicine
@FoundationATCG
Data indicates that ctDNA tumor fraction can complement prostate-specific antigen (PSA) testing & conventional radiographic assessments while also serving as a strong prognostic factor across time points of treatment. Learn more ⬇️ : www.foundationmedicine.com/research/research-spotlight-pr…
-
Foundation Medicine
@FoundationATCG
Happy 4th of July! Wishing all of our US colleagues, patients and partners a wonderful and safe holiday.
-
Foundation Medicine
@FoundationATCG
Research Spotlight – “Predictive Impact of Tumor Mutational Burden on Real-world Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma”
Foundation Medicine
@FoundationATCG
Read more about this recently published #research at the link here: ascopubs.org/doi/10.1200/PO.23.00640
-
Foundation Medicine
@FoundationATCG
Proud to share that our liquid biopsy test has been approved by the FDA as a companion #diagnostic to help identify patients w/ deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant #prostatecancer who may be appropriate for a specific targeted therapy
Foundation Medicine
@FoundationATCG
This decision follows the approval of our tissue-based test for the same therapy in August 2023. Click ⬇️ to learn more: www.foundationmedicine.com/press-release/fda-approval-fou…
-
Foundation Medicine
@FoundationATCG
Proud to support @LivingBeyondBC on the launch of this campaign and to help increase education and understanding around #biomarker testing. Learn more in the post below.
Living Beyond Breast Cancer
@LivingBeyondBC
We're excited to announce the expansion of the #noonemissed campaign! In partnership with @LUNGevity, we're raising awareness of the crucial role #biomarker testing plays in metastatic breast cancer. Visit the new website to learn more: www.lbbc.org/news/lbbc-and-lungevity-expand-no-one-missed
-
Foundation Medicine
@FoundationATCG
While strides have been made, there is still a lot of work to be done in the fight against racial & systemic injustices faced by Black Americans. Within our workplace, communities & beyond, we can all contribute to standing up for justice & speaking out against racism #juneteenth
-
Foundation Medicine
@FoundationATCG
New #research aimed to inform optimal clinical considerations for comprehensive genomic profiling (CGP) using tissue- & blood-based biopsies in patients w/ HR-positive, HER2-negative metastatic breast cancer (MBC).
Foundation Medicine
@FoundationATCG
Findings showed that CGP can help oncologists better understand why HR-positive, HER2-negative MBC patients show resistance to certain therapies and how to optimize first and subsequent lines of therapy due to acquired resistance mechanisms.
Foundation Medicine
@FoundationATCG
Read more in our latest #research #spotlight at the link here: www.foundationmedicine.com/research/research-spotlight-br…
-
Foundation Medicine
@FoundationATCG
Recognizing National Black Family Cancer Awareness Week. Through our connections & work in our communities, we are committed to helping enable greater access to #precisionmedicine and to making #cancer #care more equitable #blackfamcan
-
Foundation Medicine
@FoundationATCG
Honored to have been a part of #asco24. Take a look back at our time in Chicago last week.
-
Foundation Medicine
@FoundationATCG
#new #collaboration announcement ‼️ We’re proud to partner w/ @RepareRx to explore opportunities to develop a companion diagnostic & provide prospective genomic profiling to patients in an ongoing clinical trial.
Foundation Medicine
@FoundationATCG
Learn more about this #collaboration at the link ⬇️: www.foundationmedicine.com/press-release/repare-therapeut…
-
Foundation Medicine
@FoundationATCG
Precision medicine & #biomarkers have created the opportunity for #clinical #trials to move faster & have increased chances of success, with studies showing that trials using biomarkers have two to six times the overall probability of success compared to trials without biomarkers
Foundation Medicine
@FoundationATCG
Join Foundation Medicine for an upcoming #webinar – “Incorporating Biomarkers in Early- and Late-Stage Clinical Trials” – to learn more. Register here: event.on24.com/wcc/r/4585466/DC3E1C1BA677805B105101AF8A1F…
-
Foundation Medicine
@FoundationATCG
We’re proud to celebrate and support all members of the LGBTQ+ community, within Foundation Medicine and beyond. Wishing everyone a very happy #pride month.
-
Foundation Medicine
@FoundationATCG
Through our large and diverse cancer datasets, we’re proud to support research to help further advance our understanding of the impact of ancestry on genomic alterations.
Foundation Medicine
@FoundationATCG
Read more about the two new #presentations our team will be sharing at #asco24: www.foundationmedicine.com/press-release/asco24
-
Foundation Medicine
@FoundationATCG
New studies at #asco24 evaluate new comprehensive genomic profiling (CGP) #biomarkers
Foundation Medicine
@FoundationATCG
Biomarkers include methyl thioadenosine phosphorylase (MTAP) genomic loss and Foundation Medicine’s homologous recombination deficiency (HRD) signature. ⬇️ for more: www.foundationmedicine.com/press-release/asco24
-
Foundation Medicine
@FoundationATCG
New #research highlights emerging applications of liquid biopsy using Foundation Medicine tests.
Foundation Medicine
@FoundationATCG
Explore the research our team is presenting at #asco24 & more at the link here: www.foundationmedicine.com/press-release/asco24
-
Foundation Medicine
@FoundationATCG
Explore the utility of comprehensive genomic profiling (CGP) in earlier stages of cancer, rare cancers and using RNA sequencing. #asco24
Foundation Medicine
@FoundationATCG
Click the link ⬇️ for more on our #research being presented: www.foundationmedicine.com/press-release/asco24
-
Foundation Medicine
@FoundationATCG
Meet us in Chicago! Find us at Booth 22031 to learn more about Foundation Medicine’s high-quality tests and our work in precision cancer care: www.foundationmedicine.com/event/join-foundation-medicine… #asco24
-
Foundation Medicine
@FoundationATCG
Excited to announce our partnership w/ PMV Pharmaceuticals, Inc. to develop our tissue-based comprehensive #genomic #profiling test as a companion diagnostic for an investigational therapy for patients w/ locally advanced or metastatic solid tumors that have a TP53 Y220C mutation
Foundation Medicine
@FoundationATCG
Read more about this #partnership #announcement here: www.foundationmedicine.com/press-release/pmv-pharma-partn…
-
Foundation Medicine
@FoundationATCG
Excited to collaborate with @Roche_navify on this interactive experience including Foundation Medicine case studies. Looking forward to seeing it come to life in Chicago – May 31- June 4!
navify®
@Roche_navify
Visit @Roche (booth 19031) and @FoundationATCG (booth 22031) at #asco24 to discover how we are accelerating answers and elevating care. Learn more: navify.roche.com/roche-at-asco
#navifyatasco -
Foundation Medicine
@FoundationATCG
As the #lungcancer treatment landscape continues to evolve, it is critical that healthcare providers are equipped with the insights needed to inform decisions for their patients.
Foundation Medicine
@FoundationATCG
Our Chief Medical Officer, Dr. Mia Levy, shares more on the #progress that has been made in #lungcancer and how Foundation Medicine is continuing to innovate across our high-quality portfolio. Click ⬇️ : www.foundationmedicine.com/blog/mia-progress-nsclc
-
Foundation Medicine
@FoundationATCG
We are honored to have strong connections with veterans within our communities. This #memorialday, Foundation Medicine remembers all those who served and gave their lives in defending our country.
-
Foundation Medicine
@FoundationATCG
Excited to share over 20 new pieces of research at #asco24
Foundation Medicine
@FoundationATCG
Including data around the emerging applications of our liquid biopsy & monitoring portfolio: www.foundationmedicine.com/press-release/asco24
Foundation Medicine
@FoundationATCG
Additional research investigates new biomarkers & highlights the expanding utility of comprehensive genomic profiling (CGP), including capabilities of Foundation Medicine’s new RNA test. Learn more here: www.foundationmedicine.com/press-release/asco24
-
Foundation Medicine
@FoundationATCG
Looking forward to an evening of conversations around the biggest trends in cancer care and research at @statnews' event next week featuring a discussion with our Chief Medical Officer, Dr. Mia Levy.
Foundation Medicine
@FoundationATCG
Learn more & register at the link here: www.statnews.com/event/stat-at-asco-2024/
-
Foundation Medicine
@FoundationATCG
Fusions, although rare, are top-of-mind for many oncologists. By offering both DNA and RNA testing options for fusion detection, Foundation Medicine can help physicians can better navigate the complexities of the testing landscape.
Foundation Medicine
@FoundationATCG
Click the link here for more #insights in a new #blog from our Chief Medical Officer, Dr. Mia Levy: www.foundationmedicine.com/blog/mia-rna-fusion
-
Foundation Medicine
@FoundationATCG
#product #launch 📣: Foundation Medicine’s tissue-based RNA sequencing test for the detection of cancer-related gene fusions and rearrangements. Click the link to learn more: www.foundationmedicine.com/press-release/foundationone-rn…
-
Foundation Medicine
@FoundationATCG
May is Melanoma & Skin Cancer Awareness Month, dedicated to spreading awareness on one of the most common cancers in the United States. Scroll through below to review some stats and to learn more about the risks. #skincancerawareness
-
Foundation Medicine
@FoundationATCG
Through our connections with researchers and partners in the US and around the world, we are committed to pushing the boundaries of science with the goal of delivering breakthroughs that help more patients in the future. #nationalcancerresearchmonth.
Foundation Medicine
@FoundationATCG
Explore some of our recent research at the link here: www.foundationmedicine.com/research
-
Foundation Medicine
@FoundationATCG
Proud to recognize Asian American and Pacific Islander heritage month. Honored to celebrate all of our AAPI colleagues and all of their contributions here at Foundation Medicine and beyond. #aapiheritagemonth
-
Foundation Medicine
@FoundationATCG
Meet with us in Chicago at #asco24! Visit booth 22031 to learn how Foundation Medicine’s portfolio of high-quality tests and services can help inform treatment decisions for your advanced cancer patients.
Foundation Medicine
@FoundationATCG
Our team is excited to meet with you! Learn more about our booth, presentations & how to schedule a time with us at the meeting at the link here: www.foundationmedicine.com/event/join-foundation-medicine…
-
Foundation Medicine
@FoundationATCG
Today is #worldovariancancerday. Proud to support @NOCC_National to raise awareness around ovarian cancer. #shineonovarian #knowovarian #wocd2024
Foundation Medicine
@FoundationATCG
Learn more about ovarian cancer, its risk factors, signs and symptoms at the link here: ovarian.org/about-ovarian-cancer/
-
Foundation Medicine
@FoundationATCG
New #educational #webinar on fusion detection in advanced #nsclc. Join experts as they share information & perspectives about DNA-based and RNA-based sequencing and their advantages and drawbacks when it comes to fusion detection.
Foundation Medicine
@FoundationATCG
Register: info.foundationmedicine.com/foundationfrontiers-nsclc
-
Foundation Medicine
@FoundationATCG
Newly #published: “Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data”
Foundation Medicine
@FoundationATCG
Read this recent #research at the link ⬇️ : www.esmorwd.org/article/S2949-8201(24)00014-6/fulltext
-
Foundation Medicine
@FoundationATCG
Join us at #aua24 - May 3-6. Meet our team at booth 110 to learn more about the impact Foundation Medicine’s high-quality tests have in helping guide treatment options for advanced #prostate #cancer patients within urology practices.
Foundation Medicine
@FoundationATCG
Click ⬇️ to learn more: www.foundationmedicine.com/event/join-foundation-medicine…
-
Foundation Medicine
@FoundationATCG
“Anything that we develop using these tools still needs to undergo the rigorous clinical validation, like any other tool that we would use in clinical practice.” – Dr. Mia Levy, MD, PhD, Chief Medical Officer, Foundation Medicine.
Foundation Medicine
@FoundationATCG
More insights from the plenary session “AI at the Interface: Accelerating Evidence Generation, Advancing Disparities Research, and Improving Trial Design” at the #aacr24 Annual Meeting at the link here: www.aacrmeetingnews.org/news/plenary-session-explores-the…
-
Foundation Medicine
@FoundationATCG
Proud to have supported @LUNGevity in the development of a #new Biomarker Testing Guide, created in close collaboration w/ patients & providers.
Foundation Medicine
@FoundationATCG
#biomarkertesting can help inform patients & their care teams on the treatment options available for their specific cancers. Click below to learn more & access the guide: www.lungevity.org/biomarkerdiscussionguide
-
Foundation Medicine
@FoundationATCG
Meet with Foundation Medicine at the 14th Annual Clinical Biomarkers & Companion Diagnostics Europe Summit. Our Biopharma Partnerships team is looking forward to discussing how our global portfolio of tests & services can fit your specific needs.
Foundation Medicine
@FoundationATCG
Heading to the meeting? Schedule a time with our team, click ⬇️ www.foundationmedicine.com/event/foundation-medicine-14th…
-
Foundation Medicine
@FoundationATCG
Wishing all our lab team members a very happy Medical Laboratory Professionals Week! Thank you for all of your hard work and the dedication you bring to patients every single day. #wearefmi #ascplabweek24
-
Foundation Medicine
@FoundationATCG
Open now – a Call for Grants Notification, seeking collaborative projects & initiatives to address disparities in underserved breast or prostate cancer populations in the United States. Interested in applying? Click the link for more information: foundationmedicine.com/sites/default/files/media/document…
-
Foundation Medicine
@FoundationATCG
In collaboration w/ @genentech, researchers conducted a comprehensive characterization of the ancestry-based #genomic co-alteration landscape & patterns of IO-related biomarkers in KRAS & EGFR-altered non-squamous NSCLC. 🔗for more: www.foundationmedicine.com/research/aacr-2024-genomic-pro…
-
Foundation Medicine
@FoundationATCG
#research using data from @flatironhealth-Foundation Medicine Clinico-Genomic Database & #ai investigated digital pathology tumor microenvironment (TME) features of #immunotherapy outcomes among patients w/ non-squamous non-small cell lung cancer (NSCLC): www.foundationmedicine.com/research/aacr-2024-investigati…
Foundation Medicine
@FoundationATCG
Results indicate that the composition of TME assessed may have utility in identifying #nsclc patients who will respond to first-line immune checkpoint inhibitors beyond the established immunotherapy #biomarkers. More on this #aacr24 research 🔗 here: www.foundationmedicine.com/research/aacr-2024-investigati…
-
Foundation Medicine
@FoundationATCG
Data from @genentech’s HER2 cohort in the MyPathway study using our research use ctDNA monitoring assay looked at treatment response & survival outcomes in patients across diverse HER2 amplified or mutated tumors receiving targeted therapy: www.foundationmedicine.com/research/aacr-2024-tumor-infor…
Foundation Medicine
@FoundationATCG
Results suggest serial #ctdna #monitoring is a valuable complementary tool for real-time treatment response monitoring on #targeted #therapy across tumor types. Read more at the link here: www.foundationmedicine.com/research/aacr-2024-tumor-infor…
Foundation Medicine
@FoundationATCG
Excited to share these new #study #findings in collaboration w/ researchers at @genentech @NateraOncology @MCWCancerCenter @SAiGENCI @MDAndersonNews @TheCrick & look forward to @Dr_R_Kurzrock’s mini symposium presentation at #aacr24. 🔗 for more: www.foundationmedicine.com/research/aacr-2024-tumor-infor…
-
Foundation Medicine
@FoundationATCG
New #aacr24 #research in circulating tumor DNA (ctDNA) monitoring utilized a research use version of Foundation Medicine’s tissue naïve #ctdna monitoring assay to investigate ctDNA tumor fraction for monitoring treatment response. More at the 🔗: www.foundationmedicine.com/research/aacr-2024-validation-…
Foundation Medicine
@FoundationATCG
Leveraging plasma samples collected serially from patients in @genentech’s Prospective Clinico-Genomic (PCG) study, the test’s highly specific algorithmic filtration of non-tumor signal enabled high confidence in ctDNA quantification: www.foundationmedicine.com/research/aacr-2024-validation-…
Foundation Medicine
@FoundationATCG
#findings may enable personalized therapy approaches tailored to a patient’s risk of progression & downstream cancer treatment planning. Proud to present this #research w/ @Annechiangmd & collaborators from @genentech, @YaleMed, Alabama Oncology & @NewYorkCancer
-
Foundation Medicine
@FoundationATCG
New #educational #webinar on liquid biopsy in #breastcancer. Join experts as they share information & perspectives about biomarker testing guidelines & the biomarker ctDNA tumor fraction reported by Foundation Medicine’s liquid biopsy test. Register here: app.smartsheet.com/b/form/5fd7ad23aa86411f91bf71651dec5d31
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is looking forward to discussing the latest advancements in science and cancer care at this year’s #aacr24 Annual Meeting. Heading to San Diego? Meet with our team! Visit us at booth 3117. Learn more: www.foundationmedicine.com/event/join-foundation-medicine…
-
Foundation Medicine
@FoundationATCG
#newstudy in @CCR_AACR evaluates circulating tumor DNA tumor fraction, a determination of ctDNA in liquid biopsy samples from Foundation Medicine’s blood-based comprehensive genomic profiling test, for its utility in identifying true negative results: www.foundationmedicine.com/research/research-spotlight-me…
Foundation Medicine
@FoundationATCG
#research sought to evaluate a method of distinguishing between scenarios of negative & false-negative liquid biopsy results, as liquid biopsy for tumor profiling is increasingly used to support treatment planning for cancer patients. Highlights here 🔗: www.foundationmedicine.com/research/research-spotlight-me…
Foundation Medicine
@FoundationATCG
Excited to share this new research in collaboration with @ChristianRolfo et al. For more details on this research, click here: www.foundationmedicine.com/research/research-spotlight-me…
-
Foundation Medicine
@FoundationATCG
Join us at the 2024 Community Oncology Conference - April 4-5. Meet our team at booth 106 to learn more about our high-quality tests and how we support the oncology community through precision medicine and genomic insights: www.foundationmedicine.com/event/coa-2024-annual-meeting #coa2024
-
Foundation Medicine
@FoundationATCG
Exciting new research from Dr. Sunny Lai, Dr. Misty Dawn Shields (@drshieldsmd), et al. used our FDA-approved liquid biopsy test to detect a rare EGFR-RAD51 fusion, demonstrating the value of high-quality and comprehensive genomic profiling over more limited NGS panels.
Misty Dawn Shields
@drshieldsmd
Thanks @StephenVLiu for the shoutout on our 🚨Pub Alert 🚨in @JTOonline #jtocrr
Here’s the key 🔑 takeaways:
1️⃣ EGFR-RAD51 fusions are rare
2️⃣ osimertinib = effective/durable
3️⃣ know the coverage of #ngs panels
4️⃣ precision medicine changes lives
#lcsm #liquidbiopsy -
Foundation Medicine
@FoundationATCG
New #educational #webinar on liquid biopsy in #prostatecancer. Join experts as they share information & perspectives about biomarker testing guidelines & the biomarker ctDNA tumor fraction reported by Foundation Medicine’s liquid biopsy test. Register: events.zoom.us/eo/AjgEimpwXRspCaeDyNd8R792fUGuFbLrSUpWoDv…
-
Foundation Medicine reposted
The Boston Globe
@BostonGlobe
Biotechnology firm Foundation Medicine is consolidating its 1,100 Massachusetts employees into a 630,000-square-foot-building in the Seaport, the latest company to set up shop in the bustling business district. www.bostonglobe.com/2024/03/19/business/biotech-foundatio…
-
Foundation Medicine
@FoundationATCG
New #research published in @Histo_Journal – “Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results." Click the :link:to explore this research: onlinelibrary.wiley.com/doi/10.1111/his.15168
-
Foundation Medicine
@FoundationATCG
Every day, we are driven by the pursuit of personalized answers for all #patients, like Teresa, who are living with cancer. Learn more about us, high-quality #genomic #testing & our work to transform #cancer #care at the 🔗: www.foundationmedicine.com/about #wearefmi #breastcancer
-
Foundation Medicine
@FoundationATCG
Newly #published in the Journal of Liquid Biopsy – “Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases.” Read this piece of #research at the link: www.sciencedirect.com/science/article/pii/S2950195424000055
-
Foundation Medicine
@FoundationATCG
Are you using liquid biopsy to its potential? Join our educational webinar to learn about guidelines for liquid biopsy in NSCLC for treatment selection and the biomarker ctDNA tumor fraction. 🔗 to register for the next webinar, March 11th: events.zoom.us/eo/AgJYr2berhlGwogkAqHpFjZuf5pJNrrEfiSisli…
-
Foundation Medicine
@FoundationATCG
#announcement‼️ Excited to share new #research our team will be presenting at the #aacr24 Annual Meeting. New #studies demonstrate the capabilities of Foundation Medicine’s monitoring assays & more. Learn more about this year’s presentations: www.foundationmedicine.com/press-release/foundation-medic…
Foundation Medicine
@FoundationATCG
Additional #research highlights the value that high-quality #genomic profiling tests can provide in non-small cell lung cancer. Click the 🔗 to read more at the: www.foundationmedicine.com/press-release/foundation-medic…
-
Foundation Medicine
@FoundationATCG
Proud to celebrate #womenshistorymonth - we recognize and honor the contributions of all women, those who make up our community here at Foundation Medicine and beyond.
-
Foundation Medicine
@FoundationATCG
March is #colorectalcancerawarenessmonth. Proud to support our advocacy partners including @ColonCancerCoal, @CCAlliance & @FightCRC in spreading greater awareness and education around colorectal cancer #wearefmi #dressinblue #strongarmselfie #blueforcrc
-
Foundation Medicine
@FoundationATCG
Fostering places where patients feel supported & can get the resources they need is something that lies deep within our mission to transform cancer care. Proud to support NORD (@RareDiseases) this #rarediseaseday. Learn more here: rarediseases.org/rare-disease-day/
-
Foundation Medicine
@FoundationATCG
It is critical that DNA-based genomic profiling (CGP) tests are optimally designed to identify fusions, which are important driver events that can significantly influence treatment decisions & patient outcomes: www.foundationmedicine.com/research/research-spotlight-re…
Foundation Medicine
@FoundationATCG
#newresearch demonstrates robust detection of genomic fusions is possible using carefully designed DNA-based sequencing methodologies.
Foundation Medicine
@FoundationATCG
In an analysis of non-squamous NSCLC, fusions detected using high-quality CGP assays are associated w/ clinical benefit from matched targeted agents. Click the 🔗 to read more in a new #research spotlight: www.foundationmedicine.com/research/research-spotlight-re…
-
Foundation Medicine
@FoundationATCG
#newresearch in @JCOPO_ASCO – “Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment.” Full publication at the 🔗: ascopubs.org/doi/10.1200/PO.23.00535
-
Foundation Medicine
@FoundationATCG
Proud to be a lead sponsor at the 8th Annual Liquid Biopsy for Precision Oncology Summit! Looking forward to joining industry leaders in San Diego. Don’t miss our plenary presentation, hosted workshop & networking reception. Learn more: www.foundationmedicine.com/event/foundation-medicine-8th-…
-
Foundation Medicine
@FoundationATCG
New Research published in @CCR_AACR in collaboration w/ @DanaFarber – “RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer." Read the full paper at the 🔗: aacrjournals.org/clincancerres/article-abstract/doi/10.11…
-
Foundation Medicine
@FoundationATCG
"Anyone with lungs can get lung cancer.” As a lung cancer survivor, physician, Dr. Sydney Barned advocates for more #awareness and empathy surrounding #lungcancer. Hear more from Sydney at the link here: www.youtube.com/watch?v=eaByezQ51nI
-
Foundation Medicine
@FoundationATCG
#icymi oncology leaders at our Disparities in Lung Cancer live event discussed how we can work to change the standard of care and impact the lives of #lungcancer patients. Watch the full discussion here: www.youtube.com/watch?v=fBOfCEY1x-o
-
Foundation Medicine
@FoundationATCG
This month we recognize Gallbladder & Bile Duct Cancer Awareness Month. We honor those who have been impacted by these types of cancers & hope to help spread awareness to help support those looking to learn more. Visit the link here for more: www.aacr.org/patients-caregivers/awareness-months/gallbla…
-
Foundation Medicine
@FoundationATCG
This Sunday is #worldcancerday. Through our research & partnerships around the world, we are committed to working across the oncology community to #closethecaregap of existing disparities in cancer care. More on our latest research & initiatives: www.foundationmedicine.com/inclusive-research
-
Foundation Medicine
@FoundationATCG
This #blackhistorymonth, we celebrate the contributions of Black Americans in the history of the U.S. We are inspired by the impacts they have made & are encouraged to continue learning, growing & listening as we strive to foster places of inclusivity and equity for all.
-
Foundation Medicine
@FoundationATCG
#newresearch w/ de-identified data from patients who underwent Foundation Medicine’s liquid biopsy testing identified circulating tumor DNA tumor fraction as a prognostic marker in metastatic #renalcellcarcinoma patients. More on this research here meetings.asco.org/abstracts-presentations/229951 #gu24
-
Foundation Medicine
@FoundationATCG
#research at ASCO #gu24 hypothesized that early detection of & changes in circulating tumor DNA (ctDNA) tumor fraction are associated w/ clinical responses in patients with metastatic castration resistant #prostatecancer (mCRPC). Learn more here: meetings.asco.org/abstracts-presentations/230145
-
Foundation Medicine
@FoundationATCG
#new at ASCO #gu24: “Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig)": meetings.asco.org/abstracts-presentations/230155
Foundation Medicine
@FoundationATCG
This #study sought to evaluate the real-world effectiveness of PARPi based on HRR alterations & explore the clinical validity of HRDsig to additionally predict outcomes on PARPi in patients with metastatic castration resistant #prostatecancer. Learn more: meetings.asco.org/abstracts-presentations/230155
-
Foundation Medicine
@FoundationATCG
Excited to recognize 20 years of genitourinary cancer care at this year’s ASCO #gu24 symposium. Explore our research in genitourinary cancer & schedule time to meet w/ our team to learn more about our portfolio of comprehensive genomic profiling tests: www.foundationmedicine.com/event/asco-genitourinary-cance…
-
Foundation Medicine
@FoundationATCG
Liquid biopsy can provide a more comprehensive & quantitative picture of acquired resistance in colorectal cancer than tissue biopsy, including some potential novel mechanisms identified in a #newstudy in #colorectalcancer at ASCO #gi24. Click for more: meetings.asco.org/abstracts-presentations/229072
-
Foundation Medicine
@FoundationATCG
#newstudy at ASCO #gi24 evaluates if tumor mutational burden could be used to help decide between immune checkpoint inhibitor monotherapy or combination w/ chemotherapy in gastroesophageal cancer. More at the 🔗 here: meetings.asco.org/abstracts-presentations/229315
-
Foundation Medicine
@FoundationATCG
Heading to ASCO #gi24? Stop by Booth 7 to learn more about our portfolio of comprehensive genomic profiling tests, as well as our latest product, FoundationOne®Tracker. Click the 🔗 to explore our latest research or to schedule a time w/ us at the meeting: www.foundationmedicine.com/event/asco-gastrointestinal-ca…
-
Foundation Medicine reposted
Moffitt Cancer Center
@MoffittNews
Mark your calendars! Join us on January 18th at 12:30 p.m. as we dive into an insightful discussion on lung cancer disparities and research opportunities with Dr. @JhanelleGray and @LUNGevity. Let's work towards a more inclusive future for all!
Foundation Medicine
@FoundationATCG
We’re just 8 days away from our LinkedIn Live event with @MoffittNews & @LUNGevity, where we’ll dive into topics around disparities in #lungcancer, current research and opportunities for a more inclusive future. Learn more and join us here: www.linkedin.com/uas/login?session_redirect=https%3A%2F%2…
-
Foundation Medicine
@FoundationATCG
We’re just 8 days away from our LinkedIn Live event with @MoffittNews & @LUNGevity, where we’ll dive into topics around disparities in #lungcancer, current research and opportunities for a more inclusive future. Learn more and join us here: www.linkedin.com/uas/login?session_redirect=https%3A%2F%2…
-
Foundation Medicine
@FoundationATCG
At Endpoints at #jpm24, Foundation Medicine’s Lucas Dennis, SVP, Head of Research & Development, will join industry leaders for a discussion on the latest progress and innovations happening in oncology. Learn more: events.endpts.com/jpm/agenda
-
Foundation Medicine
@FoundationATCG
#newresearch published in @CCR_AACR examined the landscape of genomic rearrangements detected by liquid biopsy across different cancer types in over 50,000 patient samples. Click 🔗 for more: www.foundationmedicine.com/research/circulating-tumor-dna…
Foundation Medicine
@FoundationATCG
This #study reported the detection of a wide variety of rearrangements using comprehensive #genomic #profiling of circulating tumor DNA (ctDNA) using liquid #biopsy & distributions of fusion gene partners that resemble those of tissue biopsies. Learn more: www.foundationmedicine.com/research/circulating-tumor-dna…
-
Foundation Medicine
@FoundationATCG
Join Foundation Medicine, @MoffittNews & @LUNGevity for a LinkedIn Live event on January 18th to discuss disparities in #lungcancer, recent #research and more. Click the 🔗 to learn more and register: www.linkedin.com/uas/login?session_redirect=https%3A%2F%2…
-
Foundation Medicine
@FoundationATCG
Excited to announce our strategic collaboration with @AnheartTx to develop tissue- and liquid-based companion diagnostics for their investigational next-generation therapy for patients with ROS1-positive NSCLC. Read more about this news at the 🔗: www.foundationmedicine.com/press-release/anheart-therapeu…
-
Foundation Medicine
@FoundationATCG
We are thrilled to welcome our new CEO, Dan Malarek, to Foundation Medicine. Read more here: www.foundationmedicine.com/press-release/foundation-medic…
-
Foundation Medicine
@FoundationATCG
Circulating tumor DNA (ctDNA) tumor fraction has the potential to transform the #precisionmedicine landscape, enabling more confidence in #liquidbiopsy results. More on this innovative clinical measure in a new #blog from CMO @DrMiaLevy: www.foundationmedicine.com/blog/clinic-mia-further-valida…
-
Foundation Medicine
@FoundationATCG
At @SABCSanAntonio, we’re presenting #data characterizing the prevalence of ESR1 mutations in advanced #breastcancer patients and evaluating #clinical #outcomes of endocrine therapy by ESR1 status. Learn more: www.foundationmedicine.com/event/sabcs-annual-symposium #sabcs23
-
Foundation Medicine
@FoundationATCG
New in @JCOPO_ASCO: "Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2 or Homologous Recombination Deficiency Signature"🔗: www.foundationmedicine.com/research/research-spotlight-ho…
Foundation Medicine
@FoundationATCG
PARP inhibitors (PARPi) are approved for patients with HER2-negative metastatic #breast #cancer (mBC) and germline pathogenic/likely pathogenic variant, however, clinical benefit has also been demonstrated in mBC with somatic BRCA1/2 mutations or germline PALB2 (gPALB2) mutations
Foundation Medicine
@FoundationATCG
Study evaluates the genomic landscape of homologous recombination repair (HRR) gene alterations in mBC and assess PARPi treatment outcomes for patients w/ germline BRCA alterations compared to other HRR-genes & by status of a novel HRD signature (HRDsig): www.foundationmedicine.com/research/research-spotlight-ho…
-
Foundation Medicine
@FoundationATCG
Our new research at @SABCSSanAntonio reports on ESR1 genomic alterations in metastatic breast cancer detected by our high-quality tissue & liquid biopsies & explores potential clinical implications for endocrine therapy. Visit us & learn more - Booth 1247: www.foundationmedicine.com/event/sabcs-annual-symposium
-
Foundation Medicine
@FoundationATCG
Attending the San Antonio Breast Cancer Symposium? Join Foundation Medicine’s Chief Medical Officer @DrMiaLevy for a clinical #workshop & #discussion on tumor agnostic approaches to care. Learn more about Foundation Medicine at #sabcs23 at the link here: www.foundationmedicine.com/event/sabcs-annual-symposium
-
Foundation Medicine
@FoundationATCG
We’re proud to support the lung cancer community and to help spread the message around #lungcancer and the importance of #biomarkertesting. Hear more from Summer at the link here: www.youtube.com/watch?v=MvG1-DXDFLE
#lungcancerawarenessmonthThis media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Are you joining @SABCSSanAntonio for #sabcs23, December 5-9? While you’re here, visit booth 1247 to learn more about how we’re helping #community #oncologists advance #breastcancer care w/ our tailored #solutions. Let's connect! 🗓️ time w/ us at here: www.foundationmedicine.com/event/sabcs-annual-symposium
-
Foundation Medicine
@FoundationATCG
Thank you to all #caregivers & family members who work hard every day to support patients everywhere. Through stories like Ed & Sandy’s, we remain inspired in our work to help enable access & information to precision medicine options. Learn more about us: www.foundationmedicine.com/patient/start-with-step-one-re…
-
Foundation Medicine
@FoundationATCG
Through our efforts with researchers from across the globe, we’re dedicated to advancing our knowledge of correlations between #genomic #ancestry and #cancer to help with more personalized approaches to future care: www.foundationmedicine.com/inclusive-research
Foundation Medicine
@FoundationATCG
We’d like to thank patient advocates, like Sydney, for driving the importance of #research in #disparities as we continue our work in making #cancercare more equitable with #diagnostics. Learn more about our latest research and initiatives here: www.foundationmedicine.com/inclusive-research
Foundation Medicine
@FoundationATCG
#lungcancerawarenessmonth #lungcancerawareness #cancerresearch
-
Foundation Medicine
@FoundationATCG
Now FDA Approved – our tissue-based #genomic #profiling test as a companion #diagnostic to identify a subset of patients w/ HR-Positive, HER2-Negative Advanced Breast Cancer. Read more here: www.foundationmedicine.com/press-release/us-fda-approves-…
-
Foundation Medicine
@FoundationATCG
#icymi a recent observational study reported the breadth & impact of #clinical #decision #insights from solid tumor profiles utilizing our tissue-based comprehensive #genomic profiling test. Read more about this #research: academic.oup.com/oncolo/advance-article/doi/10.1093/oncol…
Foundation Medicine
@FoundationATCG
In this study, clinically significant findings were reported for approximately half of patients with genomic results. Learn more: academic.oup.com/oncolo/advance-article/doi/10.1093/oncol…
-
Foundation Medicine
@FoundationATCG
New #collaboration #announcement – Foundation Medicine & @PierreFabre to collaborate to develop Foundation Medicine’s high-quality genomic tests as companion diagnostics for new #targetedtherapies to treat patients w/ NSCLC. Read more: www.foundationmedicine.com/press-release/foundation-medic…
-
Foundation Medicine
@FoundationATCG
Personalized circulating tumor DNA (ctDNA) monitoring can help physicians gain the #insights needed to understand their patients’ response to #treatment. Learn more about our new tissue-informed #ctdna #monitoring test at the link here: www.foundationmedicine.com/solution/foundationone-cdx
-
Foundation Medicine reposted
AtlanticLIVE
@AtlanticLIVE
Sponsor Content: @FoundationATCG’s @DrMiaLevy discusses how circulating tumor DNA testing can be incorporated into oncology decisionmaking, at a #peoplevcancer Underwriter Session produced by Foundation Medicine.
Join the summit: www.youtube.com/watch?v=CZNP_Z629cw -
Foundation Medicine
@FoundationATCG
Have you implemented circulating tumor DNA (ctDNA) monitoring in your practice? Join our educational webinar to learn about how ctDNA-based treatment response monitoring (TRM) can provide objective insights into a patient’s response. 🔗 to register: survey.alchemer.com/s3/7583182/foundation-frontiers-regis…
-
Foundation Medicine
@FoundationATCG
Attending #amp2023? Come meet w/ our team! Stop by our booth to learn more about our supportive solutions for #pathologists or join us for our workshop around established & novel biomarkers that can help benefit patients through precision medicine: www.foundationmedicine.com/event/amp-2023-annual-meeting-…
-
Foundation Medicine
@FoundationATCG
Proud to have been a sponsor at @LUNGevity's #breathedeeptogether event this past weekend. Honored to have had the opportunity to join lung cancer patients, survivors & advocates for this year’s walk. Learn more: fundraise.lungevity.org/pages/2058 #lungcancerawarenessmonth #breathedeep23
-
Foundation Medicine
@FoundationATCG
Proud to be a part of @AtlanticLIVE's 6th annual People v. Cancer event. Looking forward to conversations around the latest innovations happening in the cancer space, including a session w/ @DrMiaLevy, our Chief Medical Officer. Register at the 🔗: www.theatlantic.com/live/people-v-cancer-2023/
-
Foundation Medicine reposted
GenomeWeb
@GenomeWeb
Distinct Cancer Drivers, Markers Detected in Tumor Samples from African Ancestry Patients. With hundreds of thousands of tumor samples, researchers unearthed genetic alterations that are enriched or diminished among African ancestry individuals. www.genomeweb.com/sequencing/distinct-cancer-drivers-mark…
-
Foundation Medicine
@FoundationATCG
November is Lung Cancer Awareness Month. We honor all of those within and beyond our community who have had and are living with lung cancer. #lungcancerawarenessmonth
-
Foundation Medicine
@FoundationATCG
At @sitcancer Annual Meeting, excited to showcase our new tissue-informed ctDNA monitoring test that can provide objective insights to help understand patient response to immunotherapy treatment, enabling more informed clinical care decisions. More at 🔗: www.foundationmedicine.com/event/sitc23
-
Foundation Medicine
@FoundationATCG
A new op-ed in @thehill highlights how cancer patients are increasingly searching for personalized solutions for their type of #cancer: thehill.com/sponsored-content/the-future-of-the-cancer-mo…
Foundation Medicine
@FoundationATCG
But a recent FDA pilot program could lower standards for #genomic profiling tests, which are the key to unlocking the answers to personalized #cancer #care. Read the full op-ed to learn more about the critical need for high-quality genomic profiling tests: thehill.com/sponsored-content/the-future-of-the-cancer-mo…
-
Foundation Medicine
@FoundationATCG
We're joining #cancer #immunotherapy leaders at the @sitcancer Annual Meeting. Visit booth #1028 to learn about how our portfolio can help enable providers to make informed clinical care decisions around immunotherapy treatment. Schedule time w/ us here: www.foundationmedicine.com/event/sitc23
-
Foundation Medicine
@FoundationATCG
Proud to participate in the @theNCI’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with #cancer. Read more: www.foundationmedicine.com/press-release/foundation-medic…
Post not available here, view on X
Foundation Medicine
@FoundationATCG
Foundation Medicine is one of the largest contributors of potential participants to ComboMATCH, in connection with which Foundation Medicine testing results will help determine trial eligibility for patients. Read the full press release here: www.foundationmedicine.com/press-release/foundation-medic…
Foundation Medicine
@FoundationATCG
Excited to be a part of this initiative led by NCI network groups in the US @eaonc @ALLIANCE_org @COGorg @NRGOncology @SWOG
-
Foundation Medicine
@FoundationATCG
Are you joining @UrologyUS for the #lugpa2023 Annual Meeting on November 2-4 in Orlando, FL? While you’re here, visit our booth to learn more about how our tissue- and liquid-based companion diagnostic tests are helping to optimize urologic care 🗓️: www.foundationmedicine.com/event/lugpa2023
-
Foundation Medicine
@FoundationATCG
#newstudy conducted w/ @MDAndersonNews looked at over 10,000 cases of biliary tract cancer in patients of African and European descent, identifying key clinical and genomic differences. More on this #research being presented at #esmo23 at the link here: www.foundationmedicine.com/research/esmo-2023-demonstrati…
-
Foundation Medicine
@FoundationATCG
#esmo23 - sharing two #new #studies highlighting the differentiated circulating tumor DNA (#ctdna) tumor fraction reporting capabilities of our blood-based genomic profiling test. #research highlights at the link here: www.foundationmedicine.com/research/esmo-2023-highlightin…
Foundation Medicine
@FoundationATCG
Excited to share this new research in #ctdna #tumorfraction conducted in collaboration with @FilippoDallOlio @BenjaminBesseMD @BenMironMD @shilpaonc @GustaveRoussy & others
-
Foundation Medicine
@FoundationATCG
Proud to announce our expanded partnership with Sequanta Technologies Co., Ltd. to provide #genomic profiling services to support clinical #research and the development of #oncology #therapies in China. Learn more about this news at the link here: www.foundationmedicine.com/press-release/foundation-medic…
-
Foundation Medicine
@FoundationATCG
At #esmo23, we will present #results from the CUPISCO #study, a randomized #precisiononcology study designed to prospectively assess the efficacy & safety of molecularly-guided therapy for patients w/ unfavorable subset cancer of unknown primary. More: www.foundationmedicine.com/press-release/new-research-fou…
-
Foundation Medicine
@FoundationATCG
This week, at #esmo23, we’re presenting 11 new studies demonstrating the value of high-quality biomarker tests to inform cancer care. Click the 🔗 to learn more about our research: www.foundationmedicine.com/press-release/foundation-medic…
Foundation Medicine
@FoundationATCG
Presentations feature late-breaking results from the CUPISCO study & new research highlighting expanded capabilities of #ctdna #tumorfraction reporting of our blood-based #genomic #profiling test: www.foundationmedicine.com/press-release/foundation-medic…
Foundation Medicine
@FoundationATCG
Additionally, we’re presenting a new #study demonstrating molecular differences between genetic ancestries in patients with biliary tract #cancer. Read more: www.foundationmedicine.com/press-release/foundation-medic…
-
Foundation Medicine
@FoundationATCG
Looking forward to @statnews 2023 #statsummit for two days of open discussions & conversations w/ leaders from across the #health, #tech & #lifesciences space. Learn more about this year’s #statsummit in Boston, October 18-19: www.statnews.com/stat-summit-2023/
-
Foundation Medicine
@FoundationATCG
Both our tissue- & blood-based #genomic #profiling #tests are now FDA-approved to identify patients w/ metastatic #nsclc harboring a BRAF V600E mutation who may benefit from treatment w/ a targeted combination therapy. Click here to learn more: www.foundationmedicine.com/press-release/fda-approves-fou…
-
Foundation Medicine
@FoundationATCG
#announcement 📣: Our tissue-informed circulating tumor DNA monitoring test is now available to all physicians in the US seeking personalized monitoring of their patients' response to treatment. More on this #launch news: www.foundationmedicine.com/press-release/foundation-medic…
-
Foundation Medicine
@FoundationATCG
New FDA Approval – today we announced that our tissue-based genomic profiling test is now FDA approved to identify patients with solid tumors with RET gene fusions who may benefit from a #targetedtherapy. Learn more about the announcement here: www.foundationmedicine.com/press-release/us-food-and-drug…
-
Foundation Medicine
@FoundationATCG
Hello, Boston Skyline, so great to be here! Excited to see our logo installed at our new headquarters in Boston’s Seaport District. Looking forward to our big move happening soon. Learn more about our Boston headquarters & team at the link here: careers.foundationmedicine.com/boston-seaport-and-cambridge #wearefmi
-
Foundation Medicine
@FoundationATCG
High-quality diagnostics can help identify the genomic mutations driving a patient’s cancer and match a patient to effective treatment options. We need to prioritize increasing accessibility to these tests. Read more from our CCO, Annie Murphy: www.foundationmedicine.com/blog/coverage-counts-improving…
-
Foundation Medicine
@FoundationATCG
October is #breastcancerawarenessmonth. This month, we honor all those who have been impacted by breast cancer.
-
Foundation Medicine
@FoundationATCG
Tomorrow is #rarecancerday. In our work to transform cancer care, we’re proud to support @RareDiseases in helping spread awareness on #rarecancers and supporting the patients living with them. Learn more about Rare Cancer Day and NORD at the link here: rarediseases.org/get-involved/rare-cancer-day/
National Organization for Rare Disorders (NORD)
@RareDiseases
Help raise awareness for people living with rare cancers on #rarecancerday this Saturday, September 30!
Learn all about rare #cancer and how you can get involved: rarediseases.org/get-involved/rare-cancer-day/ -
Foundation Medicine
@FoundationATCG
Last week, our team sent some “Warrior Mail” to pediatric osteosarcoma patients, "Osteowarriors". We admire the bravery and strength of all Osteowarriors & are proud to support MIB Agents and the pediatric cancer community: www.mibagents.org/patients-programs/warrior-mail #childhoodcancerawarenessmonth
-
Foundation Medicine
@FoundationATCG
In recognition of #prostatecancer awareness month - #icymi great interview w/ @urotoday featuring Dr. @neerajaiims discussing two recent studies in #prostatecancer. Our team is excited to have been part of this #research. Watch the full interview: www.urotoday.com/video-lectures/pcf-2022/video/mediaitem/…
-
Foundation Medicine
@FoundationATCG
Recognizing #worldcancerresearchday this weekend by sharing some of our recent publications in genomic ancestry #research. Read more about this research at the link here: www.foundationmedicine.com/inclusive-research
Foundation Medicine
@FoundationATCG
In our work to transform #cancer #care, we partner with researchers worldwide to conduct studies leveraging our unique cancer dataset to understand biological differences across different ancestries to better inform personalized approaches to treatment: www.foundationmedicine.com/inclusive-research
-
Foundation Medicine
@FoundationATCG
Foundation Medicine has placed #30 on @Newsweek’s list of the Top 100 Most Loved Workplaces® in America! This wouldn’t be possible without our dedicated & passionate team that works hard every day to foster an environment of passion & belonging: rankings.newsweek.com/most-loved-workplaces-america-2023 #wearefmi
-
Foundation Medicine
@FoundationATCG
We'll be joining urology leaders at @specialtynet Conference in Colorado September 28-30. Schedule time w/ us & learn more about our tissue- & blood-based companion diagnostic tests that can support treatment planning for advanced prostate cancer patients: www.foundationmedicine.com/event/snuc-2023
-
Foundation Medicine
@FoundationATCG
We're excited to share this announcement on our partnership with @Roche_France & @GustaveRoussy to provide in-house liquid biopsy testing for cancer patients in France. Read the full press release here: www.foundationmedicine.com/press-releases/roche-france,-f…
-
Foundation Medicine
@FoundationATCG
#newresearch published in @CCR_AACR utilized circulating tumor DNA (ctDNA) monitoring for risk stratification in patients w/ advanced squamous NSCLC receiving chemoIO using Foundation Medicine’s ctDNA monitoring assay. Key takeaways at the link here: www.foundationmedicine.com/research/research-spotlight-ci…
Foundation Medicine
@FoundationATCG
Monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during chemoIO may offer an opportunity to identify patients at higher risk for disease progression and inform patient selection for novel personalized maintenance strategies.
Foundation Medicine
@FoundationATCG
Thank you to @BrunaPellini @NateraGenetics & others for the collaboration on this research.
-
Foundation Medicine
@FoundationATCG
This week - Elizabeth Mansfield, PhD, VP, Regulatory Policy will be speaking at the NCI Cancer Diagnosis Program Workshop: ctDNA in Cancer Treatment and Clinical Care presenting on "Regulatory consideration for ctDNA assays." Learn more at the link here: events.cancer.gov/cdp/ctdna-workshop
-
Foundation Medicine
@FoundationATCG
Just a few days away from @NOCC_National's Together in TEAL Walk in Boston! Our team is looking forward to joining ovarian cancer community patients, survivors & advocates at Carson Beach again this year. Learn more about NOCC and this year’s walk here: www.bonterratech.com/product/donordrive
-
Foundation Medicine
@FoundationATCG
Proud to announce the launch of our broad tissue-based RNA test for research and investigational use. Click here to read the full announcement: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Join Foundation Medicine CEO, Dr. Brian Alexander (@xelamb) & @HarvardMIT_CRS next week for a virtual talk on the role high-quality diagnostics can play in helping physicians deliver precision cancer care. Click to learn more & register: hmcrs.org/events/calendar/
-
Foundation Medicine
@FoundationATCG
Honoring and recognizing all who have had or are living with childhood, blood, ovarian and prostate cancers this September.
-
Foundation Medicine
@FoundationATCG
#newstudy shows Foundation Medicine's personalized ctDNA monitoring assay can detect low levels of residual ctDNA in patients with resected muscle-invasive #bladdercancer without germline sampling. Key takeaways and more at the link here: www.foundationmedicine.com/research/research-spotlight-mo…
Foundation Medicine
@FoundationATCG
Our team is excited to share this #newresearch in collaboration with @NateraGenetics & others
-
Foundation Medicine
@FoundationATCG
Excited to be at @WorldCDx next week for important discussions w/ leaders across the #biopharma & #diagnostics industries, including the importance of corporate accountability & addressing disparities in the workplace. More about the meeting at this link: www.foundationmedicine.com/event/world-cb-and-cdx? cdx tw
-
Foundation Medicine
@FoundationATCG
Come see us at the 2023 Epic User Group Meeting (UGM) August 21-23 to learn more about our success with integrations. Find out how we deliver genomic test results directly into the patient’s episode of care in Epic by visiting our booth or clicking here: www.foundationmedicine.com/event/ugm2023
-
Foundation Medicine
@FoundationATCG
Now FDA approved - FoundationOne®CDx* to identify adult patients w/ mCRPC harboring BRCA1- or BRCA2-positive mutations who may benefit from a new targeted treatment: www.foundationmedicine.com/press-releases/u.s.-food-and-d…
*Rx only; advanced cancer; doesn't guarantee treatment match www.f1cdxlabel.com -
Foundation Medicine
@FoundationATCG
#researchspotlight - study analyzed the genomic landscape, comprehensive genomic profiling utilization & treatment patterns across a diverse cohort of patients with advanced #prostatecancer to assess ancestry-based disparities. Click here to read more: www.foundationmedicine.com/research/research-spotlight-co…
-
Foundation Medicine reposted
BLOODPAC
@blood_pac
BLOODPAC is thrilled to welcome Elizabeth Mansfield to our Scientific Co-Chair Committee! Liz has over 20 years of experience in regulatory affairs, including a decade of service at the FDA, and is a longtime member of our Analytical Validation working groups. @FoundationATCG
-
Foundation Medicine
@FoundationATCG
We are continuously committed to increasing biomarker testing education, awareness & access among underserved populations in the US. Excited to announce today a grant to @MoffittNews & @LUNGevity in support of their COMPASS initiative. Learn more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
#newresearch published in @CCR_AACR used Foundation Medicine tissue & liquid genomic profiling to further understand activating BRAF alterations in #prostatecancer and was able to identify unique AR-driven BRAF fusions: aacrjournals.org/clincancerres/article/doi/10.1158/1078-0…
Foundation Medicine
@FoundationATCG
Great work by @geoff_oxnard, @HTukachinsky and team! Excited to share this new research with our collaborators, including @EAntonarakis, @arafflemd, @neerajaiims, @BrandonMahal, @TDorffOnc, @montypal and others
-
Foundation Medicine
@FoundationATCG
Our scientists and their teams work hard every day to produce research that spans across the spectrum of #cancer #care, collaborating with renowned oncologists and institutions alike. Explore our latest #research: www.foundationmedicine.com/research
-
Foundation Medicine
@FoundationATCG
The work our teams do every day centers around patients w/in & beyond our Foundation Medicine community. Patients, like Summer, inspire us to continue our efforts to support broader awareness of genomic testing & access to precision cancer care: www.foundationmedicine.com/about #wearefmi
-
Foundation Medicine reposted
JCO Precision Oncology
@JCOPO_ASCO
👀 Check out what’s popular this week in #jcopo:
"Tumor Mutational Burden in Real-World Patients With #pancreaticcancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness" ➡️ ascopubs.org/doi/10.1200/PO.23.00092 @FoundationATCG @Amitmahipal79 #pancsm -
Foundation Medicine
@FoundationATCG
New #breastcancer #research in @NatureComms examined tumors using real-world data from tissue- & blood-based comprehensive genomic profiling. Findings revealed dynamic evolution of breast tumors over time & provide further insights on potential treatments: foundationmedicine.com/research/research-spotlight-tissue…
-
Foundation Medicine
@FoundationATCG
Next week at the @CancerResrch Public Meeting – join Foundation Medicine’s @geoff_oxnard, SVP, Clinical Development for the session “Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI (ctMoniTR Module 1)”: friendsofcancerresearch.org/event/establishing-evidence-n…
-
Foundation Medicine
@FoundationATCG
This #pridemonth, colleagues, friends & family came together in support of the LGBTQ+ community. We are grateful to have had the opportunity to celebrate & are committed to continuing our work to provide an inclusive place for employees to be their most authentic selves #wearefmi
-
Foundation Medicine
@FoundationATCG
Congratulations to our Chief People Officer, Andrew Suchoff, on his appointment to the @AmericanCancer Eastern New England Area Board of Directors: www.acsboardeasternnewengland.org
-
Foundation Medicine
@FoundationATCG
Happy to recognize Cancer Immunotherapy Month. We thank @CancerResearch for all of their hard work & commitment to advancing cancer #immunotherapy research on behalf of patients #immune2cancer
Cancer Research Institute
@CancerResearch
"At @FoundationATCG, my research focuses on analyzing real-world data to understand how biomarkers can help predict treatment response. This helps oncologists make more informed treatment decisions and provide quality care to patients," says Julia Quintanilha, PhD. #immune2cancer
-
Foundation Medicine
@FoundationATCG
Proud to support this year’s National Black Family Cancer Awareness Week, a week dedicated to spreading knowledge and awareness around cancer within one of the most vulnerable segments of the US population. Learn more about the week here: www.fda.gov/about-fda/project-community/national-black-fa… #blackfamcan
-
Foundation Medicine
@FoundationATCG
Today, we’re excited to announce new appointments to our leadership team. Read the announcement here: www.foundationmedicine.com/press-releases/foundation-medi… #wearefmi
-
Foundation Medicine
@FoundationATCG
Congratulations to our Chief Medical Officer @drmialevy on being named to @permedcoalition's Board of Directors for her unwavering commitment to personalized medicine and improved patient care: www.personalizedmedicinecoalition.org/pmc-board-of-direct…
-
Foundation Medicine
@FoundationATCG
#announcement – FDA approves FoundationOne®Liquid CDx* as a companion diagnostic to identify patients w/ BRAF V600E alterations in mCRC: www.foundationmedicine.com/press-releases/u.s.-food-and-d…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1lcdxlabel.com -
Foundation Medicine
@FoundationATCG
Congratulations to Dr. @geoff_oxnard, SVP, Clinical Development on being recognized this past weekend at #asco23 as a Fellow of the American Society of Clinical Oncology (FASCO) for exceptional commitment, dedication & volunteer service to ASCO: connection.asco.org/magazine/features/asco-congratulates-…
-
Foundation Medicine
@FoundationATCG
The level of circulating tumor DNA (ctDNA) shed by a patient’s specific tumor informs the accuracy of blood-based CGP test results. Through a tumor fraction algorithm, our scientists developed a method for quantifying ctDNA in each blood sample: www.youtube.com/watch?v=QJQm3JFnSrM #asco23
-
Foundation Medicine
@FoundationATCG
#newstudy at #asco23 in partnership w/ @west_cancer, @OneOncology, @genentech & @flatironhealth examined elements of inequity in next generation sequencing for patients w/ advanced NSCLC being treated in the community setting in the United States: www.foundationmedicine.com/research/asco-2023-addressing-…
-
Foundation Medicine
@FoundationATCG
Looking forward to expanding our collaboration with Merck KGaA Darmstadt, Germany, focusing on companion diagnostics development for selected marketed and pipeline treatments. More on this announcement: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Oncologists consider many factors when choosing the right treatment approach for their patients. Learn more about tumor fraction and how this measure for quantifying circulating tumor DNA can help determine the actionability of blood-based CGP tests: www.youtube.com/watch?v=QJQm3JFnSrM
-
Foundation Medicine
@FoundationATCG
#newstudy using de-identified Flatiron Health-Foundation Medicine Clinico-Genomic Database analyzed data from 8K+ patients across 24 cancer types who received single agent ICI, demonstrating clinical validity of TMB w/ our FDA-approved CGP test: www.foundationmedicine.com/research/asco-2023-driving-inn…
Foundation Medicine
@FoundationATCG
Thank you to our collaborators - @UCD_Cancer @huntsmancancer @CleClinicMD @MassGeneralNews @MonashCCS @UHhospitals @flatironhealth @drgandara @neerajaiims @shilpaonc @KlempnerSam @emseeay @Amitmahipal79 @VivekSubbiah @rne_md & others #thisishowwepartner
-
Foundation Medicine
@FoundationATCG
#research being presented at #asco23 features new #data on our fusion detection capabilities & our blood-based comprehensive genomic profiling test’s tumor fraction reporting. Find out more: www.foundationmedicine.com/research/asco-2023-new-capabil…
-
Foundation Medicine
@FoundationATCG
Two studies being presented at #asco23 demonstrate the validity & utility of our complex biomarkers, including #newdata utilizing our unique signature for homologous recombination deficiency. Learn more: www.foundationmedicine.com/research/asco-2023-driving-inn…
-
Foundation Medicine
@FoundationATCG
#newresearch involving our circulating tumor DNA (ctDNA) monitoring test demonstrates the value that ctDNA monitoring may have in supporting providers w/ treatment planning for advanced cancer patients. More about this research being presented at #asco23: www.foundationmedicine.com/research/asco-2023-informing-o…
Foundation Medicine
@FoundationATCG
Looking forward to presenting this #research in partnership w/ @BrunaPellini, Dr. Mark Socinski & other collaborators
-
Foundation Medicine
@FoundationATCG
#announcing the launch of FoundationOne®Monitor* for research use in retrospective studies - available for biopharma customers, test provides unique access to our ctDNA tumor fraction biomarker: www.foundationmedicine.com/press-releases/foundation-medi…
*Research Use Only. Not for use in diagnostic procedures -
Foundation Medicine
@FoundationATCG
Heading to #asco23? So are we! Find us at Booth 19081 to learn more about Foundation Medicine and our work in precision cancer care: www.foundationmedicine.com/event/asco2023
-
Foundation Medicine
@FoundationATCG
Proud that our liquid-based test has received another companion diagnostic approval in Japan. Read more about the news here: www.chugai-pharm.co.jp/english/news/detail/20230526150000…
-
Foundation Medicine
@FoundationATCG
Foundation Medicine at #asco23 - 21 new pieces of research demonstrating advancements in #cancer monitoring, expanded #liquidbiopsy capabilities and the validity and utility of complex #biomarker detection. Learn more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
ctDNA testing has potential to transform care w/ real-time assessments of prognosis & treatment response using a simple blood draw. Our research in @NatureMedicine used machine learning to model ctDNA metrics in NSCLC patients to predict overall survival: www.foundationmedicine.com/research/research-spotlight-a-…
-
Foundation Medicine
@FoundationATCG
High-quality tests, such as companion diagnostics, can provide essential information for the safe & effective use of medication, enabling oncologists to deliver precision cancer care. More in a #newblog from our CEO, Dr. Brian Alexander (@xelamb): www.foundationmedicine.com/blog/an-inflection-point-for-h…
-
Foundation Medicine
@FoundationATCG
Excited to sponsor the STAT@ASCO: Science vs. Cancer event w/ @statnews at #asco23 for a discussion on how we can outsmart cancer with high-quality diagnostic tests. We hope to see you in Chicago! Register for the live event here: www.statnews.com/event/stat-at-asco-science-vs-cancer/
-
Foundation Medicine
@FoundationATCG
Just 21 days left until #asco23, but who’s counting? Our team is busy getting ready to join industry peers and leaders in Chicago. A throwback to our booth signage from 2022! Learn more about our booth & this year's meeting: www.foundationmedicine.com/event/asco2023 #wearefmi #thisishowwepartner
-
Foundation Medicine
@FoundationATCG
We enjoyed connecting with & learning from leaders in the diagnostics and precision medicine community last week at the World CB and CDx Europe Summit. Interested in learning more about our experience in companion diagnostic development? Click here: www.foundationmedicine.com/biopharma-hub
-
Foundation Medicine
@FoundationATCG
FoundationOne®Liquid CDx* - FDA approved to identify adult patients w/ locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations: www.foundationmedicine.com/press-releases/foundationone®…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1lcdxlabel.com -
Foundation Medicine
@FoundationATCG
Foundation Medicine is here in-person #aua23 Meeting, one of the world’s leading urology meetings! If you are at AUA, come visit our booth 4063 to say hello and discover how we help providers uncover more opportunities for patients with prostate cancer: www.foundationmedicine.com/event/aua-event-2023
-
Foundation Medicine
@FoundationATCG
Enjoyed having policymakers at our Research Triangle Park, N.C. site last week
Mia Levy, MD, PhD
@DrMiaLevy
Last week, alongside Dr. Aundrea Oliver and my colleague Dr. Julia Elvin, I had the chance to meet local policy makers at our site in Research Triangle Park, N.C., and have a discussion about the value of high-quality biomarker testing and the role it plays in precision oncology.
-
Foundation Medicine
@FoundationATCG
We’re looking forward to all of the presentations and discussions planned at the upcoming 13th Annual World CB & CDx Europe Summit in London. Heading to the meeting? Stop by our booth to learn more about Foundation Medicine. Learn more about the meeting: cdx-europe.com/register/
-
Foundation Medicine
@FoundationATCG
Our commitment to environmental, social & governance practices spans across our entire organization. Hear more below from Rita Kale, Chief Financial Officer & Executive Sponsor of ESG initiatives at Foundation Medicine. Learn more: www.foundationmedicine.com/esg
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
We'll be at #aua23! Did you know, Foundation Medicine is the only company with a tissue & liquid CGP test that each detects all 24 guideline-recommended biomarkers for advanced #prostatecancer? Learn more about our work in #precisioncancercare, booth 4063: www.foundationmedicine.com/event/aua-event-2023
-
Foundation Medicine
@FoundationATCG
In a letter to @CellPressNews' Cancer Cell, our scientists share new research demonstrating a consistent association between high tumor mutational burden (TMB-H) & outcomes on immune checkpoint inhibitors in patients of European, African & Asian ancestry: www.cell.com/cancer-cell/fulltext/S1535-6108(23)00090-9
Post not available here, view on X
Foundation Medicine
@FoundationATCG
These findings endorse the FDA’s efforts to rigorously validate complex biomarkers prior to approval to ensure their applicability to a wide range of cancer populations.
Foundation Medicine
@FoundationATCG
Excited to share this new publication @RichardHuangMD @RyonGraf @geoff_oxnard
-
Foundation Medicine reposted
Cancer Discovery
@CD_AACR
Integrative Analysis of a Large Real-world Cohort of #smallcelllungcancer Identifies Distinct Genetic Subtypes and Insights into Histological Transformation— by @smruthy90, @SageJulien, @christine_lovly et al.
aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159…
@FoundationATCG @Stanford @VUMC_Cancer -
Foundation Medicine
@FoundationATCG
#newresearch in ctDNA – study used our new methylation sequencing research test to evaluate ctDNA as a prognostic biomarker for overall survival for patients with metastatic castrate resistant prostate cancer. More on this research at #aacr23: www.foundationmedicine.com/research/evaluation-of-circula…
Foundation Medicine
@FoundationATCG
Excited to share this new research at #aacr23 in partnership with @SAiGENCI, @NHSBartsHealth, @genentech, @ChrisSweens1, @tompowles1, @SanjMariathasan
-
Foundation Medicine
@FoundationATCG
The AACR annual meeting provides insights into the latest and most exciting research in oncology. We’re looking forward to showcasing new research this year at #aacr23, including a new study evaluating ctDNA using our new methylation sequencing assay: www.youtube.com/watch?v=5Yg1o-bOjZA
-
Foundation Medicine
@FoundationATCG
#newresearch in partnership w/ @SageJulien and @christine_lovly at #aacr23 examined 3,600 patient cases to provide greater understanding of new genetic subtypes and histological transformation in small cell lung cancer (SCLC). Learn more: www.foundationmedicine.com/research/comprehensive-analysi…
-
Foundation Medicine
@FoundationATCG
The data our team & collaborators are bringing to #aacr23 showcase the important developments being made to advance the frontiers of cancer medicine. Read more for highlights on the research we are presenting: www.foundationmedicine.com/blog/taming-the-wilderness-bey…
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Looking forward to the presentations & discussions ahead at #aacr23. We will be presenting 10 new studies focused on our new methylation sequencing and the utility of our robust data. Connect with us live at Booth #3053: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Our expanded partnership w/ Bristol Myers Squibb builds on our ongoing research-driven partnership and furthers our shared commitment to deliver more treatment options to patients who need them. Learn more about today’s announcement: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Excited to share 10 new studies at #aacr23 that demonstrate the utility of our robust data and new methylation sequencing, working to provide doctors and researchers w/ high-quality solutions to help aid in treatment decision making and development: www.foundationmedicine.com/press-releases/c0470e96-49cd-4…
-
Foundation Medicine
@FoundationATCG
We are committed to educating on disparities in the oncology ecosystem & our work in #advancinginclusivediagnostics. More from Dr. Douglas Mata, Sr. Pathologist and Associate Medical Director at Foundation Medicine on research published in @NEJM: www.foundationmedicine.com/research/research-spotlight-di… #nmhm2023
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Our CBO Sanket Agrawal met w/ Dr. Anthony “Nino” Sireci, SVP of Clinical Biomarkers & Diagnostics Development, Loxo@Lilly, to discuss progress in precision oncology today & how we’re working together to deliver #equitableaccess to precision cancer care: www.foundationmedicine.com/blog/collaborating-to-advance-…
-
Foundation Medicine
@FoundationATCG
We’re here in-person at the #coa2023 Conference! It’s so great to connect with members of the community oncology space to discuss how we can advance cancer care together. If you are at the event, come say hello to us at Booth 308 #wearefmi
-
Foundation Medicine
@FoundationATCG
This week, we’re joining #oncology leaders at #coa2023. Schedule a meet and greet at our Booth #308 to learn more about our tailored solutions providing confidence, ease & access to community oncologists & their advanced cancer patients: www.foundationmedicine.com/event/coa-event-2023 #wearefmi
-
Foundation Medicine
@FoundationATCG
Recent #research aimed to validate that metastatic #colorectalcancer patients w/ microsatellite instability high tumors may have more favorable outcomes when receiving first-line immune checkpoint inhibitors vs. chemotherapy. More in @JAMANetworkOpen: jamanetwork.com/journals/jamanetworkopen/fullarticle/2800…
Foundation Medicine
@FoundationATCG
We're excited to share this new research in collaboration with @KlempnerSam as part of #colorectalcancerawarenessmonth
-
Foundation Medicine
@FoundationATCG
Recent data presented at ASCO #gu23 - samples used from phase III IMbassador250 trial confirmed strong association between a baseline ctDNA tumor fraction greater than 2% at the time of switching 2nd generation hormonal therapy treatments and OS in mCRPC: www.foundationmedicine.com/research/research-spotlight-ci…
-
Foundation Medicine
@FoundationATCG
Excited to meet w/ leaders across the #communityoncology landscape at #coa2023! Schedule a meet & greet to discuss tailored solutions providing confidence, ease & access from our services & high-quality tests. Together, we’ll advance #cancercare:
-
Foundation Medicine
@FoundationATCG
Excited for next week's @TriConference where our VP of Early Clinical Development, David Fabrizio, will be speaking on the panel “Rx/Dx Collaborations: Strategies for Bringing Targeted Therapies to Market." Learn more about this event: www.triconference.com #tricon
-
Foundation Medicine
@FoundationATCG
Our collaboration with @Point32Health aims to improve #access to #precisionmedicine for patients with advanced cancer through comprehensive genomic profiling (CGP) tests. Learn more about this announcement: www.foundationmedicine.com/press-releases/point32health-a…
-
Foundation Medicine
@FoundationATCG
#icymi a recent @JCOPO_ASCO podcast w/ @shilpaonc discussed recent #research in tumor mutational burden (TMB) utilizing the @flatironhealth and Foundation Medicine real-world clinico-genomic database. Listen here: sites.libsyn.com/427415/site/tumor-mutational-burden-as-a…
-
Foundation Medicine
@FoundationATCG
Using samples from phase III IMbassador250 trial, #newresearch presented at ASCO #gu23 confirmed strong association between a baseline ctDNA tumor fraction greater than 2% at the time of switching 2nd generation hormonal therapy treatments and OS in mCRPC: meetings.asco.org/abstracts-presentations/217178
Foundation Medicine
@FoundationATCG
Excited to present this research in collaboration w/ @ChrisSweens1 during the poster session today at ASCO #gu23
-
Foundation Medicine
@FoundationATCG
New #research used comprehensive genomic profiling to characterize the genomic alteration landscape of BRAF-activated tumors in advanced #prostate #cancer patients. More on this data being presented at ASCO #gu23: meetings.asco.org/abstracts-presentations/217031
Foundation Medicine
@FoundationATCG
Thank you to our collaborators, including @arafflemd @EAntonarakis @neerajaiims. Excited to present this research this week at ASCO #gu23
-
Foundation Medicine
@FoundationATCG
#newstudy used data from the @flatironhealth-Foundation Medicine clinico-genomic database to evaluate independent associations of TMB by clinical factors, prior treatment & genomics in #prostate #cancer. More on this research being featured at ASCO #gu23: meetings.asco.org/abstracts-presentations/217122
Foundation Medicine
@FoundationATCG
Looking forward to presenting this research at ASCO #gu23. Thank you to our collaborators @HougenHY @sanojpunnen @BrandonMahal
-
Foundation Medicine
@FoundationATCG
Next week at @HansonWade's Liquid Biopsy for Precision Oncology Summit - learn more about the latest advances on how to incorporate #liquidbiopsy in drug development, including how to integrate serial ctDNA testing for early treatment response insights: lbx-summit.com
-
Foundation Medicine
@FoundationATCG
#announcement - our tissue-based biopsy and liquid biopsy tests will be covered by @UHC for multiple companion diagnostic indications meeting coverage critera. Learn more: www.foundationmedicine.com/press-releases/unitedhealthcar…
-
Foundation Medicine
@FoundationATCG
Congratulations to our CEO Brian Alexander (@xelamb) for being named to @bostonmagazine's 2023 Top Doctors List. Thank you for your commitment to transforming cancer care for patients #wearefmi
Boston Magazine
@BostonMagazine
Discover the region's 1,914 top physicians in 70 specialties, as chosen by their peers. www.bostonmagazine.com/health/2023/01/24/top-doctors-bost…
-
Foundation Medicine
@FoundationATCG
At @HansonWade's Liquid Biopsy for Precision Oncology Summit, we're excited to join industry experts to review the most recent developments in the use of liquid biopsies for biomarker detection, clinical trial enrollment & treatment response. Learn more: lbx-summit.com
-
Foundation Medicine
@FoundationATCG
KRAS mutations are among the most prevalent cancer mutations and multiple new targeted therapies are in development. Our #newresearch in @Nature_NPJ analyzes KRAS-altered cancers in the largest pan-cancer survey to date of KRAS alterations: www.foundationmedicine.com/research/research-spotlight-co…
-
Foundation Medicine reposted
GenomeWeb
@GenomeWeb
Foundation Medicine, Natera Launch Early Access for Clinical Personalized ctDNA Monitoring Test. The personalized and targeted tumor assay, also available for research use in clinical trials, provides a surrogate measure of tumor burden from blood samples. www.genomeweb.com/molecular-diagnostics/foundation-medici…
-
Foundation Medicine
@FoundationATCG
We are committed to understanding and educating around disparities in cancer. More from our #newstudy on the increase in genomic testing among underserved racial and ethnic groups, as assessed by genetic ancestry, in @NEJM: www.nejm.org/doi/full/10.1056/NEJMc2213457?query=featured… #advancinginclusivediagnostics
-
Foundation Medicine
@FoundationATCG
FoundationOne Tracker offers physicians the ability to serially monitor patients’ response to treatment, especially immunotherapies, using a simple blood draw, supporting more informed decisions for future care. Learn more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Two new studies at @ASCO #gi23, feature research on predictive biomarkers and genomic alterations, using real-world data from patients with metastatic colorectal cancer (mCRC). Learn more about this #newresearch and poster session: meetings.asco.org/abstracts-presentations/search?q=*&filt…
-
Foundation Medicine
@FoundationATCG
#newresearch at @ASCO #gi23 focused on the feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in a phase II trial for rectal cancer patients. More on this research: meetings.asco.org/abstracts-presentations/215979
-
Foundation Medicine
@FoundationATCG
Proud to share that the lead investigators on 2 of our abstracts at @ASCO #gi23 have been recognized w/ a Conquer Cancer Merit Award. We congratulate this year’s recipients for all their contributions to advancing research within the cancer care community: www.conquer.org/news/conquer-cancer-announces-2023-gastro…
-
Foundation Medicine
@FoundationATCG
A deeper understanding of the genomic mutations that drive cancer ultimately informs the development of new therapies. Excited to announce our global collaboration w/ @boehringerus to advance targeted treatment options for biliary tract cancer: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Latest #fdaapproval for our liquid biopsy test reinforces the value of liquid biopsy testing to help oncologists identify more cancer patients w/ rare alterations, who do not have a tissue sample available, for whom a targeted therapy may be appropriate: www.foundationmedicine.com/press-releases/foundationone®…
-
Foundation Medicine reposted
The Cancer Letter
@TheCancerLetter
.@FoundationATCG & @NateraGenetics provide early access to personalized circulating tumor DNA monitoring assay.
cancerletter.com/drugs-and-targets/20230113_8b/ -
Foundation Medicine
@FoundationATCG
Accessible through our online portal, FoundationReport+ is customizable to each user’s preference and strives to deliver complex molecular information in a way that is digestible and useful for physicians. Learn about our #new digital reporting experience: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Excited to announce a global collaboration w/ @Karyopharm to develop a companion diagnostic for a targeted therapy being evaluated for patients w/ advanced or recurrent endometrial cancer, furthering our work to improve access to precision medicine: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Our personalized ctDNA monitoring assay w/ @NateraGenetics now available for investigational use and early access clinical use, provides researchers and physicians with a tissue-informed solution to monitor advanced cancer patients’ response to therapy: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Endpoints at #jpm23 - join Foundation Medicine CEO, Dr. Brian Alexander (@xelamb) for a roundtable discussion on the latest advancements in oncology R&D, therapies and diagnostics. More about this live & virtual session next week, hosted by @endpts: endpoints.studio/events/
-
Foundation Medicine
@FoundationATCG
Our liquid biopsy test* is now FDA approved for 9 targeted therapies, helping patients with NSCLC & other solid tumors get access to targeted care: www.foundationmedicine.com/press-releases/d5239ed8-e26e-4…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1lcdxlabel.com -
Foundation Medicine
@FoundationATCG
Proud to be a sponsor at the virtual & live “Endpoints at #jpm23” event, next week hosted by @endpts. Looking forward to engaging in conversations with industry leaders across #healthcare. More on this event: endpoints.studio/events/
-
Foundation Medicine
@FoundationATCG
Our liquid biopsy test is now #fdaapproved to identify certain NSCLC patients who may be appropriate for treatment w/ a group of TKIs: www.foundationmedicine.com/press-releases/foundation-medi…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1lcdxlabel.com -
Foundation Medicine
@FoundationATCG
In the post-pandemic era of healthcare, patients are recognizing the advantages of digital tools while providers are adapting to a more informed and engaged patient population. More from our Chief Medical Officer, @DrMiaLevy via @MedEconomics: www.medicaleconomics.com/view/the-post-pandemic-patient-a…
-
Foundation Medicine
@FoundationATCG
The functionality of our #new FoundationReport+ offers physicians additional tools to complement integrated electronic health records and make it easier to review results, supporting more informed decisions. More about our digital reporting experience: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
New #lungcancer research in @IASLC’s @JTOonline assessed multi-gene testing in early lung adenocarcinoma, assessing the value of CGP in identifying appropriate first-line therapy options and potential cost-effectiveness in avoiding ineffective treatments: www.jto.org/article/S1556-0864(22)01937-2/fulltext
-
Foundation Medicine
@FoundationATCG
Our #newresearch published w/ @genentech in @JCOPO_ASCO evaluated the frequency and types of PIK3CA mutations detected in predicted genetic ancestry subgroups across #breastcancer subtypes. Learn more: ascopubs.org/doi/abs/10.1200/PO.22.00341 #advancinginclusivediagnostics
-
Foundation Medicine
@FoundationATCG
Proud to partner with the Addario Lung Cancer Medical Institute, @GO2forLungCancr & principal investigator
@DrMarkAwad on the new SPARK Study, using blood-based molecular profiling to better understand treatment resistance in patients with KRAS-positive cancer.
GO2 for Lung Cancer
@GO2forLungCancr
NEWS: New SPARK Study is driving research and better treatment options for #kras positive #lungcancer. Learn more. >> go2.org/blog/new-study-to-address-cancer-treatment-resist…
-
Foundation Medicine
@FoundationATCG
Circulating tumor DNA (ctDNA) response monitoring is emerging as a dynamic, personalized biomarker method. #newresearch in @MolOncology assessed ctDNA in patients receiving two immune checkpoint inhibitors using our forthcoming ctDNA-based monitoring test: www.foundationmedicine.com/research/research-spotlight-ea…
-
Foundation Medicine
@FoundationATCG
Learn from a panel of our Foundation Medicine colleagues in part 2 of the “Liquid Biopsy in Clinical Practice” webinar on Tuesday, November 29th at 10:00 a.m. ET. Register here: foundationmedicinewebinar.com/register/
-
Foundation Medicine
@FoundationATCG
In recognition of #lungcancerawarenessmonth, we’re proud to support and share a resource developed by @LUNGevity to help patients and their families understand #biomarkertesting results. Learn more: www.lungevity.org/sites/default/files/file-uploads/Readin…
-
Foundation Medicine
@FoundationATCG
We were happy to be part of the conversation about the most important topics in health at @statnews #statsummit this week. Our @DrMiaLevy and @JenMillsAU were joined by Dr. @christine_lovly to discuss how diagnostics can make cancer care more equitable.
Mia Levy, MD, PhD
@DrMiaLevy
Too often, cancer care is determined more by a person’s zip code than their genetic code. Thank you, Dr. @christine_lovly and @JenMillsAU for such an engaging panel on how diagnostics can make cancer care more equitable for all. #statsummit
-
Foundation Medicine
@FoundationATCG
FoundationReport+, our #new interactive digital reporting experience, provides physicians with an adaptable experience to view genomic insights and supports more efficient and streamlined treatment decisions for their patients. Learn more: www.foundationmedicine.com/press-releases/89b9505b-09c9-4…
-
Foundation Medicine
@FoundationATCG
This week at @HansonWade’s Liquid Biopsy Surveillance & Early Detection Summit – join Dr. @geoff_oxnard for an educational session on late breaking advances in using tissue & liquid biopsy in drug development: lbx-surveillance-early-detection-summit.com
-
Foundation Medicine
@FoundationATCG
#announcing the launch of FoundationReport+, a new interactive digital reporting experience to enhance usability, convenience and flexibility of comprehensive genomic profiling (CGP) results for physicians. Learn more: www.foundationmedicine.com/press-releases/89b9505b-09c9-4…
-
Foundation Medicine
@FoundationATCG
This #veteransday, we are proud to share stories from veterans, Matt, Federal Account Director, and Patrick, Manager, Environmental Health and Safety, who have taken the skills they gained from serving our country to now serve those impacted by cancer: careers.foundationmedicine.com/blogs/inside-foundation-me…
-
Foundation Medicine
@FoundationATCG
New JCO After Hours podcast: @rachnatshroff & @PamelaKunzMD share more about our joint research published last week in @JCO_ASCO 'Where Are All the Women in Industry Advisory Boards?' Hear more: jcopodcast.libsyn.com/lack-of-gender-equity-in-oncology-c…
-
Foundation Medicine
@FoundationATCG
Next week at @HansonWade's Liquid Biopsy Surveillance & Early Detection Summit, we’re excited to join industry experts to discuss the latest innovations and insights in #liquidbiopsy. Learn more: lbx-surveillance-early-detection-summit.com
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is committed to addressing disparities in the oncology ecosystem. Proud to have collaborated w/ trailblazing partners on this new publication in @JCO_ASCO featuring insights on gender and disparities in ad board composition. Learn more: ascopubs.org/doi/full/10.1200/JCO.21.02219
-
Foundation Medicine reposted
AtlanticLIVE
@AtlanticLIVE
SPONSORED CONTENT: In a Underwriter Session produced by Foundation Medicine, @FoundationATCG‘s @xelamb speaks with @YaleCancer @SmilowCancer’s @PamelaKunzMD at #peoplevcancer about the collective responsibility to ensure equity in access to care, clinical trials, new therapies
This media couldn't be displayed. See it on the original post. -
Foundation Medicine reposted
AtlanticLIVE
@AtlanticLIVE
We’re LIVE at #peoplevcancer, underwritten by @bmsnews, @FoundationATCG, @PhRMA, & @TakedaPharma. Join us as we explore the latest scientific breakthroughs reshaping patient care and treatment, and renewing optimism within the cancer community.
Tune in: www.youtube.com/watch?v=i_wHzNR0xGk -
Foundation Medicine
@FoundationATCG
Join CEO Dr. Brian Alexander (@xelamb) and @PamelaKunzMD of @SmilowCancer @YaleCancer for @AtlanticLIVE #peoplevcancer this Thursday. Our session "Molecular Profiling in Oncology: A Path to More Personalized Cancer Care" is at 1:05 PM. Register for free: www.theatlantic.com/live/people-v-cancer-2022/
-
Foundation Medicine
@FoundationATCG
Looking forward to joining the conversation on major areas of clinical molecular diagnostics at #ampath22 next week. Stop by Booth #807 to hear more about our latest innovations and research for precision cancer care. amp22.amp.org @AMPath
-
Foundation Medicine
@FoundationATCG
#newstudy w/ @lonardi_sara in @IJMS_MDPI: researchers established feasibility of molecular residual disease detection using our forthcoming ctDNA-based monitoring test in adv. colorectal cancer patients once metastatic lesions have been surgically removed www.foundationmedicine.com/research/research-spotlight-co…
-
Foundation Medicine
@FoundationATCG
#newresearch in @JCOPO_ASCO studied the relationship between circulating tumor DNA (ctDNA) shed and detection of actionable biomarkers in liquid biopsy-based genomic profiling across 23,000 specimens. Learn more about the findings of this study: www.foundationmedicine.com/research/research-spotlight-tu…
-
Foundation Medicine
@FoundationATCG
#newresearch w/ lead investigator @pashtoonkasi being presented at the @isliquidbiopsy 2022 Congress analyzed the use of liquid biopsy-based comprehensive genomic profiling to detect gene rearrangements in tumor suppressors: islb.info/congress-2022/ #islb2022
-
Foundation Medicine
@FoundationATCG
Excited to join #liquidbiopsy experts at this year’s @isliquidbiopsy 2022 Congress where we will be sharing new #research featuring the latest advancements in liquid biopsy-based comprehensive genomic profiling. Learn more about #islb2022: islb.info/congress-2022/
-
Foundation Medicine
@FoundationATCG
Excited for @JournPrecMed and @GenomeWeb's Precision Oncology and Diagnostics Summit in Chicago this week. Our Chief Medical Officer @DrMiaLevy will be speaking on the latest advances in implementing molecularly guided cancer care: web.cvent.com/event/4c8f4cdc-072c-4999-885b-bf9ed16cf1c1/…
-
Foundation Medicine
@FoundationATCG
Join us next week at @isliquidbiopsy 2022 congress for an educational symposium with @BrunaPellini @UmbertoMalapel1 and Foundation Medicine’s @geoff_oxnard for a discussion on utilizing #liquidbiopsy and #tissuebiopsy in patient treatment decisions: islb.info/congress-2022/
-
Foundation Medicine reposted
AtlanticLIVE
@AtlanticLIVE
For young adults cancer patients in remission, fear of recurrence and even PTSD can become the new normal. More: on.theatln.tc/atlYwSX
We'll gather the cancer community on 11/3 at #peoplevcancer, underwritten by @FoundationATCG, @PhRMA, & @TakedaPharma: on.theatln.tc/tBjalNJ -
Foundation Medicine
@FoundationATCG
The work we do for providers and patients is inspired both by our professional interests and our personal connections to cancer. Learn more from Henry, Medical Science Liaison, and co-founder of Black in Cancer, on his work in the field and the community: careers.foundationmedicine.com/blogs/inside-foundation-me…
-
Foundation Medicine
@FoundationATCG
A new #realworld study of over 1700 patients analyzed plasma ctDNA fraction as a prognostic biomarker across four advanced cancers. Learn more: www.annalsofoncology.org/article/S0923-7534(22)04186-2/fu…
-
Foundation Medicine
@FoundationATCG
Join us Wednesday, October 12th at 10:00 a.m. ET to hear from a panel of our Foundation Medicine colleagues on liquid biopsy in clinical practice. Register: foundationmedicinewebinar.com/register/
-
Foundation Medicine
@FoundationATCG
Open now: We are accepting applications for a joint grant to address disparities in oncology care. Learn more about how to apply by October 25, 2022: www.foundationmedicine.com/grants
-
Foundation Medicine
@FoundationATCG
Proud to be part of this premier event, gathering leading voices across the #oncology community
AtlanticLIVE
@AtlanticLIVE
On 11/3, @TheAtlantic will convene survivors, providers, patients, & scientists to examine the breakthroughs reshaping cancer care and treatment. Register for #peoplevcancer, underwritten by @FoundationATCG, @PhRMA, & @TakedaPharma, here: on.theatln.tc/Cs7Z0f9
-
Foundation Medicine
@FoundationATCG
We are always looking innovative ways to optimize the work that we do in order to better serve our patients and partners. Learn more about our recent integration with @EpicShares Aura Network and our Epic Scrum Team, who help bring it all together: careers.foundationmedicine.com/blogs/inside-foundation-me…
-
Foundation Medicine
@FoundationATCG
As #cancer progresses, comprehensive genomic profiling (CGP) w/ liquid biopsy can provide further insights & options to inform decision making throughout a patient’s treatment journey. Hear more about liquid biopsy CGP for patients with #prostatecancer: www.youtube.com/watch?v=k_oUfZCa1po
-
Foundation Medicine
@FoundationATCG
#research in @JAMANetworkOpen evaluated treatment class-specific outcomes of prostate cancer patients receiving immune checkpoint inhibitor (ICI) vs. taxane chemotherapy by tumor mutational burden (TMB): jamanetwork.com/journals/jamanetworkopen/fullarticle/2790572 #prostatecancerawarenessmonth
-
Foundation Medicine
@FoundationATCG
We are committed to helping shape the future of clinical care and research through cross-industry partnership. Open now – a Call for Grants Notification, seeking collaborative initiatives to address disparities in oncology care: www.foundationmedicine.com/grants
-
Foundation Medicine reposted
Flatiron Health
@flatironhealth
Ariel Bourla sat down w/ @JournPrecMed to discuss a study done in partnership w/@FoundationATCG & @Genentech, that found potential for an add'l diagnostic approach to personalized NSCLC therapy. More on the thought & design behind this innovative study. www.thejournalofprecisionmedicine.com/wp-content/uploads/…
-
Foundation Medicine reposted
Elizabeth McKenna
@ElizSMcKenna
ICYMI in @CD_AACR: The #genomics of #colorectalcancer in Populations with African & European Ancestry @MontefioreNYC @ae_cancercenter @EinsteinMed @FoundationATCG #aacrdisp22 aacrjournals.org/cancerdiscovery/article/12/5/1282/694522…
-
Foundation Medicine
@FoundationATCG
Continued research in oncology drives our mission to transform cancer care. In celebration of #worldcancerresearchday this weekend and Ovarian Cancer Awareness Month, hear from members of our medical team about the advancements being made: careers.foundationmedicine.com/blogs/inside-foundation-me…
-
Foundation Medicine
@FoundationATCG
In recognition of Ovarian Cancer Awareness Month, we’re sharing some keys facts about common symptoms and risks to be aware of. Visit our friends at @ocrahope for additional resources and support.
-
Foundation Medicine
@FoundationATCG
As #research for #prostatecancer continues to evolve and as new therapeutic options are identified, comprehensive genomic profiling with liquid biopsy can help play a critical role in treatment planning: www.youtube.com/watch?v=k_oUfZCa1po
-
Foundation Medicine
@FoundationATCG
We're collaborating w/@DayOneBio to develop a companion diagnostic for use with Day One’s investigational therapy, tovorafenib (DAY101), for the potential treatment of patients with pediatric low-grade glioma. Learn more: www.foundationmedicine.com/press-releases/foundation-medi… #childhoodcancerawareness
-
Foundation Medicine
@FoundationATCG
This #prostatecancerawarenessmonth, we’re sharing new research to better serve our partners and patients. A recent, special issue of The Prostate highlights the genetics and genomics of prostate cancer and therapeutic implications: onlinelibrary.wiley.com/toc/10970045/2022/82/S1
-
Foundation Medicine reposted
AtlanticLIVE
@AtlanticLIVE
Join us on 11/3 for demonstrations, the unveiling of groundbreaking research, and in-depth conversations from the front lines of the cancer community. Register for the #peoplevcancer summit, underwritten by @FoundationATCG, @PhRMA, & @TakedaPharma, here: on.theatln.tc/z3RBxoK
-
Foundation Medicine
@FoundationATCG
Samples from initial tissue biopsy may no longer reflect the tumor being treated today. Comprehensive genomic profiling through liquid biopsy may provide critical insights to the genomic drivers in #prostatecancer: www.youtube.com/watch?v=k_oUfZCa1po #prostatecancerawarenessmonth
-
Foundation Medicine
@FoundationATCG
Utilizing machine learning to leverage our research dataset, the development of Foundation Medicine’s novel homologous recombination deficiency (HRD) signature identifies the characteristics of HRD scarring across cancer types. Learn more: www.youtube.com/watch?v=rrOYBT2GJ88&list=PLdvW0JcZhM-JNNW… #esmo22
-
Foundation Medicine
@FoundationATCG
#newresearch at #esmo22 evaluated the association of SPOP mutations with treatment-specific outcomes with novel hormonal therapy vs. taxanes in de novo metastatic prostate cancer. Read more in @CCR_AACR: aacrjournals.org/clincancerres/article/doi/10.1158/1078-0…
-
Foundation Medicine
@FoundationATCG
Proud to be among many of our oncology community partners at @POTUS’s #cancermoonshot speech earlier today. It’s inspiring to see bright minds across industries re-commit to making significant progress in patient care, and ending cancer as we know it. #endcancer
Brian Alexander
@xelamb
Honored to attend @POTUS's #cancermoonshot address today. We’re generating so much information about this disease and have seen significant advancements, but we need to learn more from patients, share knowledge, and forge deeper collaborations to end suffering from cancer.
-
Foundation Medicine
@FoundationATCG
#newresearch at #esmo22 investigated homologous recombination deficiency (HRD) in non-small cell lung cancer. Learn more about our novel HRD signature and the new study being presented: www.youtube.com/watch?v=rrOYBT2GJ88&list=PLdvW0JcZhM-JNNW…
-
Foundation Medicine
@FoundationATCG
Partnerships play a pivotal role in our mission to improve access to precision medicine. We are excited to announce our collaboration with @Relay_Tx to advance treatment options for patients w/ cholangiocarcinoma: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
New #data presented at #esmo22 analyzes genomic findings of intrahepatic cholangiocarcinoma with low vs. high tumor mutational burden (TMB). Learn more: www.foundationmedicine.com/research/intrahepatic-cholangi…
-
Foundation Medicine
@FoundationATCG
HRD may be a biomarker for many classes of therapies, including PARP inhibitors. At #esmo22, we’re excited to expand upon our research on how HRD can be targeted with precision therapies. Hear more from Ethan Sokol, Principal Scientist: www.youtube.com/watch?v=rrOYBT2GJ88&list=PLdvW0JcZhM-JNNW…
-
Foundation Medicine
@FoundationATCG
At #esmo22, we’re discussing #newresearch on the genomic alterations found in brain metastases originating from lung cancer. More on tomorrow’s oral presentation: www.foundationmedicine.com/research/genomic-profiling-and…
-
Foundation Medicine
@FoundationATCG
Two new studies featured at #esmo22 explore the use of our novel homologous recombination deficiency (HRD) signature in patient selection or treatment benefit in different cancer types. Learn more about this #newresearch: www.foundationmedicine.com/research
-
Foundation Medicine
@FoundationATCG
#newresearch at #esmo22 analyzes the association of SPOP mutations in treatment selection and response in advanced cancers. Read more about these two new studies: www.foundationmedicine.com/research
-
Foundation Medicine
@FoundationATCG
Excited to join oncology leaders and researchers at #esmo2022 and feature new research, including data that reinforces the value of Foundation Medicine’s emerging novel homologous recombination deficiency signature. More about the data being presented: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine reposted
AtlanticLIVE
@AtlanticLIVE
At the 5th #peoplevcancer summit, @TheAtlantic will explore the scientific breakthroughs reshaping patient care and treatment, and how they've renewed community optimism. Register for this event underwritten by @FoundationATCG, @PhRMA, & @TakedaPharma : on.theatln.tc/ttgwI5k
-
Foundation Medicine
@FoundationATCG
#newresearch evaluated the effectiveness of immune checkpoint inhibitor (ICPI) monotherapy vs. chemotherapy in patients with advanced gastroesophageal cancer and tumor mutational burden (TMB) in a real-world setting. Learn more at @CRC_AACR: aacrjournals.org/cancerrescommun/article/doi/10.1158/2767…
-
Foundation Medicine
@FoundationATCG
#newresearch assessed whether TMB identifies clinical benefit of first-line immunotherapy treatment vs. chemotherapy in metastatic urothelial carcinoma patients. Learn more in @JCOPO_ASCO: ascopubs.org/doi/full/10.1200/PO.22.00121
-
Foundation Medicine
@FoundationATCG
Proud to share that our first customer has been fully integrated onto Epic's network. We are committed to continuously finding ways to better serve patients and our partners and are excited w/ the progress made since our partnership announcement: www.foundationmedicine.com/press-releases/foundation-medi… #wearefmi
-
Foundation Medicine reposted
Cancer Research Communications
@CRC_AACR
Just published: Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced #gastroesophagealcancer. Read more in this study by @RyonGraf et al.
aacrjournals.org/cancerrescommun/article/doi/10.1158/2767…
@FoundationATCG #openaccess -
Foundation Medicine
@FoundationATCG
In partnership with @oncodeinstitute and an international team of researchers, we published #newresearch in @Nature analyzing how genomic variations contribute to the formation and targeted treatment of tumors. Learn more: go.nature.com/3STVHWG
-
Foundation Medicine
@FoundationATCG
Data from the ongoing Prospective Clinicogenomic (PCG) Study reinforced the complementary value of tissue and blood-based CGP tests to help identify precision treatment options for patients. More about this new research w/ @flatironhealth and @genentech: www.jtocrr.org/article/S2666-3643(22)00110-2/fulltext
-
Foundation Medicine
@FoundationATCG
In collaboration with @CancerResrch, #newresearch published in @JCOPO_ASCO shows changes in #ctdna reflect clinical benefit to #patients. Learn more: ascopubs.org/doi/full/10.1200/PO.21.00372 #whatfriendsdoes #ctdnafriends
-
Foundation Medicine
@FoundationATCG
#newresearch w/ @flatironhealth @genentech from the Prospective Clinicogenomic (PCG) Study compared our CGP testing to limited tissue testing in detecting actionable, guideline-recommended biomarkers for targeted treatment planning in patients w/ aNSCLC: www.jtocrr.org/article/S2666-3643(22)00110-2/fulltext
-
Foundation Medicine
@FoundationATCG
#newresearch presented at #wclc22 used real-world evidence to quantify the clinical utility of confirmatory tissue biopsy testing after negative liquid biopsy testing in non-small cell lung cancer. Learn more: library.iaslc.org/conference-program?product_id=25&author…
-
Foundation Medicine
@FoundationATCG
In partnership with @flatironhealth, @genentech and a network of community oncology practices, we are excited to release new research on tumor profiling results from the ongoing Prospective Clinicogenomic (PCG) Study. More on this new data and the study: www.foundationmedicine.com/press-releases/initial-analysi…
-
Foundation Medicine
@FoundationATCG
#newresearch investigated the relationship between method of tissue acquisition (biopsy vs. fine-needle aspiration vs. resection) and comprehensive genomic profiling success in lung cancer. Learn more: meridian.allenpress.com/aplm/article/doi/10.5858/arpa.202…
-
Foundation Medicine
@FoundationATCG
We are excited to share that we have been named a best place to work by the Triangle Business Journal. We are proud to foster an environment that allows us to be our authentic selves to continue our work for our patients and providers: careers.foundationmedicine.com/rtp #wearefmi
-
Foundation Medicine
@FoundationATCG
Join @CancerResrch, our Dr. @geoff_oxnard and other industry experts for the "Expediting Drug Development: Use of ctDNA as an Early Endpoint" virtual meeting this Wednesday, 7/20. Register here: friendsofcancerresearch.org/event/expediting-drug-develop…
Friends of Cancer Research
@CancerResrch
Final agenda available for @CancerResrch’s virtual meeting "Expediting Drug Development: Use of #ctdna as an Early Endpoint."
Register now: friendsofcancerresearch.org/event/expediting-drug-develop… #ctdnafriends -
Foundation Medicine
@FoundationATCG
Foundation Medicine employees are settling into our new San Diego site located in the heart of the city’s life science cluster. We are excited to be a part of this innovative environment that will allow us to continue our work to transform cancer care: careers.foundationmedicine.com/en-US/blogs/inside-foundat…
-
Foundation Medicine
@FoundationATCG
Proud to share that we have now delivered 1 million reports, generated from our portfolio of CGP tests. Learn more about what this means for patients and the partners we serve in a blog from our CEO, Dr. Brian Alexander (@xelamb): www.foundationmedicine.com/blog/one-million-patient-repor…
-
Foundation Medicine
@FoundationATCG
We are excited about this important collaboration with @InstituteTiger, @Mizzou, and @Cerner to bring precision therapy options to more patients.
MU Health Care
@muhealth
The @InstituteTiger, a unique partnership between @Mizzou and @Cerner, has partnered with @FoundationATCG for a new automated system that will mean faster results, fewer delays and improved patient outcomes.
Read more here ➡️ www.muhealth.org/for-media/press-releases -
Foundation Medicine reposted
Nature Communications
@NatureComms
#genomic profiling of 7,494 sarcomas across 44 histologies using #targetedsequencing reveals potential therapeutic targets
#cancerresearch by Gounder et al. @DX_Jin @MSKCancerCenter @FoundationATCG
@NatResCancer
go.nature.com/3Hv45Xr -
Foundation Medicine
@FoundationATCG
Ensuring that employees can be their most authentic selves every day is one of our most pivotal commitments as a company. This month, we celebrate the LGBTQ+ community and reinforce our responsibility to fostering an inclusive environment for all. #wearefmi #pride2022
-
Foundation Medicine
@FoundationATCG
We are inspired every day from the stories we hear from our patients. Their perseverance and courage drive us in our work to advance cancer care. #cancersurvivormonth #wearefmi
-
Foundation Medicine
@FoundationATCG
Foundation Medicine offices will be closed tomorrow in recognition of the end of slavery in the United States. This #juneteenth2022, we reflect upon the progress we have made and recognize the steps we still have left to take to create a more equitable future for all.
-
Foundation Medicine reposted
Precision Medicine World Conference
@PMWCintl
Looking forward to hearing from @PritiHegde Chief Scientific Officer of @FoundationATCG #pmwc22 in Silicon Valley on June 29. Her talk is part of the Liquid Biopsy (full-day) track dedicated to the latest technical advancements www.pmwcintl.com/program/?pmwc-program=true&sidebar=true&…
-
Foundation Medicine
@FoundationATCG
Our inaugural Diversity, Equity, and Inclusion (DE&I) annual report - a critical part of our Environmental, Social & Governance journey - highlights our ever-evolving, unwavering commitment to DE&I and mission to continue making progress: assets.ctfassets.net/w98cd481qyp0/1c7IasTLommHlUAPMNNuqR/… #wearefmi
-
Foundation Medicine
@FoundationATCG
FoundationOne CDx* is now FDA-approved as a companion diagnostic to identify patients w/ ROS1-positive NSCLC or NTRK fusion-positive solid tumors: www.foundationmedicine.com/press-releases/u.s.-fda-approv…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1cdxlabel.com -
Foundation Medicine
@FoundationATCG
Chugai, our partner in Japan, announced that our tissue-based CGP test is now approved as a CDx for 4 targeted therapies for Melanoma & NSCLC: www.chugai-pharm.co.jp/english/news/detail/20220603170000…
*Rx only; doesn't guarantee treatment match or that all alterations will be found -
Foundation Medicine
@FoundationATCG
#newresearch at #asco22 in collaboration with @CleClinicMD’s Nathan A. Pennell, MD, PhD, FASCO (@n8pennell) & @flatironhealth assessed the potential value of multi-gene testing in early-stage lung adenocarcinoma. Don’t miss out on today‘s session: www.foundationmedicine.com/research/a-real-world-rw-evide…
-
Foundation Medicine
@FoundationATCG
Supporting the progression of #research and #clinicaltrials will help accelerate therapeutic options in early cancer. More on our partnership with @lcrf_org & the Lung Cancer Mutation Consortium from our Chief Scientific Officer, Priti Hegde: www.foundationmedicine.com/blog/whats-next-with-priti-heg…
-
Foundation Medicine
@FoundationATCG
Deepening a collective understanding of cancer with our partners is an essential part of our mission to transform cancer care. We are proud to announce our collaboration with @ArvinasInc to advance the development of novel therapies for prostate cancer: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Partnering with @DanaFarber @sands_jacob research at #asco22 used real-world data from the @flatironhealth-Foundation Medicine Clinico-Genomic Database to better understand patients with durable benefit from immune checkpoint inhibitors in advanced NSCLC: www.foundationmedicine.com/research/clinical-and-genomic-…
-
Foundation Medicine reposted
Lung Cancer Research Foundation
@lcrf_org
#asco22 – June 6, 8 AM CT, Hall A, poster 219a: Dr. Boris Sepesi and LCRF Scientific Advisory Board member Dr. Mark Kris - poster session on the LCMC LEADER neoadjuvant screening trial, LCMC4 evaluation of actionable drivers in early stage #lungcancer. lcrf.org/asco2266mk
-
Foundation Medicine
@FoundationATCG
Chief Scientific Officer @PritiHegde discusses #asco22 data using the @flatironhealth-Foundation Medicine Clinico-Genomic database to assess the clinical value of comprehensive genomic profiling in early-stage NSCLC, in collaboration with @CleClinicMD: www.foundationmedicine.com/blog/whats-next-with-priti-heg…
-
Foundation Medicine
@FoundationATCG
Using real-world data, we explored the genomic landscape of MET amplification of NSCLC and its association with outcomes to MET tyrosine kinase inhibitors. More about this research, in partnership with @CUCancerCenter: www.foundationmedicine.com/research/real-world-rw-analysi…
-
Foundation Medicine
@FoundationATCG
Our data at #asco22 showcases our commitment to understanding cancer at the genomic level. Establishing precision medicine as the standard of care in early cancer is the next step in the journey. Learn more from Chief Scientific Officer, Priti Hegde: www.youtube.com/watch?v=dEPdbxAV2jU
-
Foundation Medicine
@FoundationATCG
#newresearch at #asco22 investigates circulating tumor DNA shed as an indicator to support treatment selection in advanced NSCLC using @flatironhealth-Foundation Medicine Clinico-Genomic Database. Read more on this study w/ @GustaveRoussy: www.foundationmedicine.com/research/ctdna-shed-as-a-tool-…
-
Foundation Medicine
@FoundationATCG
We are committed to being an engaged collaborator in the pivotal research needed to shape the future of cancer care for patients at all stages. Read more about our partnership with @lcrf_org & the Lung Cancer Mutation Consortium: www.foundationmedicine.com/press-releases/foundation-medi… #asco22
-
Foundation Medicine
@FoundationATCG
We’re proud to announce that the lead investigators on four of our studies at #asco22 have been awarded a Conquer Cancer Merit Award. Congratulations to all the other honorees on making important progress for patients. Learn more about this recognition: conquer.org/news/conquer-cancer-announces-2022-asco-annua…
-
Foundation Medicine
@FoundationATCG
Excited to discuss the latest innovations in cancer research at #asco22. Along with our collaborators, we will be presenting 26 studies on genomic research that provide new insights around potential targeted treatment options for patients. Learn more: www.foundationmedicine.com/event/asco2022
-
Foundation Medicine
@FoundationATCG
Key data presented at #asco22 reinforces the utility of Foundation Medicine’s tissue- and blood-based comprehensive genomic profiling to support treatment planning, and demonstrates the value of real-world genomic data to facilitate research. Read more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Celebrating National Cancer Research Month with #newresearch that assessed blood tumor mutational burden as a biomarker for first-line treatment in non-small cell lung cancer in a phase 2 trial. Learn more in @NatureMedicine: go.nature.com/37RYY6p #ncrm22
-
Foundation Medicine
@FoundationATCG
Tomorrow at 12 PM ET, join Dr. Julia Elvin, SVP, Pathology & Diagnostic Medicine, for @targetcancer’s
Women on TRACK Lunch & Learn panel
TargetCancer Fdn
@targetcancer
Thursday! Join us for a Lunch and Learn featuring the amazing women leading the @targetcancer TRACK study. us02web.zoom.us/webinar/register/WN_TThP7l9iQyu04miiilHvwA
-
Foundation Medicine
@FoundationATCG
#newresearch UV radiation exposure causes a characteristic genomic mutational pattern associated with elevated tumor mutational burden that can also help to confirm diagnosis. More in @JAMANetworkOpen: jamanetwork.com/journals/jamanetworkopen/fullarticle/2790435 #skincancer #sharethefacts
-
Foundation Medicine
@FoundationATCG
Congratulations to our Chief Commercial Officer, Dymeka Harrison, on being selected as a 2022 Exceptional Women Awardee #wearefmi
Exceptional Women Alliance
@ExceptionalEWA
We are delighted to welcome Dymeka Harrison, Chief Commercial Officer at Foundation Medicine as an Exceptional Women Awardee! We look forward to learning and growing with her.
www.prweb.com/releases/the_exceptional_women_awardees_fou… -
Foundation Medicine
@FoundationATCG
Our mission is to ensure more patients living with cancer can benefit from precision treatment options. We’re proud to collaborate with Aadi Bioscience to expand access to precision medicine in the clinic, and ultimately enable more treatment options for patients in the future
Aadi Bioscience
@aadibio
We are excited to announce the start of new partnerships with @FoundationATCG and @TempusLabs to expedite identification of advanced cancer patients with TSC1 and TSC2 inactivating alterations for the PRECISION 1 #clinicaltrial. Learn more here: ir.aadibio.com/news-releases/news-release-details/aadi-bi… #ngs
-
Foundation Medicine
@FoundationATCG
Thanks @AnneMostue for joining us today for a behind the scenes look at the work we’re doing for patients. Hope everyone tunes in at 2:30.
-
Foundation Medicine
@FoundationATCG
Our teams in the lab collaborate every day to ensure that patients and oncologists are getting the results they need to support treatment planning. Hear more from Anna, a Molecular Technologist II, about her role: careers.foundationmedicine.com/en-US/blogs/inside-foundat… #wearefmi
-
Foundation Medicine
@FoundationATCG
Helping to inform treatment decisions for patients with advanced cancer drive us in the work we do every day. Learn more about Marianne and how comprehensive genomic profiling (CGP) helped her and her doctor learn more about potential treatment options: www.youtube.com/watch?v=268D41hqWDE
-
Foundation Medicine
@FoundationATCG
Our Accessioning team is the first point of contact for patient samples received at Foundation Medicine. Robin, team lead at our Research Triangle Park lab, discusses her team's role in helping oncologists make informed treatment plans. careers.foundationmedicine.com/en-US/blogs/inside-foundat… #wearefmi
-
Foundation Medicine
@FoundationATCG
Our employees are at the core of the work that we do to transform cancer care. We are honored to be included as a @BosBizJournal Best Places to Work for a third year in a row: careers.foundationmedicine.com/blogs/inside-foundation-me… #wearefmi #bbjbestplaces
-
Foundation Medicine
@FoundationATCG
As part of the @BBGNewEconomy International Cancer Coalition, leaders at Foundation Medicine have partnered with global experts to address barriers to cancer clinical trial enrollment and accelerate drug development. Read more in @NatureMedicine: go.nature.com/3uZ0mwH
-
Foundation Medicine
@FoundationATCG
We’re excited to partner with @TexasOncology to further expand precision medicine to cancer patients through access to our blood-based comprehensive genomic profiling. Read more from Dr. @geoff_oxnard VP, Head of Clinical Development: bwnews.pr/3uFM8Rf
-
Foundation Medicine
@FoundationATCG
In collaboration with @ScienceAtBMS we explored concordance between tumor mutational burden (TMB) and blood TMB to reveal the complementary nature of assessments from tissue and blood comprehensive genomic profiling. Don’t miss the presentation at #aacr22: www.foundationmedicine.com/research/evaluation-of-tissue-…
-
Foundation Medicine
@FoundationATCG
Identifying the right patients for PARP inhibitors across multiple disease types remains a challenge. We’re introducing our new algorithm to predict homologous recombination deficiency (HRD) status at #aacr22. Read more: www.foundationmedicine.com/research/development-of-a-pan-…
-
Foundation Medicine
@FoundationATCG
Lack of knowledge about ancestry-specific alterations is a barrier to implementing precision medicine. We partnered w/ @DanaFarber to identify ancestry-associated features across multiple cancer types using our broad data sets. Read more: www.foundationmedicine.com/research/leveraging-existing-d… #aacr22
-
Foundation Medicine
@FoundationATCG
Our data at #aacr22 uses tissue and blood biopsy-based comprehensive genomic profiling to offer insights for the identification and treatment of cancers with reversion mutations. Read more: www.foundationmedicine.com/research/comprehensive-genomic…
-
Foundation Medicine
@FoundationATCG
Looking forward to the joining the discussion on the latest advancements in cancer research at #aacr22. With our collaborators, we will be presenting nine studies that reinforce the importance of genomic testing in precision cancer care. Learn more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
New research at #aacr22 demonstrates the ability of our portfolio of tests to identify treatment options for patients, and reinforces our role as an essential partner to researchers. Read more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Diversity, inclusivity and opportunity are important elements of the culture at Foundation Medicine. As we round out #womenshistorymonth, our CEO Dr. Brian Alexander (@xelamb) chatted with CMO @DrMiaLevy on her experience as a #womaninscience. Read more: www.foundationmedicine.com/blog/celebrating-womens-histor…
-
Foundation Medicine
@FoundationATCG
Black Americans have a higher prevalence of #colorectalcancer and worse survival rates compared to White Americans. Using comprehensive genomic profiling and genomic ancestry, our researchers uncovered insights to address this disparity. aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159… #crcawareness
-
Foundation Medicine
@FoundationATCG
FoundationOne CDx* is now FDA-approved as a companion diagnostic for a group of targeted therapies to treat NSCLC. Learn more about this approval: www.foundationmedicine.com/press-releases/fb0e7ea2-3228-4…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1cdxlabel.com -
Foundation Medicine
@FoundationATCG
We’re joining others from @AdaptiveBiotech & @YaleGICancers for a workshop @MAPSmedaffairs about increasing gender equity in advisory boards. The session will define the observed gaps and share practical tips for addressing this disparity. Read more: nola2022.medicalaffairs.org/main-program/
-
Foundation Medicine
@FoundationATCG
Cancer can often evolve & evade therapeutic interventions. At #miamibreast22, we examine patients profiled with tissue & liquid biopsy, to identify potential vulnerabilities in the relapsed setting that may provide insights on additional treatment options. www.foundationmedicine.com/research/tissue-and-liquid-bio…
-
Foundation Medicine
@FoundationATCG
In recognition of #rarediseaseday, we are shedding light on the importance of comprehensive genomic profiling to help oncologists match rare cancer patients to targeted treatment options. Read more from our partners at @RareDiseases Rare Cancer Coalition: www.conquer-magazine.com/web-exclusives/1691-treating-rar…
-
Foundation Medicine
@FoundationATCG
Comprehensive genomic profiling is a critical tool to uncover rare mutations within a patient’s cancer that may impact treatment decisions. Our VP of Clinical Development, Dr. @geoff_oxnard share’s his thoughts in our partner @Takeda’s new #rarediseaseday blog:
Takeda
@TakedaPharma
You might not think of lung cancer as a #raredisease, but many subtypes are. Through partnerships with @FoundationATCG and @thermofisher, we’ve leveraged next-gen sequencing #tech to improve diagnosis for cancer subtypes. www.takeda.com/science/areas-of-focus/rare-diseases/
-
Foundation Medicine
@FoundationATCG
Our innovative approach to biomarker research is laying the foundation for future advancement in cancer care. Learn about what’s next in immunotherapy from our Chief Scientific Officer @PritiHegde. www.foundationmedicine.com/blog/whats-next-with-priti-heg…
-
Foundation Medicine
@FoundationATCG
Real world data can play an important role in informing precision cancer care. Alan Braly, our Senior Director of Data & Insights Delivery, shares how we’re working with this data to help improve drug development research and clinical treatment decisions. www.oncozine.com/the-importance-of-real-world-data-in-can…
-
Foundation Medicine
@FoundationATCG
FoundationOne CDx* is now FDA-approved to identify patients with MSI-H solid tumors who may be appropriate for an immunotherapy treatment option: www.foundationmedicine.com/press-releases/u.s.-fda-approv…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1cdxlabel.com -
Foundation Medicine
@FoundationATCG
We're sharing research at @ASCO #gu22 on the genomics of resected early stage bladder cancer to validate CGP-informed minimal residual disease detection in circulating tumor DNA using the prototype of our tissue-informed personalized monitoring assay: www.foundationmedicine.com/research/molecular-residual-di…
-
Foundation Medicine
@FoundationATCG
Our new research being presented this week @ASCO #gu22 suggests immune checkpoint inhibitors may be a viable alternative to taxane chemo for patients with metastatic castration-resistant prostate cancer with TMB greater than or equal to 10: meetings.asco.org/abstracts-presentations/205478
-
Foundation Medicine
@FoundationATCG
Our circulating tumor DNA (ctDNA) monitoring assay has been granted Breakthrough Device Designation by the FDA. Read more about how we are working to shape the future of clinical care and research through our innovative tests: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Happy #womeninscience Day! Our Chief Scientific Officer @PritiHegde shares her thoughts on the value of mentorship and the importance of having diverse perspectives represented in the sciences careers.foundationmedicine.com/research-and-development-t…
-
Foundation Medicine
@FoundationATCG
Today we announced a broad partnership with @LillyPad to explore ways to bring more targeted treatment options to cancer patients. Read more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
On #worldcancerday, we’re bringing awareness to the importance of comprehensive genomic profiling (CGP). Learn how CGP can help identify alterations that may be driving a patient’s cancer and provide information on potential treatment options. www.foundationmedicine.com/resource/why-comprehensive-gen…
-
Foundation Medicine
@FoundationATCG
We’re proud to collaborate with @CancerResrch and others on a new #hrd publication, out now in @OncJournal. These findings set the stage for Phase 2 of the HRD Harmonization project focused on identifying concordance between assays that measure HRD.
Friends of Cancer Research
@CancerResrch
@CancerResrch is excited to announce a new publication highlighting findings from collaborative working group discussions about ways to define and measure #hrd. This manuscript sets the foundation for the ongoing #hrdharmonization Project. doi.org/10.1093/oncolo/oyab053
-
Foundation Medicine
@FoundationATCG
Check out @Ryongraf's Tweetorial on our recent paper published in @EUplatinum exploring androgen receptor amplification status as a candidate biomarker to predict poor effectiveness of novel hormonal therapies relative to taxanes in metastatic castrate resistant prostate cancer.
Ryon Graf, PhD
@RyonGraf
(1 of 13) Tweetorial (and poll at end). Hi everyone! Tweetorial rookie here. Wanted to share our recent paper in @EUplatinum We encourage dialogue on any of these tweets. Open access for paper here: www.sciencedirect.com/sdfe/reader/pii/S0302283821020601/pdf #pcsm @PCF_Science #prostatecancer
-
Foundation Medicine
@FoundationATCG
Join us Friday, January 28 at 8:00 a.m. ET to hear from Foundation Medicine’s Merrida Childress, Ph.D., on guiding personalized medicine in sarcoma with comprehensive genomic profiling. Register: foundationmedicinewebinar.com/register/
-
Foundation Medicine
@FoundationATCG
Congratulations to our CEO Brian Alexandar (@xelamb) on being named to @bostonmagazine’s Top Doctor’s List for the fourth year in a row. We’re so proud of your commitment to transforming cancer care, both in the clinic and here at Foundation Medicine!
Boston Magazine
@BostonMagazine
1,797 of the region's finest physicians, organized for your use. www.bostonmagazine.com/health/2022/01/25/top-doctors-bost…
-
Foundation Medicine
@FoundationATCG
Our 2021 interns brought their unique perspectives, skills, and passion to Foundation Medicine. Openings for our 2022 internship program are now posted and more are on the way. careers.foundationmedicine.com/internship-program #wearefmi
-
Foundation Medicine
@FoundationATCG
Congratulations to first author, @MDAndersonNews’s @NgoiYl and our other collaborators, on receiving the ASCO Conquer Cancer Merit Award for our study on MTAP loss in pancreatic ductal cancer. Proud to see the award presented this week at @ASCO #gi22 meetings.asco.org/abstracts-presentations/205075
-
Foundation Medicine
@FoundationATCG
MRD detection has the promise to help guide cancer care. At @ASCO #gi22, we present data on its feasibility using a prototype of our tissue-informed personalized monitoring assay in mCRC patients who have undergone curative intent surgical resection: www.foundationmedicine.com/research/comprehensive-genomic…
-
Foundation Medicine
@FoundationATCG
A #lungcancer diagnosis can come unexpectedly. This was certainly true for Amanda (@amand12827). Read her story in @AuthorityMgzine and learn about her experience with genomic testing: medium.com/authority-magazine/amanda-nerstad-i-survived-c…
-
Foundation Medicine
@FoundationATCG
Genomic testing can help so many, yet less than 50% of those diagnosed with #nsclc get tested. Read Jeff’s story in @cancerwellmag told by his wife @RhondaMeckstro1 to see how genomic testing helped guide his treatment journey: cancerwellness.com/essays/as-told-to/learning-to-live-mec…
-
Foundation Medicine
@FoundationATCG
Tune in to newest @TheUSCAP @ModernPathology ModPath Chat podcast to hear editor in chief @DrNetto review five of its highest-cited manuscripts of 2021, including our pan-cancer analysis of predicative biomarkers for immune checkpoint inhibitor response. shows.acast.com/modpath-chat/episodes/2021-year-in-review
-
Foundation Medicine
@FoundationATCG
Happy 10th anniversary to @CD_AACR! Thanks for featuring our own Garrett Frampton (@BostonGenomics) in your series on the paradigm-shifting discoveries you’ve published over the past decade. Read more: aacrjournals.org/cancerdiscovery/pages/frampton-paik-subb…
-
Foundation Medicine
@FoundationATCG
Congratulations to our own Diana Rastegayeva, who was named a Bostonian of the Year by @BostonGlobeMag for increasing COVID-19 vaccine equity & accessibility. Diana & a team of volunteers booked over 25,000 vaccination appointments this year. Read more: www.bostonglobe.com/2021/12/15/magazine/when-vaccination-…
Foundation Medicine
@FoundationATCG
Kunal Shah, a Product Manager at Foundation Medicine was also recognized by @BostonGlobeMag for his work launching VaccinateMA. “We were all in communication with one another and trying to get to the same end goal,” he told the Globe. www.bostonglobe.com/2021/12/15/magazine/when-vaccination-…
-
Foundation Medicine
@FoundationATCG
FoundationOne CDx* is now the first and only CGP test to be FDA-approved as a companion diagnostic for 2 groups of targeted therapies in melanoma. www.foundationmedicine.com/press-releases/foundationone®…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1lcdxlabel.com -
Foundation Medicine
@FoundationATCG
Genomic testing can offer patients invaluable information about their specific cancer. 6-year cancer survivor @GinaHollenbeck and oncologist @christine_lovly chat with @iowasnewsnow about the importance of genomic testing: cbs2iowa.com/community/more-fun-in-the-morning/lung-cance…
-
Foundation Medicine
@FoundationATCG
We’re proud serve as an essential partner to patients, physicians & researchers navigating the complexities of cancer care. Hear from our CEO, @xelamb about our commitment to shaping the future of cancer care by providing answers & empowering action. www.foundationmedicine.com/blog/finding-answers-empowerin…
-
Foundation Medicine
@FoundationATCG
New research in @CCR_AACR shows our liquid biopsy test provides pan-tumor detection of kinase fusions in ctDNA, which are historically challenging to uncover using liquid biopsy. Read more: aacrjournals.org/clincancerres/article/28/4/728/678111/Th…
-
Foundation Medicine
@FoundationATCG
Our CEO, Dr. Brian Alexander is sharing his gratitude for our inspiring, patient-focused team at Foundation Medicine who continue to dedicate themselves to transforming cancer care. Read more: careers.foundationmedicine.com/en-US/blogs/inside-foundat… #thanksgiving @xelamb
-
Foundation Medicine
@FoundationATCG
Discover how comprehensive genomic profiling is informing the future of lung cancer research and enabling more targeted treatment options for patients. #lungcancerawarenessmonth www.youtube.com/watch?v=cUxZAREXndQ
-
Foundation Medicine reposted
Maryam Lustberg MD, MPH, FASCO
@maryam_lustberg
Collaborations across @YaleCancer network with @FoundationATCG and #breastcancer team to advance #personalizedmedicine with the legendary Jeff Ross MD. Cc @geoff_oxnard #lajospusztai #neilfischbach @SmilowCancer #bcsm @mcprn48 @NitaAhujaMD
-
Foundation Medicine
@FoundationATCG
We're proud to be certified as a Great Place to Work in Germany. At all of our Foundation Medicine sites, our people-first culture allows us to do our best work each day to transform cancer care for patients, physicians, and researchers. #wearefmi careers.foundationmedicine.com/germany
-
Foundation Medicine
@FoundationATCG
Congratulations to our Chief Scientific Officer, @PritiHegde, who has been named one of @FiercePharma's Fiercest Women in Life Sciences. We are grateful for Priti’s inspiring leadership and deep dedication to our mission and our people. #wearefmi www.fiercepharma.com/special-report/women-life-sciences-2…
FiercePharma
@FiercePharma
Our 2021 Fiercest Women in Life Sciences special report is here. #wils2021 www.fiercepharma.com/special-report/women-life-sciences-2021
-
Foundation Medicine
@FoundationATCG
Throughout #lungcancerawarenessmonth, learn more from @geoff_oxnard about the important role blood-based genomic testing can have in improving #lungcancer outcomes: www.youtube.com/watch?v=cUxZAREXndQ
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is proud to honor our veterans, and to share how they continue to make an impact through their dedication to our mission to transform cancer care. Thank you to all veterans for your service to our country. #veteransday careers.foundationmedicine.com/en-US/blogs/inside-foundat…
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
For people with non-small cell #lungcancer, it's important to #knowyourbiomarker. Foundation Medicine is proud to partner with @LUNGevity to spread awareness about precision medicine options. Learn more: no1missed.org/3zedL2z #noonemissed #lcam
LUNGevity Foundation
@LUNGevity
ANNOUNCING: KNOWvember as part of #lungcancerawarenessmonth! As we recognize the importance of lung cancer education, we want to ensure that comprehensive biomarker testing stays top of mind. Read more here no1missed.org/3w6So3f #noonemissed #lcam #lcsm #knowyourbiomarker
-
Foundation Medicine
@FoundationATCG
Foundation Medicine has signed agreements for in-network provider status with Humana Military and Health Net Federal Services, which administer the TRICARE health program for military members, retirees and their families. Read more in our press release: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Last week, our Chief Scientific Officer @PritiHegde joined a panel at HLTH for an important conversation around drug discovery and development, and how the data pipeline from the lab is connected to the real world. #hlth21
Vineeta Agarwala
@vintweeta
What a fun privilege to moderate a panel chat last week w this group! #hlth21
@rplenge (@bmsnews)
@PritiHegde (@FoundationATCG)
@AndreEsteva (ex @salesforce AI)
Joel Dudley (@TempusLabs)
We chatted re using multimodal molecular + clinical data to guide every step of drug/dx dev -
Foundation Medicine reposted
Geoff Oxnard MD
@geoff_oxnard
My pleasure to speak with the Journal of Clinical Pathways about our recent @FoundationATCG data at @myESMO re: CGP timing to support precision therapy in advanced NSCLC!
www.hmpgloballearningnetwork.com/site/jcp/videos/real-wor… -
Foundation Medicine
@FoundationATCG
Genomic testing can identify rare alterations like NTRK gene fusions which can help oncologists match patients to more targeted treatment options. Learn how genomic testing is helping to treat rare cancer: www.conquer-magazine.com/web-exclusives/1691-treating-rar…
-
Foundation Medicine reposted
UroToday.com
@urotoday
Molecular-based predictive biomarkers of response to immune checkpoint blockade. #expertcommentary from @FaltasLab @WCMEnglanderIPM of a recent study by Banchereau et al. published in @NatureComms. #readnow details on UroToday > www.urotoday.com/recent-abstracts/urologic-oncology/bladd… @genentech @FoundationATCG
-
Foundation Medicine
@FoundationATCG
We are excited to welcome our new Chief Commercial Officer Dymeka Harrison (@DymekaH) to Foundation Medicine. Read more in our press release: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Our Dr. Julia Elvin, Laboratory Director and SVP, Pathology and Diagnostic Medicine, joined @targetcancer last night to discuss the importance of genomic testing in rare cancers on @boston25. Watch the full segment below. #rarecancerday
Boston 25 News
@boston25
Local foundation building hope for families facing rare cancer diagnosis www.boston25news.com/news/local/local-foundation-building…
-
Foundation Medicine
@FoundationATCG
Insights from comprehensive genomic profiling (CGP) can help oncologists match rare cancer patients to targeted treatment options. Learn why the co-chairs of @RareDiseases Rare Cancer Coalition believe that CGP should be available to all patients: www.conquer-magazine.com/web-exclusives/1691-treating-rar…
-
Foundation Medicine
@FoundationATCG
For years there was no FDA-approved targeted treatment for cholangiocarcinoma. Genomic profiling is helping to inform precision medicine. Learn why the @RareDiseases Rare Cancer Coalition believes cancer patients should have access to CGP: www.conquer-magazine.com/web-exclusives/1691-treating-rar… #rarecancerday
-
Foundation Medicine
@FoundationATCG
We’ve partnered with @ZEROCancer to encourage men to learn more about #prostatecancer, PSA testing, and genomic testing, which is available for patients to help identify targeted treatment options. zerocancer.org #prostatecancerawarenessmonth #endprostatecancer
-
Foundation Medicine
@FoundationATCG
Hear from @ZEROCancer advocate Landi Maduro as she explains the importance of education and awareness of #prostatecancer, especially when it comes to breaking down barriers that may cause racial disparities in healthcare. Learn more: www.youtube.com/watch?v=L4509wez1lM #endprostatecancer
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
We are thrilled to welcome @DrMiaLevy, M.D., Ph.D., to Foundation Medicine as our new Chief Medical Officer. Read more in our press release: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
From evaluating clinical outcomes to showcasing implications for testing, our studies at #esmo21 highlight real-world data at work. Learn how data collected via comprehensive genomic profiling is transforming cancer research: www.foundationmedicine.com/blog/how-real-world-clinico-ge…
-
Foundation Medicine
@FoundationATCG
#esmo21: We analyzed treatment outcomes in HR+/HER2-metastatic breast cancer patients w/ high TMB using data from the @flatironhealth-Foundation Medicine clinico-genomic database. See how this research can help inform decisions in this patient population www.foundationmedicine.com/blog/how-real-world-clinico-ge…
-
Foundation Medicine reposted
Roche
@Roche
Any cancer diagnosis can be emotionally traumatic, but it’s particularly difficult to hear “we don’t know where your cancer is coming from.” Marlene, a Roche biochemist, says we’re shedding light on the unknown in cancer. #fightforcup #esmo21 www.roche.com/stories/voices
-
Foundation Medicine
@FoundationATCG
At #esmo21, we’re presenting studies supported by real-world data from the @flatironhealth - Foundation Medicine clinico-genomic database, as well as data that reinforces the clinical utility of liquid-based genomic testing to inform treatment decisions: cslide.ctimeetingtech.com/esmo2021/attendee/confcal/sessi…
-
Foundation Medicine reposted
Precision Medicine World Conference
@PMWCintl
Brian Alexander @FoundationATCG to present #pmwc21 #cancer #novel #trial #designs for #precisionmedicine with colleagues @LauraEsserman and @derekangus
-
Foundation Medicine
@FoundationATCG
This #prostatecancerawarenessmonth, we are collaborating with @ZEROCancer to share writer, director and producer Landi Maduro’s story of her role as an advocate working to educate men about #prostatecancer, and the importance of early detection. www.youtube.com/watch?v=L4509wez1lM
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
Congratulations to our SVP of U.S. Operations and Client Services, Jami DeBrango-Palumbo for being recognized as one of San Diego’s 2021 Women of Influence in Life Science by @SDbusiness! www.sdbj.com/news/2021/aug/27/women-influence-life-scienc… #wearefmi
-
Foundation Medicine
@FoundationATCG
In the last year, tremendous progress has been made in expanding access to targeted therapies through precision medicine. Dr. @geoff_oxnard, our Head of Clinical Development, weighs in on this milestone in our latest blog post: www.foundationmedicine.com/blog/what-a-difference-a-year-…
-
Foundation Medicine reposted
Journal of Clinical Oncology
@JCO_ASCO
Data from @FoundationATCG using Comphrensinve Genomic profiling in 73 pts with Combined hepatocellular cholangiocarcinoma (cHCC-CCA) demonstrated cHCC-CCA as HCC like or CCA ike based on genomic profiling ascopubs.org/doi/abs/10.1200/PO.20.00397 #jcopo
-
Foundation Medicine
@FoundationATCG
MyImpact, our new hire orientation program, has been recognized with a @BrandonHallGrp Bronze Award for the second year in a row. Congratulations to the teams who make this extraordinary experience possible for all of our new employees. brandonhall.com/excellenceawards/excellence-talentacquisi… #wearefmi
-
Foundation Medicine
@FoundationATCG
Foundation Medicine is presenting data in partnership with @genentech & others at @IASLC’s #wclc21 annual meeting evaluating circulating tumor DNA to predict overall survival risk & treatment response in #nsclc. Read more: library.iaslc.org/conference-program?product_id=24&author…
-
Foundation Medicine
@FoundationATCG
"Through this partnership with Science 37, leveraging our combined assets and expertise, our goal is to improve access to clinical trials for patients that aren’t frequently able to participate,” says CEO Brian Alexander, MD, MPH. Learn more: www.foundationmedicine.com/press-releases/science-37®-an… @Science37x
-
Foundation Medicine
@FoundationATCG
One year ago, we pushed the boundaries of precision oncology with the launch of FoundationOne®Liquid CDx*. Read more from @geoff_oxnard: www.foundationmedicine.com/blog/what-a-difference-a-year-…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1lcdxlabel.com -
Foundation Medicine
@FoundationATCG
A year after FDA approval, FoundationOne®Liquid CDx* has 9 CDx claims for targeted therapies across breast, prostate, ovarian & lung cancers. More: www.foundationmedicine.com/blog/what-a-difference-a-year-…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1lcdxlabel.com -
Foundation Medicine
@FoundationATCG
Foundation Medicine’s announced integration with Epic is designed to provide easy access to clinical & genomic information, enabling more efficient clinical decision making & allowing teams to focus on providing the best treatment for patients. Read more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
See how comprehensive genomic profiling can help identify a specific NUT carcinoma fusion and explain unexpected responses to immunotherapy in a case series of these rare tumors: www.sciencedirect.com/science/article/pii/S1936523321001765
-
Foundation Medicine
@FoundationATCG
TMB is a pan-tumor genomic signature that measures the quantity of mutations in a tumor. In combination with other biomarkers and genomic signatures, it can play an important role in identifying patients likely to benefit from immunotherapy. Read more: www.foundationmedicine.com/resource/immunotherapy-biomarkers
-
Foundation Medicine
@FoundationATCG
We are excited to announce the appointment of Sanket Agrawal as our Chief Biopharma Business Officer. Read more in our press release: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Deep collaboration across the global oncology ecosystem is helping make comprehensive genomic profiling a reality for patients around the world. Read more from our CEO @xelamb: www.foundationmedicine.com/blog/making-comprehensive-geno…
-
Foundation Medicine
@FoundationATCG
Our friends at @GO2Foundation share more about what the most recent companion diagnostic approval for our liquid biopsy test could mean for patients with #nsclc.
Read more about the approval: www.foundationmedicine.com/press-releases/foundation-medi… -
Foundation Medicine
@FoundationATCG
For some patients, their own immune system is the most helpful tool in their cancer treatment. The measurement of TMB through comprehensive genomic profiling may help identify patients who can benefit from immunotherapies. Learn more: www.foundationmedicine.com/resource/immunotherapy-biomarkers
-
Foundation Medicine
@FoundationATCG
We're proud to be honored as a @SDbusiness 2021 Best Place to Work. At Foundation Medicine, our people-first culture cultivates passion, innovation and collaboration, allowing us to do our best work each day to transform cancer care for patients. careers.foundationmedicine.com/san-diego-office #wearefmi
-
Foundation Medicine
@FoundationATCG
Advancements in lung cancer research have redefined how clinicians approach diagnosis & treatment decisions. Our Dr. @geoff_oxnard spoke w/ @TakedaOncology about the critical role CGP plays in improving care for patients w/ rare lung cancers. www.takedaoncology.com/externalcontentview/d5dfb485-cefd-…
-
Foundation Medicine
@FoundationATCG
For healthcare professionals: Join us July 28 at 11am EDT or 6pm EDT to hear from Dr. Fadi Braiteh of Comprehensive Cancer Centers of NV about comprehensive genomic profiling & how Foundation Medicine may help you overcome common barriers to use. Register: events.foundationmedicine.com/speakerprogram072821/home
-
Foundation Medicine
@FoundationATCG
FoundationOne®Liquid CDx* is now FDA approved to detect mutations that lead to METex14 & match appropriate patients w/ a targeted therapy for #nsclc. www.foundationmedicine.com/press-releases/foundation-medi…
*Rx only; doesn't guarantee treatment match or that all alterations will be found www.f1lcdxlabel.com -
Foundation Medicine
@FoundationATCG
Our colleagues at Foundation Medicine GmbH in Penzberg, Germany strive to empower every employee. It's a guiding principle that helps them continue to transform cancer care every day. Read more about the Penzberg team here: careers.foundationmedicine.com/blogs/inside-foundation-me… #wearefmi
-
Foundation Medicine
@FoundationATCG
Join us Thursday July 15 at 7:00 a.m. ET to hear from Foundation Medicine’s Mehlika Hazar Rethinam, Ph.D., on using genomic alterations as guides for resistance/response to immunotherapy. Register: foundationmedicinewebinar.com/register/
-
Foundation Medicine
@FoundationATCG
Companion diagnostics inform personalized treatment by connecting advanced cancer patients w/ potential treatment options. Learn more: www.foundationmedicine.com/blog/companion-diagnostics-exp…
*Rx only; doesn't guarantee treatment match or that all alterations will be found f1lcdxlabel.com -
Foundation Medicine reposted
GeneOnline
@GeneOnlineNews
After being undruggable for years, drugs against KRAS, a major #cancer driver are entering clinical practice. New research now reveals how cancers overcome KRAS inhibitors via multiple resistance mechanisms.
#kras #oncology @FoundationATCG #geneonline
geneonline.news/en/genomic-profiling-reveals-multiple-res… -
Foundation Medicine
@FoundationATCG
FoundationOne CDx is now FDA-approved as a companion diagnostic for a @TakedaOncology therapy that is approved for patients w/ ALK+ mNSCLC. www.foundationmedicine.com/press-releases/foundationone®…
*Rx only; advanced cancer, doesn't guarantee match to treatment. www.f1cdxlabel.com -
Foundation Medicine
@FoundationATCG
“The integration of Foundation Medicine tests into @flatironhealth's OncoEMR, and other leading EMR systems to follow, is just one way we’re improving our offerings to fuel precision medicine for cancer patients," says Kathleen Kaa, Interim CCO. Read more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
In honor of Pride month, our PROUD employee resource network hosted virtual education sessions throughout June on topics including parenthood for all and allyship. Read our newest blog to learn how we foster inclusivity year-round: careers.foundationmedicine.com/en-US/blogs/inside-foundat… #wearefmi #pride2021
-
Foundation Medicine
@FoundationATCG
Our Chief Scientific Officer @PritiHegde is sharing her key takeaways from #asco2021. Read more here: www.foundationmedicine.com/blog/promise-and-potential-gen…
-
Foundation Medicine
@FoundationATCG
Foundation Medicine collaborated on research published this week in @NEJM. Led by @DanaFarber Cancer Institute, the study incorporated our genomic testing to glean new insights on resistance to KRAS G12C inhibition. Read more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
Our Lab Operations team knows that every patient sample is a story. A shared passion for serving patients and commitment to our values inspires the collective approach the team takes to transforming cancer care. Learn more here: careers.foundationmedicine.com/lab-operations
-
Foundation Medicine
@FoundationATCG
Peggy, a member of our Patient Community Council, shares her perspective this #cancersurvivormonth on the importance of patient advocates in the oncology community. This month, and all year, we celebrate the patients like Peggy who inspire us to continue to transform cancer care.
-
Foundation Medicine
@FoundationATCG
Our 2nd annual Hackathon took place virtually, with teams innovating across 3 tracks: DE&I, Working Remotely & Customer Experience. Winning team members share what they gained from collaborating with colleagues: careers.foundationmedicine.com/jobs/search #wearefmi
-
Foundation Medicine
@FoundationATCG
Don’t miss this important insight from @genentech's Quita Highsmith on the lack of diversity in clinical trials. We're presenting data at #asco2021 examining access to testing & disparities in prostate cancer and are committed to collaboration to address unmet needs.
Genentech
@genentech
#asco21 is our annual opportunity to gather and discuss the needs that still exist in cancer research. Quita Highsmith, our Chief Diversity Officer, shares her perspective on the current lack of diversity in clinical trials. Read more here: www.statnews.com/sponsor/2021/05/17/the-biopharma-industr…
#asco21 -
Foundation Medicine
@FoundationATCG
"The addition of FoundationOne Tracker for research use provides our biopharma and academic partners access to Foundation Medicine’s broad, advanced-stage CGP footprint," says Foundation Medicine Chief Scientific Officer @PritiHegde. Read more: www.foundationmedicine.com/press-releases/bdeffc0c-20e6-4…
-
Foundation Medicine reposted
The Cancer Letter
@TheCancerLetter
Biomarker-based cancer therapies are the cornerstone of #precisiononcology and hold promise for expanding access to the most effective treatment options for every patient. .@SylvesterCancer's @BrandonMahal and @FoundationATCG's Jeffrey Venstrom.
cancerletter.com/trials-and-tribulations/20210604_6/ -
Foundation Medicine
@FoundationATCG
#asco21: Using real-world data from our joint clinico-genomic database with @flatironhealth, we found a broader range of metastatic breast cancer patients who may benefit from targeted PARP inhibitor treatment. Learn more: www.foundationmedicine.com/event/asco2021
-
Foundation Medicine
@FoundationATCG
Genomic testing is pivotal to informing targeted treatment decisions. #asco21: We collaborated on research in ALK+ solid tumors supporting the potential of decentralized clinical trials to diversify enrollment and expand access to precision medicine: www.foundationmedicine.com/event/asco2021
-
Foundation Medicine
@FoundationATCG
Our own @smruthy90 joins #asco21 study partner @BrandonMahal to discuss the importance of research exploring disparities in #prostatecancer. Studies like this may help identify barriers patients face in getting the quality care they need. Learn more: www.youtube.com/watch?v=wwqLT5au2cI
-
Foundation Medicine
@FoundationATCG
#asco21: We’re proud to partner with @targetcancer on the decentralized TRACK study assessing if patients with #rarecancer could benefit from molecular therapy informed by comprehensive genomic profiling. Learn more: www.foundationmedicine.com/event/asco2021
-
Foundation Medicine
@FoundationATCG
#asco21: We’re sharing data demonstrating the clinical value of comprehensive genomic testing & importance of ensuring all patients regardless of treatment setting or social barriers receive the highest quality #cancer care. Read more in @TheCancerLetter: cancerletter.com/clinical/20210604_6/
-
Foundation Medicine
@FoundationATCG
Today at #asco21: New data suggest limited access to early comprehensive genomic testing and clinical trials in patients of African descent may help explain disparities in #prostatecancer care. Learn more: www.foundationmedicine.com/press-releases/new-study-resul…
-
Foundation Medicine
@FoundationATCG
We're honored that our video for Transgender Day of Visibility, which celebrates and increases visibility for transgender and non-binary individuals, was recognized for its important message with 3 @tellyawards. careers.foundationmedicine.com/blogs/inside-foundation-me… #wearefmi
-
Foundation Medicine
@FoundationATCG
FoundationOne®CDx can help identify patients with FGFR2 fusions and select rearrangements in cholangiocarcinoma who may benefit from a new targeted therapy: www.foundationmedicine.com/blog/companion-diagnostics-exp… *Rx only; advanced cancer, doesn't guarantee match to treatment. www.f1cdxlabel.com
-
Foundation Medicine
@FoundationATCG
We collaborated with architectural designer @jennysabin to develop Data Knit, a visualization of our genomic data. Installed in our Cambridge office, it shows the power of data and promotes dialogue about the importance of precision medicine options for patients. #wearefmi
This media couldn't be displayed. See it on the original post. -
Foundation Medicine
@FoundationATCG
We are excited to announce the appointment of Dr. Brian Alexander (@xelamb) as chief executive officer. Visit the press release to read more: www.foundationmedicine.com/press-releases/foundation-medi…
-
Foundation Medicine
@FoundationATCG
A cancer diagnosis can be dizzying to navigate, but genomic testing can help chart an informed treatment path. WIRED chronicles a patient’s experience and how genomic profiling impacted his prostate cancer treatment.
-
Foundation Medicine
@FoundationATCG
#liquidbiopsy has the potential to “dramatically increase the amount of information doctors use to figure out the best treatments for their patients.” @TIME explores how blood-based genomic tests like ours can help guide use of targeted cancer treatments: time.com/5889982/cancer-liquid-biopsies/
-
Foundation Medicine
@FoundationATCG
We're proud to be named No. 1 on this year's @FastCompany most innovative #biotech company list for our work to transform cancer care. #fcmostinnovative #uniquelyfmi www.fastcompany.com/90299046/foundation-medicine-most-inn…
-
Foundation Medicine
@FoundationATCG
Proud to support @Pablove Foundation’s Spreading the pabLOVE in Boston event – fighting #childhoodcancer with love through art & #science #childhoodcancerawarenessmonth @MassBio @BobCoughlin
-
Foundation Medicine
@FoundationATCG
We’re excited to have @Pablove in our office today to learn about their Shutterbugs program that helps children w/ cancer develop their creative voice. 📷 #pediatriccancer

















































































































































































































































































































































































































































































